<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral antihistamine‐decongestant‐analgesic combinations for the common cold - De Sutter, AIM - 2022 | Cochrane Library</title> <meta content="Oral antihistamine‐decongestant‐analgesic combinations for the common cold - De Sutter, AIM - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004976.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral antihistamine‐decongestant‐analgesic combinations for the common cold - De Sutter, AIM - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004976.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004976.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Oral antihistamine‐decongestant‐analgesic combinations for the common cold" name="citation_title"/> <meta content="An IM De Sutter" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="an.desutter@UGent.be" name="citation_author_email"/> <meta content="Lars Eriksson" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Mieke L van Driel" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD004976.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/01/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004976.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004976.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004976.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics [therapeutic use]; *Common Cold [drug therapy]; Cough; Histamine Antagonists [therapeutic use]; *Nasal Decongestants [therapeutic use]; United States" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004976.pub4&amp;doi=10.1002/14651858.CD004976.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="Oy81c7tH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004976\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004976\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","ms","hr","fr","zh_HANS","zh_HANT","th","ja","fa","pl","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004976.pub4",title:"Oral antihistamine\\u2010decongestant\\u2010analgesic combinations for the common cold",firstPublishedDate:"Jan 21, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004976.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004976.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004976.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004976.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004976.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004976.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004976.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004976.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004976.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004976.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10694 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004976.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/appendices#CD004976-sec-0117"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/supinfo/CD004976StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/supinfo/CD004976StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral antihistamine‐decongestant‐analgesic combinations for the common cold</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/information#CD004976-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>An IM De Sutter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/information#CD004976-cr-0005">Lars Eriksson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004976.pub4/information#CD004976-cr-0006">Mieke L van Driel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/information/en#CD004976-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 January 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004976.pub4">https://doi.org/10.1002/14651858.CD004976.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004976-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004976-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004976-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004976-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004976-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004976-abs-0004">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD004976-abs-0015">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004976-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004976-abs-0001" lang="en"> <section id="CD004976-sec-0001"> <h3 class="title" id="CD004976-sec-0001">Background</h3> <p>Although combination formulas containing antihistamines, decongestants, and/or analgesics are sold over‐the‐counter in large quantities for the common cold, the evidence for their effectiveness is limited. This is an update of a review first published in 2012. </p> </section> <section id="CD004976-sec-0002"> <h3 class="title" id="CD004976-sec-0002">Objectives</h3> <p>To assess the effectiveness of antihistamine‐decongestant‐analgesic combinations compared with placebo or other active controls (excluding antibiotics) in reducing the duration of symptoms and alleviating symptoms (general feeling of illness, nasal congestion, rhinorrhoea, sneezing, and cough) in children and adults with the common cold. </p> </section> <section id="CD004976-sec-0003"> <h3 class="title" id="CD004976-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE via EBSCOhost, Embase, CINAHL via EBSCOhost, LILACS, and Web of Science to 10 June 2021. We searched the WHO ICTRP and ClinicalTrials.gov on 10 June 2021. </p> </section> <section id="CD004976-sec-0004"> <h3 class="title" id="CD004976-sec-0004">Selection criteria</h3> <p>Randomised controlled trials investigating the effectiveness of antihistamine‐decongestant‐analgesic combinations compared with placebo, other active treatment (excluding antibiotics), or no treatment in children and adults with the common cold. </p> </section> <section id="CD004976-sec-0005"> <h3 class="title" id="CD004976-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. We assessed the certainty of the evidence using the GRADE approach. We categorised the included trials according to the active ingredients. </p> </section> <section id="CD004976-sec-0006"> <h3 class="title" id="CD004976-sec-0006">Main results</h3> <p>We identified 30 studies (6304 participants) including 31 treatment comparisons. The control intervention was placebo in 26 trials and an active substance (paracetamol, chlorphenindione + phenylpropanolamine + belladonna, diphenhydramine) in six trials (two trials had placebo as well as active treatment arms). Reporting of methods was generally poor, and there were large differences in study design, participants, interventions, and outcomes. Most of the included trials involved adult participants. Children were included in nine trials. Three trials included very young children (from six months to five years), and five trials included children aged 2 to 16. One trial included adults and children aged 12 years or older. The trials took place in different settings: university clinics, paediatric departments, family medicine departments, and general practice surgeries.  </p> <p><b>Antihistamine‐decongestant:</b> 14 trials (1298 participants). Eight trials reported on global effectiveness, of which six studies were pooled (281 participants on active treatment and 284 participants on placebo). The odds ratio (OR) of treatment failure was 0.31 (95% confidence interval (CI) 0.20 to 0.48; moderate certainty evidence); number needed to treat for an additional beneficial outcome (NNTB) 3.9 (95% CI 3.03 to 5.2). On the final evaluation day (follow‐up: 3 to 10 days), 55% of participants in the placebo group had a favourable response compared to 70% on active treatment. Of the two trials not pooled, one showed some global effect, whilst the other showed no effect. </p> <p>Adverse effects: the antihistamine‐decongestant group experienced more adverse effects than the control group: 128/419 (31%) versus 100/423 (13%) participants suffered one or more adverse effects (OR 1.58, 95%CI 0.78 to 3.21; moderate certainty of evidence). </p> <p><b>Antihistamine‐analgesic:</b> four trials (1608 participants). Two trials reported on global effectiveness; data from one trial were presented (290 participants on active treatment and 292 participants on ascorbic acid). The OR of treatment failure was 0.33 (95% CI 0.23 to 0.46; moderate certainty evidence); NNTB 6.67 (95% CI 4.76 to 12.5). Forty‐three per cent of participants in the control group and 70% in the active treatment group were cured after six days of treatment. The second trial also showed an effect in favour of the active treatment. </p> <p>Adverse effects: there were not significantly more adverse effects in the active treatment group compared to placebo (drowsiness, hypersomnia, sleepiness  10/152 versus 4/120; OR 1.64 (95 % CI 0.48 to 5.59; low certainty evidence). </p> <p><b>Analgesic‐decongestant:</b> seven trials (2575 participants). One trial reported on global effectiveness: 73% of participants in the analgesic‐decongestant group reported a benefit compared with 52% in the control group (paracetamol) (OR of treatment failure 0.28, 95% CI 0.15 to 0.52; moderate certainty evidence; NNTB 4.7). </p> <p>Adverse effects: the decongestant‐analgesic group experienced significantly more adverse effects than the control group (199/1122 versus 75/675; OR 1.62  95% CI 1.18 to 2.23; high certainty evidence; number needed to treat for an additional harmful outcome (NNTH 17).  </p> <p><b>Antihistamine‐analgesic‐decongestant:</b> six trials (1014 participants). Five trials reported on global effectiveness, of which two studies in adults could be pooled: global effect reported with active treatment (52%) and placebo (34%) was equivalent to a difference of less than one point on a four‐ or five‐point scale; the OR of treatment failure was 0.47 (95% CI 0.33 to 0.67; low certainty evidence); NNTB 5.6 (95% CI 3.8 to 10.2). One trial in children aged 2 to 12 years, and two trials in adults found no beneficial effect. </p> <p>Adverse effects: in one trial 5/224 (2%) suffered adverse effects with the active treatment versus 9/208 (4%) with placebo. Two other trials reported no differences between treatment groups. </p> </section> <section id="CD004976-sec-0007"> <h3 class="title" id="CD004976-sec-0007">Authors' conclusions</h3> <p>We found a lack of data on the effectiveness of antihistamine‐analgesic‐decongestant combinations for the common cold. Based on these scarce data, the effect on individual symptoms is probably too small to be clinically relevant. The current evidence suggests that antihistamine‐analgesic‐decongestant combinations have some general benefit in adults and older children. These benefits must be weighed against the risk of adverse effects. There is no evidence of effectiveness in young children. In 2005, the US Food and Drug Administration issued a warning about adverse effects associated with the use of over‐the‐counter nasal preparations containing phenylpropanolamine. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004976-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004976-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004976-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004976-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004976-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004976-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004976-abs-0017">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004976-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD004976-abs-0020">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004976-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/ro#CD004976-abs-0021">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004976-abs-0003">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD004976-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004976-abs-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004976-abs-0014">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004976-abs-0002" lang="en"> <h3>Oral antihistamine‐decongestant‐analgesic combinations for the common cold</h3> <p><b>Review question</b> </p> <p>Are combination formulas containing antihistamines (AH), decongestants (DC), and/or analgesics (AN), sold over‐the‐counter, effective in treating the symptoms of the common cold? </p> <p><b>Background</b> </p> <p>On average, young children have six to eight colds per year, and adults have two to four. The common cold is caused by viruses, and symptoms include sore throat, nasal stuffiness and discharge, sneezing, and cough. The common cold usually resolves by itself within one to two weeks; however, it has a large impact on time off work or school. </p> <p>As there is no cure for the common cold, only symptomatic treatment is available. Several treatments are needed to tackle the variety of symptoms, therefore different products are combined in one pill: antihistamines against sneezing, cough, and nasal discharge; decongestants against nasal stuffiness; and analgesics against sore throat. </p> <p><b>Search date</b> </p> <p>The evidence is current to 10 June 2021.</p> <p><b>Study characteristics</b> </p> <p>Study participants were adults or children with the common cold. The effects of four combinations (AH + DC; AH + AN; AN + DC; AH + AN + DC) were compared to those of placebo (dummy treatment) (24 trials) or an active substance (6 trials). A beneficial effect was defined as a decrease in severity or duration of overall symptoms or of specific symptoms such as stuffy nose, runny nose, cough, or sneezing. We also investigated whether side effects were more common with the combination treatments than with placebo. </p> <p><b>Study funding sources</b> </p> <p>Only three studies reported independent financing.</p> <p><b>Key results</b> </p> <p>We identified three new three new trials (1038 participants) in this 2021 update, bringing the total number of included trials to 30 (6304 participants). The evidence suggests that all combinations have some beneficial effect on overall symptoms of the common cold in adults and older children. There was no effect in younger children. The AH + DC and DC + AN combinations result in more side effects than placebo; however, there was no difference between groups in side effects for the other combinations. In 2005, the US Food and Drug Administration issued a warning about adverse effects associated with the use of over‐the‐counter nasal preparations containing phenylpropanolamine. </p> <p><b>Certainty of the evidence</b> </p> <p>The 30 included studies differed in the way they were conducted, the included participants, the treatments used, and in the way the effect was measured. There was frequently not enough information in the trials to judge the certainty of the evidence. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004976-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004976-sec-0112"></div> <h3 class="title" id="CD004976-sec-0113">Implications for practice</h3> <section id="CD004976-sec-0113"> <p>The scarce data on the effectiveness of antihistamine‐analgesic‐decongestant combinations for the common cold show that there is some general benefit in adults and older children, which must be weighed against the risk of adverse events. The effect on individual symptoms is probably too small to be clinically relevant. Combinations containing phenylpropanolamine must be avoided. In young children these combinations should not be used given that evidence of their effectiveness is lacking and their potentially associated dangers.  </p> </section> <h3 class="title" id="CD004976-sec-0114">Implications for research</h3> <section id="CD004976-sec-0114"> <p>We found evidence to support the effectiveness of combinations with antihistamines, analgesics, and decongestants compared to placebo. However, it is unclear if the effect is due to one of the components alone or the combination product. Further trials are needed to explore the added value of combining these individual components in comparison with each in monotherapy. Analgesics, decongestants, and antihistamines have some effect in monotherapy (<a href="./references#CD004976-bbs2-0073" title="DeckxL , De SutterAIM , GuoL , MirNA , vanDrielML .Nasal decongestants in monotherapy for the common cold. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD009612. [DOI: 10.1002/14651858.CD009612.pub2]">Deckx 2016</a>; <a href="./references#CD004976-bbs2-0074" title="De SutterA , SaraswatA , vanDrielML .Antihistamines for the common cold. Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009345. [DOI: 10.1002/14651858.CD009345.pub2]">De Sutter 2015</a>; <a href="./references#CD004976-bbs2-0075" title="EcclesR .Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. Journal of Clinical Pharmacy and Therapeutics2006;31:309-19.">Eccles 2006b</a>). Further trials comparing the effectiveness of a single component with a combination may show that the single component is equally effective. Attention should be given to investigating the balance between increased risk of adverse events and clinical benefit. Future trials should report on participant recruitment and randomisation procedures, and include information on the participants' expectations. All trials should report participant well‐being as the primary outcome, as the benign course of the common cold makes laboratory outcomes or quantification of mucus, etc., irrelevant for clinical practice. We do not recommend new trials in small children, given the potentially dangerous adverse effects in children and the benign course of the common cold. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004976-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004976-sec-0008"></div> <div class="table" id="CD004976-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antihistamine‐decongestant compared to placebo for the common cold</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihistamine‐decongestant compared to placebo for the common cold</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> otherwise healthy adults and children with common cold symptoms<br/><b>Setting:</b> multicentre, university hospital, general practice. Studies were performed in the UK, Peru, Spain, Belgium, Austria, and Finland.<br/><b>Intervention:</b> antihistamine‐decongestant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antihistamine‐decongestant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.31<br/>(0.20 to 0.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>565<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants or physicians evaluated the overall response to the treatment at end of follow‐up. Treatment failure means participants or physicians did not evaluate the treatment as beneficial.   </p> <p>On the final evaluation day (follow‐up: 3 to 10 days), 41% of participants in the placebo group had a favourable response, compared to 66% of participants in the active treatment group.  </p> <p>It should be noted that 1 trial reported number of colds as the unit of analysis (<a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>298 per 1000<br/>(223 to 363) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: all</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.58<br/>(0.78 to 3.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>842<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>328 per 1000<br/>(195 to 498) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: drowsiness, hypersomnia, and excessive sleepiness</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.38<br/>(0.63 to 3.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>692<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In 2 of the 5 studies reporting this adverse effect, it was less frequent with active treatment, whilst in the other 3 studies it was less frequent with placebo. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/>(35 to 148) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: dry mouth</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.75<br/>(1.74 to 8.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/>(48 to 190) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: insomnia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.89<br/>(0.88 to 9.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>344<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(26 to 227) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: gastrointestinal upset</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.81<br/>(0.64 to 12.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>296<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(8 to 141) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because most trials are at risk of bias due to lack of reporting on blinding, randomisation, and allocation method; two trials are also at risk of reporting bias.<br/><sup>b</sup>Downgraded one level due to imprecision: wide confidence interval includes 1.<br/><sup>c</sup>Downgraded two levels due to serious inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004976-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antihistamine‐analgesic compared to placebo for the common cold</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihistamine‐analgesic compared to placebo for the common cold</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> otherwise healthy adults and children with common cold symptoms<br/><b>Setting:</b> general practice, or setting not mentioned. Studies performed in the USA and the UK.<br/><b>Intervention:</b> antihistamine‐analgesic<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b> </b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antihistamine‐analgesic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.33<br/>(0.23 to 0.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>582<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The active treatment also contained caffeine and ascorbic acid; control was ascorbic acid. </p> <p>Outcome based on results of <a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a>, reported on day 6. </p> <p>In <a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a>, the proportion of participants who were completely cured at the end of the trial was 70% with Grippostad and 43% with control (ascorbic acid). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>303 per 1000<br/>(233 to 377) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: drowsiness, hypersomnia, and excessive sleepiness</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.64<br/>(0.48 to 5.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The active treatment also contained caffeine, which also may have adverse effects; wide confidence interval including 1: uncertain whether adverse effects are more frequent with treatment. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/>(16 to 162) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias (random sequence generation and allocation concealment unclear, inadequate blinding).<br/><sup>b</sup>Downgraded one level due to imprecision: limited number of participants; broad confidence interval including 1.  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004976-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Analgesic‐decongestant compared to placebo for the common cold</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Analgesic‐decongestant compared to placebo for the common cold</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> otherwise healthy adults and children with common cold symptoms<br/><b>Setting:</b> university hospital, general practice, or setting not mentioned. Studies performed in the UK, Germany, and the USA.<br/><b>Intervention:</b> analgesic‐decongestant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with analgesic‐decongestant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.28<br/>(0.15 to 0.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>181<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> assessed this outcome. On day 5, overall subjective effectiveness at the end of the study was assessed by asking "on the whole do you think the tablets have helped you?".  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>277 per 1000<br/>(170 to 416) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: all</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.62<br/>(1.18 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1797<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000<br/>(129 to 218) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: drowsiness, hypersomnia, lethargy, excessive sleepiness, and other central nervous system adverse effects </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.34<br/>(0.76 to 2.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1644<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/>(24 to 72) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: dry mouth</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.43<br/>(0.53 to 3.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>764<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/>(10 to 67) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: gastrointestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.71<br/>(0.97 to 3.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1644<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000<br/>(26 to 81) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: dizziness, lightheadedness</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.86<br/>(1.02 to 8.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1287<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(9 to 64) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to lack of reporting on blinding, randomisation, and allocation concealment. One study was also at risk of randomisation and allocation bias, and one study was at risk of reporting bias.<sup> </sup><br/><sup>b</sup>Downgraded one level due to imprecision: wide confidence interval includes 1.<br/><sup>c</sup>Downgraded one level due to inconsistency between trial results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004976-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antihistamine‐analgesic‐decongestant compared to placebo for the common cold</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihistamine‐analgesic‐decongestant compared to placebo for the common cold</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> otherwise healthy adults or children with common cold symptoms<br/><b>Setting:</b> paediatric clinic (1 study), setting not mentioned (2 studies). Studies performed in Turkey, the USA, and the UK.<br/><b>Intervention:</b> antihistamine‐analgesic‐decongestant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antihistamine‐analgesic‐decongestant</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation: after 3 days of treatment (included children 2 to 12 years old only) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.34<br/>(0.09 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>109<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome reported as clinical recovery.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>938 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>836 per 1000<br/>(574 to 952) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation: after 5 days of treatment (included children 2 to 12 years old only) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.17<br/>(0.49 to 2.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>83<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome reported as clinical recovery.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>489 per 1000<br/>(286 to 694) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation: on the morning after evening dosing (included adults only)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.47<br/>(0.33 to 0.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>548<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>, participants rated their general feeling (useless, almost useless, not very good, good, very good, excellent) in the morning. </p> <p>In <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>, overall relief was measured on a 5‐point severity scale the morning following the nighttime intake of medication.  </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>658 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>475 per 1000<br/>(388 to 563) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to lack of reporting on random sequence generation, allocation concealment, and blinding.<sup> </sup>One study was at risk of attrition bias.<br/><sup>b</sup>Downgraded one level due to imprecision: confidence interval includes 1. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004976-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004976-sec-0009"></div> <section id="CD004976-sec-0010"> <h3 class="title" id="CD004976-sec-0010">Description of the condition</h3> <p>The common cold is probably the most common illness known. It is a recurrent, acute respiratory tract infection which affects the whole population. On average, young children have six to eight colds per year, and adults have two to four (<a href="./references#CD004976-bbs2-0079" title="GwaltneyJM .Clinical significance and pathogenesis of viral respiratory infections. American Journal of Medicine2002;112(Suppl 6A):13-8.">Gwaltney 2002a</a>; <a href="./references#CD004976-bbs2-0081" title="HeikkinnenT , JärvinenA .The common cold. Lancet2003;361(9351):51-9.">Heikkinnen 2003</a>). The occurrence of the common cold is clearly related to the seasons. In temperate regions of the Northern Hemisphere, the frequency of respiratory infections increases rapidly in the autumn, remains fairly high throughout the winter, and decreases in the spring. In tropical areas, most colds occur during the rainy season (<a href="./references#CD004976-bbs2-0081" title="HeikkinnenT , JärvinenA .The common cold. Lancet2003;361(9351):51-9.">Heikkinnen 2003</a>). </p> <p>Although the common cold is not a serious condition, it has a substantial impact on time off from work and school, general practitioner consultations, and money spent on both prescription and over‐the counter (OTC) medications. In the USA there is a loss of approximately 22 million school days and 20 million work days, as well as 25 million visits to the family physician annually due to the common cold (<a href="./references#CD004976-bbs2-0081" title="HeikkinnenT , JärvinenA .The common cold. Lancet2003;361(9351):51-9.">Heikkinnen 2003</a>; <a href="./references#CD004976-bbs2-0085" title="NIAID.Common cold. Review. www3.niaid.nih.gov/healthsicence/healthtopics/colds/overview.htm (accessed 1 February 2007).">NIAID 2007</a>). </p> <p>More than 200 different viruses are known to cause the common cold. Rhinovirus is by far the most frequent cause of the common cold (30% to 50%), although a substantial number of colds are caused by coronaviruses (10% to 15%). Respiratory syncytial virus, influenza, parainfluenza, and adenovirus have also been implicated (<a href="./references#CD004976-bbs2-0090" title="WatD .The common cold: a review of the literature. European Journal of Internal Medicine2004;15(2):79-88.">Wat 2004</a>). The relative proportion of the different virus types depends on several factors such as age, season, virus sampling and detection methods. In 20% to 30% of cases no cause can be found. </p> <p>Most studies of common colds are based on rhinovirus due to its prevalence (<a href="./references#CD004976-bbs2-0090" title="WatD .The common cold: a review of the literature. European Journal of Internal Medicine2004;15(2):79-88.">Wat 2004</a>). The infection is transmitted to the nasal epithelium by airborne droplets, and by hand from fomites. The initial accumulation of rhinovirus in the eyes and nose leads to attachment of the virus to intercellular receptors at the back of the throat. The detailed mechanisms by which viral infection causes changes in the nasal mucosa are still not fully understood. The absence of epithelial destruction during rhinovirus infections has led to the hypothesis that the clinical symptoms of the common cold might not be caused by a direct cytopathic effect of the viruses, but instead are primarily caused by the inflammatory response of the host. There is evidence of increased concentrations of several mediators which affect the vascular tissues of the nasal epithelium causing engorgement and vascular permeability (<a href="./references#CD004976-bbs2-0079" title="GwaltneyJM .Clinical significance and pathogenesis of viral respiratory infections. American Journal of Medicine2002;112(Suppl 6A):13-8.">Gwaltney 2002a</a>; <a href="./references#CD004976-bbs2-0080" title="GwaltneyJM .Viral respiratory infection therapy: historical perspective and current trials. American Journal of Medicine2002;112(Suppl 6A):33-41.">Gwaltney 2002b</a>; <a href="./references#CD004976-bbs2-0081" title="HeikkinnenT , JärvinenA .The common cold. Lancet2003;361(9351):51-9.">Heikkinnen 2003</a>; <a href="./references#CD004976-bbs2-0083" title="JacobsS , LamsonD , St GeorgeK , WalshT .Human rhinoviruses. Clinical Microbial Reviews2013;26:135-62.">Jacobs 2013</a>; <a href="./references#CD004976-bbs2-0090" title="WatD .The common cold: a review of the literature. European Journal of Internal Medicine2004;15(2):79-88.">Wat 2004</a>). </p> <p>The symptoms of the common cold arise after an incubation period that can vary considerably between different viruses. The incubation period for a rhinovirus infection is 8 to 12 hours (<a href="./references#CD004976-bbs2-0079" title="GwaltneyJM .Clinical significance and pathogenesis of viral respiratory infections. American Journal of Medicine2002;112(Suppl 6A):13-8.">Gwaltney 2002a</a>). Generally symptom severity increases rapidly, peaking within two to three days after infection, and decreasing soon after. The mean duration of the common cold is 7 to 10 days, but in a proportion of people some symptoms may still be present after three weeks. Rhinovirus infections typically start with a 'scratchy' throat, which is soon accompanied by nasal stuffiness and discharge, sneezing, and cough. The soreness of the throat usually disappears quickly, whereas the initial watery rhinorrhoea turns thicker and more purulent. The purulence of the nasal discharge is not associated with changes in the nasopharyngeal bacterial flora. Fever is an infrequent finding during rhinovirus infections in adults, but is fairly common in children (<a href="./references#CD004976-bbs2-0081" title="HeikkinnenT , JärvinenA .The common cold. Lancet2003;361(9351):51-9.">Heikkinnen 2003</a>). </p> </section> <section id="CD004976-sec-0011"> <h3 class="title" id="CD004976-sec-0011">Description of the intervention</h3> <p>Since there is no widely available cure or vaccination for the common cold, treatment is focused on alleviating the symptoms. There is a small amount of evidence that first‐generation antihistamines have a limited effect on rhinorrhoea and sneezing (<a href="./references#CD004976-bbs2-0074" title="De SutterA , SaraswatA , vanDrielML .Antihistamines for the common cold. Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009345. [DOI: 10.1002/14651858.CD009345.pub2]">De Sutter 2015</a>). Decongestants can reduce nasal blockage and secretion through vasoconstriction of the nasal vessels (<a href="./references#CD004976-bbs2-0073" title="DeckxL , De SutterAIM , GuoL , MirNA , vanDrielML .Nasal decongestants in monotherapy for the common cold. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD009612. [DOI: 10.1002/14651858.CD009612.pub2]">Deckx 2016</a>). Analgesics can relieve headache, muscle ache, sore throat, or mild fever, and non‐steroidal anti‐inflammatory drugs (NSAIDs) may suppress the inflammatory response caused by the viral infection. There is some evidence that NSAIDs relieve discomfort caused by a cold (<a href="./references#CD004976-bbs2-0084" title="KimSY , ChangYJ , ChoHM , HwangYW , MoonYS .Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD006362. [DOI: 10.1002/14651858.CD006362.pub4]">Kim 2015</a>). </p> </section> <section id="CD004976-sec-0012"> <h3 class="title" id="CD004976-sec-0012">How the intervention might work</h3> <p>Combinations of antihistamines, decongestants, and analgesics are used to relieve the broad spectrum of common cold symptoms. The evidence of the effectiveness of these combinations in relieving cold symptoms is summarised in this review. </p> </section> <section id="CD004976-sec-0013"> <h3 class="title" id="CD004976-sec-0013">Why it is important to do this review</h3> <p>Although combination formulas containing antihistamines, decongestants, and/or analgesics are prescribed or sold OTC in large quantities for the common cold, their effectiveness is not clear. A previous Cochrane Review reviewed the evidence for the effectiveness of antihistamines in monotherapy in treating the common cold (<a href="./references#CD004976-bbs2-0074" title="De SutterA , SaraswatA , vanDrielML .Antihistamines for the common cold. Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009345. [DOI: 10.1002/14651858.CD009345.pub2]">De Sutter 2015</a>). Our review complements that work by summarising the evidence on the effectiveness of a broader range of therapies containing antihistamines in combination with other active agents such as analgesics or decongestants, or both. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004976-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004976-sec-0014"></div> <p>To assess the effectiveness of antihistamine‐decongestant‐analgesic combinations compared with placebo or other active controls (excluding antibiotics) in reducing the duration of symptoms and alleviating symptoms (general feeling of illness, nasal congestion, rhinorrhoea, sneezing, and cough) in children and adults with the common cold. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004976-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004976-sec-0015"></div> <section id="CD004976-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004976-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials comparing treatment of the common cold with a combination of antihistamine and/or decongestant and/or analgesic versus placebo or other active treatments (excluding antibiotics) in adults and children. </p> </section> <section id="CD004976-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included otherwise healthy adults and children with common cold symptoms, who met the case definition for inclusion in the review. The case definition of the common cold comprises symptoms of runny and/or stuffy nose and sneezing, with or without symptoms of headache and cough. We excluded participants if they suffered from allergic rhinitis, had concurrent respiratory infections or other chronic diseases, atopic eczema, asthma, fever (&gt; 38 °C), sinusitis, exudative pharyngitis, or had had symptoms for more than a week. Participants were volunteers recruited from the community, hospital, or community outpatients. We assessed additional evidence from studies of healthy volunteers challenged with rhinovirus in experimental conditions. </p> </section> <section id="CD004976-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included combination therapies containing analgesics and/or decongestants and/or antihistamines administered orally. We permitted other active ingredients with the exception of antibiotics. This treatment was compared with a control. The control was either active, placebo, or no treatment. </p> </section> <section id="CD004976-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD004976-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004976-list-0001"> <li> <p>Global evaluation of effectiveness (expressed as complete relief, marked, moderate, slight/no relief at all; or the proportion of participants with treatment failure). </p> </li> <li> <p>Adverse effects of treatment.</p> </li> </ol> </p> </section> <section id="CD004976-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD004976-list-0002"> <li> <p>Decrease in the amount, or duration, of individual common cold symptoms (sneezing, nasal congestion, rhinorrhoea, or cough). These symptoms can be assessed by means of severity scales (absent, mild, moderate, severe) or by global evaluation of effectiveness (complete relief, marked, moderate, slight or no relief at all). </p> </li> <li> <p>Objective assessments such as rhinometry to assess mean nasal airflow, rhinoscopy to assess redness and swelling of nasal mucosa, nasal secretions and nasal obstruction, counts of number of sneezes and weight of nasal secretions. </p> </li> </ol> </p> </section> </section> </section> <section id="CD004976-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004976-sec-0024"> <h4 class="title">Electronic searches</h4> <p>For the 2021 search update we searched additional databases. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library; 2021, Issue 5) (<a href="https://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com/</a>) (accessed 10 June 2021), MEDLINE via (EBSCOhost) (2012 to 10 June 2021), Embase (2012 to 10 June 2021), CINAHL via EBSCOhost (Cumulative Index to Nursing and Allied Health Literature) (10 June 2021), LILACS (Latin American and Caribbean Health Science Information database) (10 June 2021), and Web of Science, Clarivate (10 June 2021). </p> <p>The search terms we used for MEDLINE and CENTRAL are provided in <a href="./appendices#CD004976-sec-0118">Appendix 1</a>. We adapted the search for Embase (<a href="./appendices#CD004976-sec-0119">Appendix 2</a>), CINAHL (<a href="./appendices#CD004976-sec-0120">Appendix 3</a>), LILACS (<a href="./appendices#CD004976-sec-0121">Appendix 4</a>), and Web of Science (<a href="./appendices#CD004976-sec-0122">Appendix 5</a>). </p> <p>Details of the previous search are provided in <a href="./appendices#CD004976-sec-0123">Appendix 6</a>. </p> </section> <section id="CD004976-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched two trials registries: the World Health Organization International Clinical Trials Registry Platform (<a href="https://www.who.int/clinical-trials-registry-platform" target="_blank">www.who.int/clinical-trials-registry-platform</a>) and ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>) (latest search 10 June 2021). We searched the reference lists of the retrieved articles and contacted experts and pharmaceutical companies to locate any potentially relevant studies. We imposed no language or publication restrictions. </p> </section> </section> <section id="CD004976-sec-0026"> <h3 class="title" id="CD004976-sec-0026">Data collection and analysis</h3> <section id="CD004976-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ADS, AS) independently screened the titles and abstracts of studies identified by the search of the original review. One review author (LE) performed the searches for this review update. We excluded trials that failed to meet the inclusion criteria. We retrieved and assessed the full papers of studies identified by the search for which there was no abstract. </p> </section> <section id="CD004976-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (ADS, AS) independently extracted data from the trials identified in the original review. One review author (ADS) extracted data from the three new trials included in this update. Any disagreements were resolved by discussion between two review authors (ADS, MVD). It was not necessary to include a third review author as arbiter. We attempted to contact trial authors for additional data where necessary, but were unsuccessful. We analysed trials including young children, and trials in older children and adults independently, where applicable. We divided the included trials into four categories: </p> <p> <ol id="CD004976-list-0003"> <li> <p>combination 1: antihistamine and decongestant;</p> </li> <li> <p>combination 2: antihistamine and analgesic;</p> </li> <li> <p>combination 3: analgesic and decongestant; and</p> </li> <li> <p>combination 4: antihistamine and analgesic and decongestant.</p> </li> </ol> </p> <p>We extracted data on the amount, or duration, of individual common cold symptoms (sneezing, nasal congestion, rhinorrhoea, or cough) and on objective assessments such as rhinometry to assess mean nasal airflow, rhinoscopy to assess redness and swelling of nasal mucosa, nasal secretions and nasal obstruction, counts of number of sneezes and weight of nasal secretions. </p> </section> <section id="CD004976-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias of the included trials using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004976-bbs2-0082" title="HigginsJP , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). In the first publication of this review, two review authors (AK, OL with supervision from MVD) independently assessed risk of bias based on the following risk of bias domains: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other potential sources of bias. Any disagreements were discussed with the supervisor and resolved by consensus. The results of the risk of bias assessment are reported in the risk of bias tables in the <a href="./references#CD004976-sec-0133" title="">Characteristics of included studies</a> section. </p> </section> <section id="CD004976-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>The ways in which outcome measures were presented varied widely across trials. In most studies the outcome measures were a global evaluation of effectiveness (e.g. complete relief, marked, moderate, slight or no relief at all) or a decrease in the severity of individual common cold symptoms assessed by severity scales or by global evaluation of effectiveness. We did not extract data where individual severity scores were added up and effectiveness was evaluated by comparing these sum scores, because the clinical meaning of sum scores is unclear. We compared the proportion of participants with treatment failure at the end of treatment to evaluate the global effectiveness. We used odds ratio (OR) of treatment failure with 95% confidence interval (CI) to report the effect estimate for dichotomous data. We used mean difference (MD) or standardised mean difference (SMD) with standard deviation (SD) for continuous variables (<a href="./references#CD004976-bbs2-0086" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD004976-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We used the individual participant as the unit of analysis for meta‐analysis. If the unit of randomisation was not the same as the unit of analysis, such as in cluster‐randomised trials, we would apply the correction for clustering using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004976-bbs2-0082" title="HigginsJP , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). If studies included separate arms with different drugs from the same class (e.g. one arm with paracetamol and another arm with acetylsalicylic acid), these groups were combined. We included one cross‐over trial in the review (<a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>). </p> </section> <section id="CD004976-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact the trial authors to obtain missing data where required. If this information was not available or could not be obtained, we used intention‐to‐treat (ITT) analysis when pooling the available data. ITT analysis assumes that all missing data represent unsuccessful outcomes. </p> </section> <section id="CD004976-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the presence of heterogeneity using a two‐step approach. Firstly, we assessed heterogeneity between trials at face value (e.g. obviously different populations, settings, treatment regimens). We did not pool data if clinical heterogeneity was clearly present. Secondly, we assessed statistical heterogeneity using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004976-bbs2-0082" title="HigginsJP , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). This evaluates whether variations in the results of different trials are attributable to chance alone or are the result of differences in trial design. We considered a Chi<sup>2</sup> test result with a P &lt; 0.10 and an I<sup>2</sup> statistical result of 50% or higher as indicative of substantial heterogeneity. </p> </section> <section id="CD004976-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We aimed to assess risk of publication bias by using funnel plots if 10 or more studies were available for a given outcome. In the presence of asymmetry, we intended to use the 'trim and fill' method to assess the effect of this asymmetry on the conclusions (<a href="./references#CD004976-bbs2-0082" title="HigginsJP , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </section> <section id="CD004976-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We included in the meta‐analysis the results from included studies that reported any of the prespecified outcomes. We pooled data only if they were available, sufficiently similar, and of sufficient quality as described in <a href="#CD004976-sec-0030">Measures of treatment effect</a>. We used a random‐effects model for meta‐analysis (<a href="./references#CD004976-bbs2-0082" title="HigginsJP , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>).  </p> </section> <section id="CD004976-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We explored the effects of treatments in children versus adults in a subgroup analysis.</p> </section> <section id="CD004976-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform sensitivity analyses, as insufficient data were available for the pooling of treatment effects. </p> </section> <section id="CD004976-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created four summary of findings tables (<a href="./full#CD004976-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD004976-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD004976-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD004976-tbl-0004">summary of findings Table 4</a>) using the following outcomes for each comparison: global effectiveness and adverse effects<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies which contributed data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD004976-bbs2-0070" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al, GRADE Working Group.Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Atkins 2004</a>). We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004976-bbs2-0082" title="HigginsJP , GreenS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), employing GRADEpro GDT software (<a href="./references#CD004976-bbs2-0077" title="GRADEpro GDT.Version accessed 13 April 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). We justified all decisions to down‐ or upgrade the certainty of the evidence using footnotes and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004976-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004976-sec-0039"></div> <section id="CD004976-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD004976-sec-0133" title="">Characteristics of included studies</a> and <a href="./references#CD004976-sec-0134" title="">Characteristics of excluded studies</a> tables and the PRISMA flow chart (<a href="#CD004976-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD004976-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram of searches after 2012." data-id="CD004976-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram of searches after 2012.</p> </div> </div> </div> <section id="CD004976-sec-0041"> <h4 class="title">Results of the search</h4> <p>We performed searches in 2012 and 2021. We identified 5642 references in the searches since 2012, of which 4781 remained after duplicates were removed. Of these, 4712 studies were excluded on the basis of title or abstract, or both. In total, we retrieved 69 papers for more detailed evaluation. We included 27 trials in the 2012 publication of this review (<a href="./references#CD004976-bbs2-0092" title="De SutterA , vanDrielM , KumarAA , LesslarO , SkrtA .Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD004976. [DOI: 10.1002/14651858.CD004976.pub3]">De Sutter 2012</a>), and three new trials in the 2021 update (<a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a>; <a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. ">Montijo‐Barrios 2011</a>; <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a>). This review is based on 30 studies (31 comparisons). We excluded 37 trials. We identified one ongoing study, <a href="./references#CD004976-bbs2-0069" title="NCT02904304.Desloratadine, phenylephrine Hcl, ibuprofen compared to placebo in treatment of symptoms associated with common cold/flu. clinicaltrials.gov/show/nct02904304 (first received 16 September 2016). ">NCT02904304</a>, and one study awaiting classification (<a href="./references#CD004976-bbs2-0068" title="NCT02246166.The effect of paracetamol, pseudoephedrine hydrochloride, dextromethorphan hydrobromide and chlorpheniramine maleate tablets compared to placebo in subjects suffering from the common cold or influenza. clinicaltrials.gov/show/nct02246166 (first received 22 September 2014). ">NCT02246166</a>). </p> </section> <section id="CD004976-sec-0042"> <h4 class="title">Included studies</h4> <p>The included trials showed important differences in participants, interventions, outcomes, and study designs. In most trials there was inadequate information to allow pooling of data, and our requests to trial authors for additional data remained unanswered. Pooling of data was therefore very limited, and consequently we analysed four different treatment combinations in the review. Available numerical outcomes of the different trials are summarised in Additional tables. </p> <p>Details of included population, setting, inclusion and exclusion criteria, intervention and dosage, outcome measures, and main methodological shortcomings (risk of bias assessment) for the individual studies are presented in the <a href="./references#CD004976-sec-0133" title="">Characteristics of included studies</a> table. </p> <p>We included 30 randomised controlled trials involving a total of 6304 participants suffering from the common cold. The interventions consisted of combinations of antihistamines (azatadine, pyrilamine, diphenylpyraline, clemastine, diphenhydramine, dexchlorpheniramine, doxylamine, brompheniramine, chlorpheniramine, pheniramine, triprolidine, promethazine, loratadine, dexbrompheniramine, carbinoxamine) with decongestants (ephedrine, pseudoephedrine, phenylpropanolamine, 1,2,3,4‐tetrahydro‐1‐naphtyl imidazoline) and/or analgesics (paracetamol; NSAIDs (acetylsalicylic acid, ibuprofen, ketoprofen, naproxen) or aminophenazone). </p> <p>We divided the trials into four treatment comparison groups. The first group consisted of 14 trials evaluating antihistamine‐decongestant combinations; in three of these trials active treatment also contained an antitussive. The second group consisted of three trials that evaluated antihistamine‐analgesic combinations. The third group comprised six trials examining analgesic‐decongestant combinations. Finally, the fourth group of six studies investigated a combination of the three agents. In this comparison also three trials active treatment also contained an antitussive. In one study two different combinations were used: analgesic + antihistamine for nighttime and analgesic + decongestant for daytime. We included the daytime combination in the analgesic‐decongestant group and the nighttime combination in the antihistamine‐analgesic group. </p> <p>Twenty‐one trials compared active treatment with placebo. One trial had a cross‐over design. Four trials had more than one active treatment arm (one of the components of the combination, a different dosage of the same combination, or a different combination). In five trials the control group received an active treatment: paracetamol (three trials), chlorphenindione + phenylpropanolamine + belladonna (one trial), and diphenhydramine (one trial). </p> <p>Most of the included trials involved adult participants. Children were included in nine trials: three trials included very young children (from six months to five years; <a href="./references#CD004976-bbs2-0005" title="ClemensCJ , TaylorJA , AlmquistJR , QuinnHC , MehtaA , NaylorGS .Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children?Journal of Pediatrics1997;130(3):463-6. ">Clemens 1997</a>; <a href="./references#CD004976-bbs2-0012" title="HuttonN , WilsonMH , MellitsED , BaumgardnerR , WissowLS , BonuccelliC , et al.Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. Journal of Pediatrics1991;118(1):125-30. ">Hutton 1991</a>; <a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. ">Montijo‐Barrios 2011</a>); one trial included children aged 2 to 16 years (<a href="./references#CD004976-bbs2-0016" title="Martinez GallardoF , López FiescoA , ZamoraG .Symptomatic treatment of common cold in children with a new combination of naproxen sodium plus pseudoephedrine hydrochloride: a comparative trial against pseudoephedrine syrup. Proceedings of the Western Pharmacology Society1994;37:157-8. ">Martinez 1994</a>), in one trial children were at least four years old (<a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>), in two trials at least six years old (<a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. ">Galvez 1985</a>; <a href="./references#CD004976-bbs2-0022" title="ScavinoY .Combination therapy in patients with the common cold. Current Therapeutic Research1985;38(5):746-54. ">Scavino 1985</a>), and in one trial two to 12 years (<a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>). One trial included adults and children aged 12 years or older (<a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>). </p> <p>The trials took place in a variety of settings, including university clinics, paediatric departments, family medicine departments, and general practice surgeries. Eight trials were multicentre trials. Participants in two trials were experimentally infected with cold viruses, whilst participants in the remaining 28 trials had community‐acquired colds. In most studies the recruitment of the participants was not clearly defined. </p> <p>In the vast majority of trials the inclusion criterion was the presence of common cold symptoms. There was significant diversity amongst trials. In general a minimal score on a symptom severity scale was required. This score was calculated by adding the individual severity scores of a number of typical common cold symptoms such as headache, sneezing, chills, sore throat, nasal discharge, nasal obstruction, cough, and malaise. In two trials the inclusion criterion was the serum neutralising antibody titre (1:2) to the challenge rhinovirus. In one trial the inclusion criterion was the presence of cough attributed to an upper respiratory tract infection. In another study the inclusion criterion was nasal obstruction assessed by rhinomanometry. In yet another trial the inclusion criterion was the presence of congestive rhinitis. </p> <p>In 18 trials respiratory allergy was an explicit exclusion criterion. One trial was conducted outside the pollen season, and another trial excluded participants with recent hay fever. In 10 trials it was unclear whether patients with allergies were excluded. </p> <p>In the majority of trials the duration of symptoms before inclusion was less than 48 hours. In three trials this was up to three days, in two trials up to five days, and in two (paediatric) trials up to seven days. In one paediatric trial this was unclear. In the trials in which participants were experimentally infected with cold viruses, the therapy started 24 and 30 hours after virus challenge. The majority of trials lasted five days, but this varied from single administration to eight days of treatment. Diaries were usually kept for the duration of treatment. The longest follow‐up period was 14 days. </p> <p>Only three trials reported independent financial support. All others were fully or partly supported by pharmaceutical companies by means of grants, supply of study drugs, or other forms of assistance. In 10 trials the source of financial support was not clear. </p> </section> <section id="CD004976-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded 34 trials after detailed assessment, as follows:</p> <p> <ol id="CD004976-list-0004"> <li> <p>the inclusion criteria were not in agreement with our protocol (10 trials) (<a href="./references#CD004976-bbs2-0031" title="AxelssonA , HammerG .Treatment of vasomotor rhinitis with a combined antihistaminic-sympathomimetic preparation. Acta Allergologica1971;26(5):357-62. ">Axelsson 1971</a>; <a href="./references#CD004976-bbs2-0039" title="ConnellJT .Long-acting antihistamine-decongestant evaluation. Archives of Otolaryngology1967;85(2):218-22. ">Connell 1967</a>; <a href="./references#CD004976-bbs2-0040" title="GhorayebN , FissE , De Castro BrandaoD .Evaluation of the clinical efficacy and safety of the use of the association between dipiron, caffeine and clorfeniramine maleate compared to the association of paracetamol, chloridrate of fenilefrine and carbinoxamine maleate on the symptomatic treatment of flu and cold. Revista Brasileira de Medicina2006;63:219-23. ">Ghorayeb 2006</a>; <a href="./references#CD004976-bbs2-0042" title="KaminszczikI , BarbonL .Relieving symptoms of upper respiratory allergies and the common cold: azatadine maleate/pseudoephedrine sulfate syrup versus placebo. Journal of International Medical Research1983;11(2):101-7. ">Kaminszczik 1983</a>; <a href="./references#CD004976-bbs2-0049" title="McLaurinJW , GravesTA , KometH .Efficacy of Actifed as a decongestant. Laryngoscope1966;76(9):1612-4. ">McLaurin 1966</a>; <a href="./references#CD004976-bbs2-0050" title="MoraA , PriegoO , MoralesF , MelgarojoMA .Experiences with a combination of astemizol and pseudoephedrine in the treatment of children with rhinitis [Experiencia en ninos con astemizol combinado con pseudoefedrina en el tratamiento de la rinitis]. Investigacion Medica International1993;20:167-71. ">Mora 1993</a>; <a href="./references#CD004976-bbs2-0054" title="NelsonLS , StoesserAV .An oral combination of antihistamines and nasal decongestants. Minnesota Medicine1970;53(2):149-51. ">Nelson 1970</a>; <a href="./references#CD004976-bbs2-0058" title="PiconPD , CostaMB , da Veiga PiconR , Costa Cabral FendtL , Leichter SuksterisM , Carmanim SaccilottoI , et al.Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial. BMC Infectious Diseases2013;13:556. ">Picon 2013</a>; <a href="./references#CD004976-bbs2-0064" title="TaborelliG , ChierichettiS .New contributions to the symptomatic treatment of non-specific rhinitis and its complications [Nuovo contributo alla terapia sintomatica delle riniti aspecifiche e delle loro complicazioni]. Minerva Otorinolaringologica1975;25:266-77. ">Taborelli 1975</a>; <a href="./references#CD004976-bbs2-0065" title="ToddJK , ToddN , DamatoJ , ToddWA .Bacteriology and treatment of purulent nasopharyngitis: a double blind, placebo-controlled evaluation. Pediatric Infectious Disease Journal1984;3(3):226-32. ">Todd 1984</a>); </p> </li> <li> <p>other interventions were studied (15 trials) (<a href="./references#CD004976-bbs2-0032" title="BachertC , ChuchalinAG , EisebittR , NetayazhenkoVZ , VoelkerM .Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study. Clinical Therapeutics2005;27(7):993-1003. ">Bachert 2005</a>; <a href="./references#CD004976-bbs2-0033" title="BhattacharyaM , JoshiN , YadavS .To compare the effect of dextromethorphan, promethazine and placebo on nocturnal cough in children aged 1-12 y with upper respiratory infections: a randomised controlled trial. Indian Journal of Pediatrics2013;80(11):891-5. ">Bhattacharya 2013</a>; <a href="./references#CD004976-bbs2-0034" title="BonifaciE , Giorgi-ConciatoM , VibelliC .Symptomatic treatment of acute inflammation of the upper respiratory airways in pediatrics. Minerva Pediatrica1970;29(5):285-96. ">Bonifaci 1977</a>; <a href="./references#CD004976-bbs2-0036" title="CartaF .Clinical experience with the vasoconstrictor action of H 1032 on the nasal mucosa. Archivio Italiano di Otologia, Rinologia-Laringologia e Patologia Cervico-facciale1967;78(4):510-9. ">Carta 1967</a>; <a href="./references#CD004976-bbs2-0038" title="CohenHA , HoshenM , GurS , BahirA , LaksY , BlauH .Efficacy and tolerability of a polysaccharide-resin-honey based cough syrup as compared to carbocysteine syrup for children with colds: a randomized, single-blinded, multicenter study. World Journal of Pediatrics2017;13(1):27-33. ">Cohen 2017</a>; <a href="./references#CD004976-bbs2-0041" title="HosseiniF , MahjoubH , AmanatiA , FazlianMM , SedighiI .Comparison of zataria multiflora extract syrup and diphenhydramine in the treatment of common cold-induced cough in children: a double-blind, randomized, clinical trial. Archives of Pediatric Infectious Diseases2016;4(3):e35495. ">Hosseini 2016</a>; <a href="./references#CD004976-bbs2-0043" title="KrishnaprasadK , ManshaniP , KarankumarJ .Health outcome and safety assessment of a fixed dose combination of amantadine, paracetamol, chlorpheniramine maleate, and phenylephrine introduction in India: a prescription event monitoring study. Perspectives in Clinical Research2012;3:62-5. ">Krishnaprasad 2012</a>; <a href="./references#CD004976-bbs2-0044" title="KuspertA .On the vaso-active therapy of the nasal mucosa with a new adrianol-imidazol combination [Über die vasoaktive Therapie der Nasenschleimhaut mit einer neuartigen Adrianol-Imidazolin-Kombination]. Medizinische Welt1965;45:2563-4. ">Kuspert 1965</a>; <a href="./references#CD004976-bbs2-0045" title="LeaP .A double-blind controlled evaluation of the nasal decongestant effect of Day Nurse in the common cold. Journal of International Medical Research1984;12(2):124-7. ">Lea 1984</a>; <a href="./references#CD004976-bbs2-0048" title="MarianoHG , SolomonG , StewardEC , AlbrechtHH .Quality of life in patients taking guaifenesin and pseudoephedrine in an extended-release bi-layer tablet as first-line symptomatic therapy for acute upper respiratory tract infections (URI). Journal of Allergy and Clinical Immunology2011;127(Suppl 2):AB201. [DOI: 10.1016/j.jaci.2010.12.804]">Mariano 2011</a>; <a href="./references#CD004976-bbs2-0056" title="PaulIM , YoderKE , CrowellKR , ShafferML , McMillanHS , CarlsonLC , et al.Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics2004;114(1):e85-90. ">Paul 2004</a>; <a href="./references#CD004976-bbs2-0057" title="PeterM .Treatment of common cold with a new drug Co-Tylenol. Schweizerische Rundschau fur Medizin Praxis1972;61(20):682-3. ">Peter 1972</a>; <a href="./references#CD004976-bbs2-0060" title="SakchainanontB , RuangkanchanasetrS , ChantarojanasiriT , TapasartC , SuwanjuthaS .Effectiveness of antihistamines in common cold. Journal of the Medical Association of Thailand1990;73(2):96-101. ">Sakchainanont 1990</a>; <a href="./references#CD004976-bbs2-0062" title="SchuetzP .Randomized controlled trial: neither ibuprofen nor steam improves symptom control compared with paracetamol in patients with acute respiratory tract infection in primary care. BMJ Evidence-Based Medicine2014;19(3):120. ">Schuetz 2014</a>; <a href="./references#CD004976-bbs2-0063" title="SeptimusEJ , AlbrechtHH , SolomonG , SheaT , GueninEP .Extended-release guaifenesin/pseudoephedrine hydrochloride for symptom relieve in support of a wait-and-see approach for the treatment of acute respiratory tract infections: a randomized, double-blind, placebo-controlled study. Current Therapeutic Research2017;84:54-61. ">Septimus 2017</a>); </p> </li> <li> <p>outcome measures were different (four trials) (<a href="./references#CD004976-bbs2-0035" title="CantekinEI , BluestoneCD , RocketteHE , BeeryQC .Effect of decongestant with or without antihistamine on Eustachian tube function. Annals of Otology, Rhinology, and Laryngology Supplement1980;89(3 Pt 2):290-5. ">Cantekin 1980</a>; <a href="./references#CD004976-bbs2-0059" title="RandallJE , HendleyJO .A decongestant-antihistamine mixture in the prevention of otitis media in children with colds. Pediatrics1979;63(3):483-5. ">Randall 1979</a>; <a href="./references#CD004976-bbs2-0061" title="SchachtelBP , VoelkerM , SannerKM , GagneyD , BeyM , SchachtelE , et al.Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine. Journal of Clinical Pharmacology2010;50:1429-37. ">Schachtel 2010</a>; <a href="./references#CD004976-bbs2-0066" title="VirtanenH .The effect of an oral combined preparation (antihistamine and decongestant) on Eustachian tube function in the common cold. ORL: Journal for Oto-Rhino-Laryngology and its Related Specialties1982;44(5):268-76. ">Virtanen 1982</a>); and </p> </li> <li> <p>the study design was not in agreement with the protocol (five trials) (<a href="./references#CD004976-bbs2-0037" title="ChungBC , KimKW , WooUJ , LeeYS , KimSW , ChoiYH , et al.Clinical effects of SJ-002 URI. Korean Journal of Pharmacology1991;27(2):211-4. ">Chung 1991</a>; <a href="./references#CD004976-bbs2-0046" title="LuC , ZhiqiangH , QinmingH .Studies on simultaneous determination of paracetamol, caffeine and chlorpheniramine maleate in multicomponent cold-curing medicine by GCS. Chinese Journal of Pharmaceutical Analysis1993;13:15-8. ">Lu 1993</a>; <a href="./references#CD004976-bbs2-0047" title="LuQ , for the Clinical Research Coordination Group of Guaifenesin Compound Pseudoephedrine Hydrochloride Oral Solution.A prospective multicenter randomized controlled clinical study on the efficacy and safety of guaifenesin compound pseudoephedrine hydrochloride oral solution. Zhonghua Erke Zazhi2010;48:204-7. ">Lu 2010</a>; <a href="./references#CD004976-bbs2-0055" title="PasottiC , BrembillaE , CorviG .Sequential clinical analysis of a new product with an antirhinitis action. Il Farmaco1966;21(1):40-8. ">Pasotti 1966</a>; <a href="./references#CD004976-bbs2-0067" title="YongSJ , LeeJG .A clinical study of SJ-002. Korean Journal of Pharmacology1991;27(2):207-10. ">Yong 1991</a>). </p> </li> </ol> </p> <p>Five studies were registered as ongoing, but we could not find published data: three studies were withdrawn by the sponsor and have been excluded (<a href="./references#CD004976-bbs2-0051" title="NCT01938144.Evaluation of the efficacy and safety of two ibuprofen combination products for the treatment of the common cold and flu in Latin America. clinicaltrials.gov/ct2/show/nct01938144 (first received 10 September 2013). ">NCT01938144</a>; <a href="./references#CD004976-bbs2-0052" title="NCT02678234.An efficacy and safety study of Theraflu Day Powder as oral solution for cold and flu. clinicaltrials.gov/ct2/show/nct02678234 (first received 9 February 2016). ">NCT02678234</a>; <a href="./references#CD004976-bbs2-0053" title="NCT02730364.An efficacy and safety study of Theraflu Night Powder as oral solution for cold and flu. clinicaltrials.gov/ct2/show/nct02730364 (first received 6 April 2016). ">NCT02730364</a>); one study has been completed and we are awaiting the publication of findings (<a href="./references#CD004976-bbs2-0068" title="NCT02246166.The effect of paracetamol, pseudoephedrine hydrochloride, dextromethorphan hydrobromide and chlorpheniramine maleate tablets compared to placebo in subjects suffering from the common cold or influenza. clinicaltrials.gov/show/nct02246166 (first received 22 September 2014). ">NCT02246166</a>); and one study was registered in 2016 but is planning to start recruitment in 2020 and has been assessed as an ongoing study (<a href="./references#CD004976-bbs2-0069" title="NCT02904304.Desloratadine, phenylephrine Hcl, ibuprofen compared to placebo in treatment of symptoms associated with common cold/flu. clinicaltrials.gov/show/nct02904304 (first received 16 September 2016). ">NCT02904304</a>). We will enter the data in the review as soon as they are available. There was complete agreement amongst the review authors assessing the trials. </p> </section> </section> <section id="CD004976-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the risk of bias assessment is illustrated in <a href="#CD004976-fig-0002">Figure 2</a> and <a href="#CD004976-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD004976-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004976-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004976-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004976-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD004976-sec-0045"> <h4 class="title">Allocation</h4> <p>The method of sequence generation was not described in the majority of the included trials. Only seven trials described the sequence generation, such as the use of a computerised random number generator or envelopes (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a>; <a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a>; <a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a>; <a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. ">Montijo‐Barrios 2011</a>; <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>; <a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>). </p> <p>There was insufficient information regarding allocation concealment in almost all of the included trials, with either no description of the method of concealment or insufficient detail provided to permit a definitive judgement on how concealment was achieved. </p> </section> <section id="CD004976-sec-0046"> <h4 class="title">Blinding</h4> <p>Blinding was poorly reported in most trials. There was insufficient information documented to permit a judgement as to whether blinding was successful. Blinding of study participants and assessors was seldom reported, with only a few trials stating that they were double‐blinded. Only half of the trials reported that the placebo and active drugs were identical in nature. </p> </section> <section id="CD004976-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition and exclusion were adequately addressed across most trials. However, the impact of incomplete data is seldom discussed, thereby making interpretation of the results and assessment of their generalisability difficult. Most trials did not carry out ITT analysis for the clinical outcomes, but reported ITT analysis for adverse events. </p> </section> <section id="CD004976-sec-0048"> <h4 class="title">Selective reporting</h4> <p>Seventeen trials documented their study protocol and reported on their prespecified outcomes. Adverse effects were reported in only a small proportion of the trials, some of which failed to clarify if the adverse reactions were seen in the placebo or treatment group(s). </p> </section> <section id="CD004976-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>It was noted that 12 of the trials were either funded by pharmaceutical companies or that the authors of the trial were employed by a pharmaceutical company with interests in the trial drug. The majority of trials also failed to document the methods used to recruit participants, which could introduce selection bias. </p> </section> </section> <section id="CD004976-sec-0050"> <h3 class="title" id="CD004976-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD004976-tbl-0001"><b>Summary of findings 1</b> Antihistamine‐decongestant compared to placebo for the common cold</a>; <a href="./full#CD004976-tbl-0002"><b>Summary of findings 2</b> Antihistamine‐analgesic compared to placebo for the common cold</a>; <a href="./full#CD004976-tbl-0003"><b>Summary of findings 3</b> Analgesic‐decongestant compared to placebo for the common cold</a>; <a href="./full#CD004976-tbl-0004"><b>Summary of findings 4</b> Antihistamine‐analgesic‐decongestant compared to placebo for the common cold</a> </p> <p>We included 30 trials involving a total of 6304 participants with the common cold including 31 treatment comparisons. The control intervention was placebo in 26 trials and an active substance (paracetamol, chlorphenindione + phenylpropanolamine + belladonna, diphenhydramine) in six trials (two trials had placebo as well as active treatment arms). Fourteen trials studied antihistamine and decongestant combinations (antihistamine‐decongestant); three studied antihistamine and analgesic combinations (antihistamine‐analgesic); six studied analgesic and decongestant combinations (antihistamine‐decongestant); and six studied antihistamine, analgesic, and decongestant combinations (antihistamine‐analgesic‐decongestant). In one trial two different combinations were used: analgesic + antihistamine for nighttime and analgesic + decongestant for daytime. We included the daytime combination in the analgesic‐decongestant group, and the nighttime combination in the antihistamine‐analgesic group. The reporting of methods used was poor in most trials, and there were large differences in trial design, participants, interventions, control conditions, and outcomes. </p> <p>Overall, most combinations had a significant effect on general recovery in adults and older children. Antihistamine‐decongestant odds ratio (OR) of treatment failure was 0.27 (95% confidence interval (CI) 0.15 to 0.50). We could not pool data for the other outcomes. The combinations containing a decongestant also had some effect on nasal obstruction. Rhinorrhoea and cough improved with antihistamine‐decongestant‐analgesic, whilst antihistamine‐decongestant combinations may have some effect on severity of sneezing, but not on the first day of treatment. The size of the effect on specific symptoms, when reported, was less than one severity point on a four‐ or five‐point scale. The combinations containing antihistamine‐decongestant and analgesic‐decongestant had significantly more adverse effects than placebo. Many different adverse effects are mentioned. There is insufficient evidence for the effectiveness (global recovery) in young children. </p> <section id="CD004976-sec-0051"> <h4 class="title">Combination 1: oral antihistamine‐decongestant</h4> <p>Fourteen trials evaluated the effectiveness of oral antihistamine‐decongestant in combination: 12 in adults, and two in children. </p> <section id="CD004976-sec-0052"> <h5 class="title">Short description of the studies</h5> <p><a href="./references#CD004976-bbs2-0001" title="AschanG .Decongestion of nasal mucous membranes by oral medication in acute rhinitis. A rhinomanometric study to demonstrate synergism between antihistamines and adrenergic substance. Acta Otolaryngologica1974;77(6):433-8. ">Aschan 1974</a> studied the effect of promethazine + ephedrine and clemastine + phenylpropanolamine compared to placebo in 60 adults with nasal blockage due to acute rhinitis. Repeated rhinometric recordings at 30‐ to 50‐minute intervals were performed after one dose of the medication. The recordings took place over a nine‐hour period. The effect was evaluated as a positive or negative rhinometric response. </p> <p><a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> treated 261 participants with cold‐like symptoms with loratadine + pseudoephedrine or placebo. Participants kept a diary during the five days of treatment, and scored the overall response and the severity of different symptoms (nasal stuffiness, nasal discharge, sneezing, and cough) daily. The overall response and severity score of the different symptoms were evaluated by the physician on days three and five of treatment. </p> <p><a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a> studied the effect of triprolidine + pseudoephedrine in 199 cold episodes in adults. Some participants were entered several times, having had several cold episodes during the course of the trial. Participants marked the severity of 12 symptoms (e.g. runny nose, sneezing, blocked nose, cough) and seven signs (four of which were possible unwanted adverse effects) on a daily diary card. Treatment was provided for as long as required. An overall assessment was made by the participants 8 to 10 days after the start of treatment.  </p> <p><a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a> studied the effect of dexbrompheniramine maleate + pseudoephedrine in comparison with placebo in 86 adults with symptoms of the common cold. Treatment lasted one week. Symptom severity was scored daily on a five‐point scale in a 14‐day diary. </p> <p><a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a> studied the effect of clemastine + phenylpropanolamine in comparison with belladonna + chlorphenamine + phenylpropanolamine in 40 adults. There was no placebo or 'no treatment' group. The medication was administrated twice daily for eight days. Severity of nasal obstruction, rhinorrhoea (counts of used tissues), and sneezing were assessed daily. Global effectiveness was rated by participants and physicians separately on the last day of treatment. </p> <p><a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. ">Galvez 1985</a> included 60 participants aged six years or older. Almost a quarter of participants were lost to follow‐up. The active treatment consisted of azatadine + dextromethorphan + pseudoephedrine for five days. Effectiveness was evaluated using a sum score of different symptoms including rhinorrhoea, nasal congestion, cough, and sneezing. Individual scores were not provided. Overall therapeutic response was evaluated on days three and five using a five‐point scale (exacerbated/poor/fair/good/excellent). </p> <p><a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. ">Lebacq 1994</a> included 36 participants (18 adults and 18 children aged 6 to 12 years) with acute congestive rhinitis and compared the effect of phenylpropanolamine + carbinoxamine and phenylpropanolamine + pheniramine maleate + mepyramine maleate with placebo on bilateral rhinometry results, the subjective evaluation of nasal congestion, and the aspect of the nasal mucosa. Participants were kept under standardised circumstances for one day, and measurements were performed at different time points after one dose of medication (0.5, 1, 2, 4, 6.5, 11 hours (adults), or 10 hours (children) after medication administration). In children, the treatment was continued over four days, and effectiveness of the combination was assessed by the parents. This trial had methodological problems: the aetiology of congestive rhinitis and duration of symptoms before the start of treatment were unclear; investigators were not blinded; and one of the treatment groups was not masked (combination 2). </p> <p><a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a> studied the effect of the combination of ebastine + pseudoephedrine compared with placebo in 204 participants with the common cold. The medication was administrated once daily for three days. On the last day, a physician evaluated the overall effectiveness, the evolution of the symptoms (runny nose, blocked nose, sneezing), determined nasal peak flow, and estimated the likelihood of the participant to take the medication again. </p> <p><a href="./references#CD004976-bbs2-0022" title="ScavinoY .Combination therapy in patients with the common cold. Current Therapeutic Research1985;38(5):746-54. ">Scavino 1985</a> (in a trial identical to the trial by <a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. ">Galvez 1985</a>) included 58 participants aged six years or older. Ten participants were lost to follow‐up. The active treatment consisted of azatadine + dextromethorphan + pseudoephedrine. Effectiveness was evaluated in the same way as in the Galvez trial. </p> <p><a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a> evaluated the effect of a combination of astemizole + pseudoephedrine in comparison with placebo in 83 participants aged 12 to 65 years. During seven days of treatment the total nasal symptom severity score (nasal discharge, nasal obstruction, sneezing, postnasal drip), total symptom severity score (nasal symptoms plus coughing, sore throat, headache, myalgia, and general discomfort), and adverse effects were recorded daily by a pharmacist co‐investigator. Used nasal tissues were collected and weighed. </p> <p><a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a> studied the effectiveness of dexchlorpheniramine maleate + pseudoephedrine in comparison with placebo in 92 adults with acute rhinitis. Participants registered the mean severity score of nasal obstruction, secretion, itching, and sneezing on a four‐point severity scale (absent, mild, moderate, severe) daily for 10 days. </p> <p><a href="./references#CD004976-bbs2-0012" title="HuttonN , WilsonMH , MellitsED , BaumgardnerR , WissowLS , BonuccelliC , et al.Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. Journal of Pediatrics1991;118(1):125-30. ">Hutton 1991</a> studied brompheniramine + phenylephrine + phenylpropanolamine in comparison with placebo in 54 children aged six months to five years. Evaluation took place 48 hours after the start of treatment. Congested or runny nose was assessed by the parents by means of a four‐point severity scale. </p> <p><a href="./references#CD004976-bbs2-0005" title="ClemensCJ , TaylorJA , AlmquistJR , QuinnHC , MehtaA , NaylorGS .Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children?Journal of Pediatrics1997;130(3):463-6. ">Clemens 1997</a> included 59 children aged six months to five years in a study comparing brompheniramine + phenylpropanolamine with placebo. Parents were asked to evaluate the cold symptoms two hours after the child taking the medication. In total, 175 responses were registered in the 59 children. </p> <p>Finally, the <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a> trial included 60 children aged four years and older. Overall therapeutic response of the combination of azatadine maleate + pseudoephedrine + dextromethorphan was compared with an expectorant containing diphenhydramine. The overall therapeutic response and the change in severity score for symptoms of common cold, including rhinorrhoea, nasal congestion, sneezing, and cough, were rated by a physician on days three and five of treatment. The time of onset of symptomatic relief was noted. </p> </section> <section id="CD004976-sec-0053"> <h5 class="title">Primary outcomes</h5> <section id="CD004976-sec-0054"> <h6 class="title">1. Global evaluation of effectiveness</h6> <section id="CD004976-sec-0055"> <p><b>Adults</b></p> <p>Eight trials evaluating cold episodes assessed the global effectiveness of an oral combination of antihistamine and decongestant on the course of the common cold (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>; <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>; <a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. ">Galvez 1985</a>; <a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>; <a href="./references#CD004976-bbs2-0022" title="ScavinoY .Combination therapy in patients with the common cold. Current Therapeutic Research1985;38(5):746-54. ">Scavino 1985</a>; <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>; <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>). Six trials showed some effect. </p> <p>In <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>, active treatment was significantly more effective on cold symptoms compared to placebo at final evaluation, that is 8 to 10 days after the start of therapy (P &lt; 0.01). In <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>, physicians' scores of overall effectiveness favoured active treatment at both evaluation time points (P = 0.01 and P = 0.02), but participant diary scores favoured active treatment only on day three (P = 0.02). In <a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>, the proportion of participants for whom the investigator scored the effectiveness of the treatment received as good or excellent after three days of therapy was significantly higher in the active treatment group (75.8%) compared to the placebo group (57.6%; P &lt; 0.001). In <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>, the global impression expressed by the participants on day seven favoured the combination, with 55% of participants reporting good to excellent results on astemizole‐pseudoephedrine versus 35% on placebo (P = 0.013). In <a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. ">Galvez 1985</a>, there was a significant difference in the total number of participants evaluated by the physician as having a favourable response (fair to excellent) between the active treatment group and the placebo group (P = 0.014 and P = 0.024) at both evaluation times. In <a href="./references#CD004976-bbs2-0022" title="ScavinoY .Combination therapy in patients with the common cold. Current Therapeutic Research1985;38(5):746-54. ">Scavino 1985</a>, the response was better (fair to excellent) with active treatment compared to placebo (P = 0.010 and P = 0.012) at both evaluation times. The <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a> trial compared two active combinations, finding no difference between the two treatment groups in the number of participants reporting treatment as good or excellent. In <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>, the overall response was rated at day three and on the final visit (day five) by the physician on a four‐point scale. On day three, physicians evaluated the response as good or excellent in 83% of participants in the active treatment group and 7% of participants in the control group (P &lt; 0.001). At day five this was 86% and 30%, respectively (P &lt; 0.001). </p> <p>Six trials reported adequate data to include in a meta‐analysis (<a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>; <a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. ">Galvez 1985</a>; <a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>; <a href="./references#CD004976-bbs2-0022" title="ScavinoY .Combination therapy in patients with the common cold. Current Therapeutic Research1985;38(5):746-54. ">Scavino 1985</a>; <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>; <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>). The pooled odds ratio of therapy failure at final evaluation was 0.31 (odds ratio (OR) 0.31, confidence interval (CI) 0.20 to 0.48; 6 trials, 565 adults; moderate certainty evidence; <a href="./references#CD004976-fig-0004" title="">Analysis 1.1</a>), and the number needed to treat for an additional beneficial outcome (NNTB) was 3.9. We downgraded the certainty of the evidence one level to moderate due to a serious risk of bias. We could not include <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> and <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a> in the meta‐analysis because numerical data were not reported; however, the results of <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> were in line with the other trials, whilst <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a> showed no effect. </p> <p>We therefore concluded that antihistamine‐decongestant combinations have some effect on general recovery compared to placebo. </p> </section> <section id="CD004976-sec-0056"> <p><b>Children</b></p> <p>In <a href="./references#CD004976-bbs2-0012" title="HuttonN , WilsonMH , MellitsED , BaumgardnerR , WissowLS , BonuccelliC , et al.Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. Journal of Pediatrics1991;118(1):125-30. ">Hutton 1991</a>, there was no difference between treatment groups in the number of parents reporting overall improvement (P = 0.74). </p> <p>In <a href="./references#CD004976-bbs2-0005" title="ClemensCJ , TaylorJA , AlmquistJR , QuinnHC , MehtaA , NaylorGS .Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children?Journal of Pediatrics1997;130(3):463-6. ">Clemens 1997</a>, child overall improvement was not an outcome. However, children were more likely to fall asleep within two hours after administration with active treatment, which was considered as a favourable outcome (P = 0.01). </p> </section> </section> <section id="CD004976-sec-0057"> <h6 class="title">2. Adverse effects of treatment</h6> <section id="CD004976-sec-0058"> <p><b>Adults</b></p> <p>Adverse effects were evaluated in eight trials including 1997 cold episodes (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>; <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>; <a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. ">Galvez 1985</a>; <a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>; <a href="./references#CD004976-bbs2-0022" title="ScavinoY .Combination therapy in patients with the common cold. Current Therapeutic Research1985;38(5):746-54. ">Scavino 1985</a>; <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>; <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>). Many different adverse effects were described, such as drowsiness, excessive sleepiness, dry mouth, insomnia, dizziness, palpitations, nervousness, headache, and gastrointestinal upset. </p> <p>The number of trials reporting specific adverse effects is presented in <a href="#CD004976-tbl-0005">Table 1</a>. We pooled data from different trials where possible. Other data are summarised in <a href="#CD004976-tbl-0006">Table 2</a>. </p> <div class="table" id="CD004976-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Combination 1: number of trials reporting specific adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gingival swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004976-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Combination 1: adverse effects data not meta‐analysed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nervousness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 5/133, placebo 3/128; P = 0.51</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 5/133, placebo 2/128; P = 0.45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment: 13/38, placebo 10/35; P = 0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/38, placebo 0/35; P = 0.33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palpitations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/44, placebo 0/48; P = 0.29</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 8/44, placebo 11/48; P = 0.25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a> (comparison of 2 active treatments) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clemastine + phenylpropanolamine (= treatment)<br/>Adverse effects:<br/>Insomnia 4<br/>Sleepiness 0<br/>Dry mouth 4<br/>Dizziness 3<br/>Palpitations 0<br/>Nausea 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belladonna, chlorpheniramine, phenylpropanolamine (= control)<br/>Adverse effects:<br/>Insomnia 3<br/>Sleepiness 5<br/>Dry mouth 7<br/>Dizziness 2<br/>Palpitations 4<br/>Nausea 1 </p> </td> </tr> </tbody> </table> </div> <p> <ul id="CD004976-list-0005"> <li> <p>Total number of participants suffering adverse effects</p> </li> </ul> </p> <p>In seven trials, the total number of participants with one or more adverse effects was provided (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>; <a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. ">Galvez 1985</a>; <a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>; <a href="./references#CD004976-bbs2-0022" title="ScavinoY .Combination therapy in patients with the common cold. Current Therapeutic Research1985;38(5):746-54. ">Scavino 1985</a>; <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>; <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>). A total of 842 participants were evaluated for adverse effects: 419 in the active treatment group, of which 128 (31%) experienced adverse effects, and 423 in the placebo group, of which 100 (24%) experienced adverse effects (OR 1.58, 95% CI 0.78 to 3.21; 7 trials, 842 adults; moderate certainty evidence due to imprecision) (<a href="./references#CD004976-fig-0005" title="">Analysis 1.2</a>). Whilst in six trials adverse effects were more frequent in the active treatment group, in <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>, adverse effects were remarkably more frequent in the placebo group, causing significant heterogeneity. In <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>, which compared two active treatments, 19 of 40 participants experienced adverse effects. </p> <p> <ul id="CD004976-list-0006"> <li> <p>Participants experiencing sedation</p> </li> </ul> </p> <p>In five trials, 692 participants were evaluated for sedation (drowsiness, hypersomnia, excessive sleepiness, asthenia): 345 in the active treatment group, of which 26 (8%) suffered from sedation, and 347 in the placebo group, of which 19 (5%) suffered from sedation (OR 1.38, 95% CI 0.63 to 3.00; 5 studies, 692 adults; <a href="./references#CD004976-fig-0006" title="">Analysis 1.3</a>; low certainty evidence due to imprecision and inconsistency) (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. ">Galvez 1985</a>; <a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>; <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>; <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>). There was significant heterogeneity between the trials. In <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>, five participants treated with the combination containing belladonna experienced sleepiness. </p> <p> <ul id="CD004976-list-0007"> <li> <p>Participants experiencing dry mouth</p> </li> </ul> </p> <p>In four trials, 713 participants were evaluated for dry mouth: 358 in the active treatment group, of which 63 (18%) experienced dry mouth, and 355 in the placebo group, of which 28 (8%) had dry mouth (OR 3.75, 95% CI 1.74 to 8.10; 4 trials, 640 adults; <a href="./references#CD004976-fig-0007" title="">Analysis 1.4</a>; high certainty evidence) (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>; <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>; <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>). Likewise, in <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a>, an increase in dry mouth on days two to nine in the active treatment group was reported. In <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>, 11 of 40 participants experienced dry mouth. </p> <p> <ul id="CD004976-list-0008"> <li> <p>Participants experiencing insomnia</p> </li> </ul> </p> <p>In two trials, 344 participants were evaluated for insomnia (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>). Fifteen of 176 participants in the active treatment group (8.5%) and 5 of 168 participants in the placebo group (3%) experienced insomnia (OR 2.89, 95% CI 0.88 to 9.56; 2 trials, 344 adults; <a href="./references#CD004976-fig-0008" title="">Analysis 1.5</a>; moderate certainty evidence due to imprecision). In <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>, 7 of 40 participants experienced insomnia. </p> <p> <ul id="CD004976-list-0009"> <li> <p>Participants experiencing gastrointestinal upset</p> </li> </ul> </p> <p>In two trials, 296 participants were evaluated for gastrointestinal upset (<a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>; <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>). Six of 144 participants in the active treatment group and two of 152 participants in the placebo group suffered this adverse effect (OR 2.81, 95% CI 0.64 to 12.33; 2 studies, 296 adults; <a href="./references#CD004976-fig-0009" title="">Analysis 1.6</a>; moderate certainty evidence due to imprecision). In <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>, one participant experienced nausea, and in <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a> there was no increase in gastrointestinal upset in the active treatment group. </p> <p> <ul id="CD004976-list-0010"> <li> <p>Participants experiencing dizziness</p> </li> </ul> </p> <p>In <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>, dizziness was evaluated in 261 participants. Five of 133 participants in the active treatment group (3.8%) and 2 of 128 participants in the placebo group (1.6%) experienced dizziness (P = 0.29). In <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a>, an increase in dizziness in the active treatment group was recorded on days five to seven. In <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>, 5 of 40 participants felt dizzy. </p> <p>In conclusion, although the total number of adverse effects was not significantly different between antihistamine‐decongestant combinations and placebo, dry mouth and possibly insomnia occurred more frequently with the active treatment. </p> </section> <section id="CD004976-sec-0059"> <p><b>Children</b></p> <p>In <a href="./references#CD004976-bbs2-0012" title="HuttonN , WilsonMH , MellitsED , BaumgardnerR , WissowLS , BonuccelliC , et al.Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. Journal of Pediatrics1991;118(1):125-30. ">Hutton 1991</a>, the adverse effects sleep disturbance, excessive sleepiness, and vomiting were evaluated, but there was no difference between groups (P &gt; 0.2). </p> </section> </section> </section> <section id="CD004976-sec-0060"> <h5 class="title">Secondary outcomes</h5> <section id="CD004976-sec-0061"> <h6 class="title">1. Decrease in the amount, or duration, of individual common cold symptoms</h6> <section id="CD004976-sec-0062"> <p><b>Nasal symptoms and cough</b></p> <p> <ul id="CD004976-list-0011"> <li> <p>Adults</p> </li> </ul> </p> <p> <ol id="CD004976-list-0012"> <li> <p>Subjective severity assessment of nasal obstruction</p> </li> </ol> </p> <p>Seven trials including a total of 677 participants assessed the effect of antihistamine‐decongestant combinations on the subjective severity of nasal obstruction (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>; <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a>; <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>; <a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. ">Lebacq 1994</a>; <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>; <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>). </p> <p>In <a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. ">Lebacq 1994</a>, parents assessed severity of nasal congestion in their children. There was no significant difference between groups (P values not mentioned) on any of the four treatment days, nor was there any significant difference in nasal congestion between groups in two trials (P values not mentioned) (<a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>; <a href="./references#CD004976-bbs2-0066" title="VirtanenH .The effect of an oral combined preparation (antihistamine and decongestant) on Eustachian tube function in the common cold. ORL: Journal for Oto-Rhino-Laryngology and its Related Specialties1982;44(5):268-76. ">Virtanen 1982</a>). </p> <p>On the other hand, <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a> found significantly less nasal obstruction with active treatment, but only on day one (P value not mentioned). </p> <p>In <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>, the severity scores for nasal obstruction were significantly lower in the active treatment group from day one to day five (exact P value not provided). This was also the case in the <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a> study on days two and three (P &lt; 0.01), four (exact P value not provided), and five (P &lt; 0.01). </p> <p><a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a> showed a significant effect on nasal congestion with active treatment compared with control at both evaluation times (P &lt; 0.001). </p> <p>We could not pool data from these trials because of differences in outcome measures and a lack of adequate data. We summarised the results in <a href="#CD004976-tbl-0007">Table 3</a>. The trials showing no effect had methodological problems (<a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. ">Lebacq 1994</a>); had a small sample size (<a href="./references#CD004976-bbs2-0066" title="VirtanenH .The effect of an oral combined preparation (antihistamine and decongestant) on Eustachian tube function in the common cold. ORL: Journal for Oto-Rhino-Laryngology and its Related Specialties1982;44(5):268-76. ">Virtanen 1982</a>); or compared two active treatments (<a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>). The trials demonstrating some positive effect were larger and of higher methodological quality. Only the size of the effect is reported in <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> (the difference in mean severity score of nasal congestion between groups being at most 0.3 severity points on a four‐point scale). We can conclude that antihistamine + decongestant combinations may have a limited effect on subjective severity of nasal obstruction, but it is not clear whether this is clinically significant. </p> <div class="table" id="CD004976-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Combination 1: results antihistamine‐decongestant</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0001" title="AschanG .Decongestion of nasal mucous membranes by oral medication in acute rhinitis. A rhinomanometric study to demonstrate synergism between antihistamines and adrenergic substance. Acta Otolaryngologica1974;77(6):433-8. "><b>Aschan 1974</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Objective nasal obstruction<br/>Promethazine + ephedrine: pmr 15/15; placebo: pmr 0/15. P &lt; 0.001<br/>Clemastine + phenylpropanolamine: pmr 14/15; placebo: pmr 0/15. P &lt; 0.001<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. "><b>Berkowitz 1989</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>1. Overall response evaluated by physicians on a 4‐point scale: day 3, P = 0.01; day 5, P = 0.02 in favour of active treatment<br/>2. Overall response evaluated by participants on a 4‐point scale: day 3, P = 0.02 in favour of active treatment<br/>No further data available.<br/>b. Subjective severity assessment of nasal obstruction<br/>Mean scores: active treatment/placebo<br/>Day 1: 1.8/2.1<br/>Day 3: 1.7/1.9<br/>Day 3: 1.4/1.7<br/>Day 4: 1.3/1.6<br/>Day 5: 1.2/1.5<br/>P ≤0.05 for all presented days*<br/>c. Rhinorrhoea<br/>Mean scores: active treatment/placebo<br/>Day 1: 1.8/1.9<br/>Day 2: 1.5/1.9, P &lt; 0.05*<br/>Day 3: 1.4/1.5<br/>Day 4: 1.2/1.4, P &lt; 0.05*<br/>Day 5: 1.1/1.3<br/>d. Sneezing<br/>Mean scores: active treatment/placebo<br/>Day 1: 0.9/1<br/>Day 2: 0.6/0.9, P &lt; 0.05*<br/>Day 3: 0.5/0.7, P &lt; 0.05*<br/>Day 4: 0.3/0.6, P &lt; 0.05*<br/>Day 5: 0.3/0.5, P &lt; 0.05*<br/>e. Cough<br/>Mean scores: active treatment/placebo<br/>Day 1: 1.2/1.3<br/>Day 2: 1.2/1.2<br/>Day 3: 1.0/1.1<br/>Day 4: 0.8/1.0<br/>Day 5: 0.8/0.9<br/>No statistically significant difference </p> <p> </p> <p>*Exact P values not provided.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. "><b>Bye 1980</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Severity score significantly reduced on day 1.<br/>b. Rhinorrhoea<br/>Severity score not significantly reduced with active treatment compared with placebo.<br/>c. Sneezing<br/>Severity score of sneezing significantly reduced on days 2, 3, and 4 in the active group in comparison with the placebo group.<br/>d. Cough<br/>Severity score not significantly reduced with active treatment compared with placebo.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0005" title="ClemensCJ , TaylorJA , AlmquistJR , QuinnHC , MehtaA , NaylorGS .Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children?Journal of Pediatrics1997;130(3):463-6. "><b>Clemens 1997</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Proportion of participants with improvement of nasal congestion 2 hours after intake of:<br/>active treatment 41/84 (48.8%); placebo 40/79 (50.6%); P = 0.94<br/>b. Rhinorrhoea<br/>Proportion of participants with improvement of nasal congestion 2 hours after intake of:<br/>active treatment 42/83 (50.6%); placebo 46/80 (57.5%); P = 0.48<br/>Comparison between scores made on 7‐point Likert scale:<br/>active treatment 4.69; placebo 4.76; P = 0.56<br/>c. Cough<br/>Proportion of participants with improvement of nasal congestion 2 hours after intake of:<br/>active treatment 24/49 (49.0%); placebo 28/65 (43.1%); P = 0.66<br/>Comparison between scores made on 7‐point Likert scale:<br/>active treatment 4.67; placebo 4.57; P = 0.53<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. "><b>Curley 1988</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>(1) Graphical display of mean severity score shows a significant difference on:<br/>Day 1: P = 0.01<br/>Day 2: P = 0.05<br/>Day 3: P = 0.01<br/>Day 4: P = 0.01<br/>Day 5: P = 0.01<br/>No further data available.<br/>(2) Prevalence of nasal obstruction after 14 days of treatment:<br/>active treatment 6/38, placebo 20/35. P &lt; 0.001<br/>b. Rhinorrhoea<br/>(1) Graphical display of mean severity score shows a significant difference on:<br/>Day 2: P = 0.05<br/>Day 3: P = 0.01<br/>No further data available.<br/>(2) Prevalence of nasal obstruction after 14 days of treatment:<br/>active group: 14/38; placebo group: 12/35; P = 0.82<br/>c. Cough<br/>(1) Graphical display of mean severity score shows a significant difference on:<br/>Day 3: P = 0.05<br/>Day 4: P = 0.05<br/>Day 5: P = 0.05<br/>No further data available.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0012" title="HuttonN , WilsonMH , MellitsED , BaumgardnerR , WissowLS , BonuccelliC , et al.Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. Journal of Pediatrics1991;118(1):125-30. "><b>Hutton 1991</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>(1) Effect is expressed as "severity score changes" and presented as z‐score: negative z‐score means "less than average improvement", positive z‐score means "more than average improvement".<br/>z‐score on "congested and runny nose":<br/>active treatment −0.166, placebo +0.194; difference not significant<br/>(2) Number of parents reporting "improvement" of runny or congested nose:<br/>active treatment: 16/30; placebo 19/24; P = 0.05<br/>b. Rhinorrhoea<br/>(1) Effect is expressed as "severity score changes" and presented as z‐score: negative z‐score means "less than average improvement", positive z‐score means "more than average improvement".<br/>z‐score on "congested and runny nose":<br/>active treatment −0.166, placebo +0.194; difference not significant<br/>(2) Number of parents reporting "improvement" of runny or congested nose:<br/>active treatment: 16/30; placebo 19/24; P = 0.05<br/>c. Cough<br/>(1) Effect is expressed as "severity score changes" and presented as z‐score: negative z‐score means "less than average improvement", positive z‐score means "more than average improvement".<br/>z‐score on "cough":<br/>active treatment +0.024, placebo −0.058; difference not significant<br/>(2) Number of parents reporting "improvement" of cough:<br/>active treatment 20/30; placebo 14/24; not statistically significant<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. "><b>Lebacq 1994</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Objective nasal obstruction<br/>Nasal resistance as percentage of pre‐value<br/>P (placebo) (n = 6), A1 (combination 1) (n = 6), A2 (combination 2) (n = 6)<br/>Adult:<br/>0.5 h postdose: P 116%; A1 61% (P &lt; 0.05)*; A2 106%<br/>1 h postdose: P 96%; A1 52% (P &lt; 0.05)*; A2 96%<br/>2 h postdose: P 100%; A1 58% (P &lt; 0.05)*; A2 81%<br/>4 h postdose: P 103%; A3 77%; A2 83%<br/>6.5 h postdose: P 100%; A1 72%; A2 77%<br/>11 h postdose: P 96%; A1 69%; A2 76%<br/>*Significantly different from placebo<br/>Children:<br/>0.5 h postdose: P 96%; A1 63%; A2 115%<br/>1 h postdose: P 68%; A1 70%; A2 99%<br/>2 h postdose P 60%; A1 75%; A2 112%<br/>4 h postdose: P 103%; A3 77%; A2 83%<br/>6.5 h postdose: P 64%, A1 78%; A2 97%<br/>11 h postdose: P 65%; A1 72%; A2 99%<br/>No significant difference<br/>b. Subjective severity assessment of nasal obstruction<br/>Severity assessment is presented in 6 scores on a 3‐point scale. There was no difference between treatment groups. We show (as an example) results of 1 evaluation point (2 hours after intake of medication).<br/>Median score<br/>1. adults, 2. children<br/>Placebo (n = 6) 2; placebo (n = 6) 2<br/>A1 (n = 6) 2; A1 (n = 6) 1.5<br/>A2 (n = 6) 2; A5 (n = 6) 2<br/>A1 = combination 1, A2 = combination 2<br/>c. Effects assessed by anterior rhinoscopia<br/>Rhinoscopia results are presented as median of 6 scores on a 3‐point scale. There was no difference between treatment groups. We show (as an example) results of 1 evaluation point (2 hours after intake of medication).<br/>Median score<br/>1. adults 2. children<br/>Placebo (n = 6) 2; placebo (n = 6) 1.5<br/>A1 (n = 6) 2; A1 (n = 6) 1<br/>A2 (n = 6) 2; A5 (n = 6) 1.5<br/>A1 = combination 1, A2 = combination<br/>* Exact P‐value not provided. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. "><b>Robert 2004</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Evaluation of overall efficacy was made by the investigators on a 4‐point scale. Percentage of participants rating "good" or "excellent" was 75.8% (n = 100) for the treatment group and 57.6% (n = 104) for the control group (P &lt; 0.001)*.<br/>b. Objective nasal obstruction<br/>In the "Results" chapter of the paper it is reported that no differences were observed between treatment and placebo groups regarding an increase of mean values for nasal peak flow carried out before and after 3 days of treatment.<br/>  </p> <p>* Exact P‐value not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. "><b>Virtanen 1983</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Graphical presentation of mean severity scores of nasal obstruction register during 10 days (treatment on first 5 days) shows no significant difference between treatment groups. No further data available.<br/>b. Rhinorrhoea<br/>Graphical presentation of mean severity scores of nasal obstruction register during 10 days (treatment on first 5 days) shows no significant difference between treatment groups, except for day 3 (P &lt; 0.05)*.<br/>No further data presented.<br/>c. Sneezing<br/>Graphical presentation of mean severity scores of nasal obstruction register during 10 days (treatment on first 5 days) shows a significant difference between treatment groups on:<br/>Day 2, P &lt; 0.05*<br/>Day 3, P &lt; 0.001<br/>Day 4, P &lt; 0.01*<br/>Day 5, P &lt; 0.001<br/>Day 6, P &lt; 0.01*<br/>Day 7, P &lt; 0.01*<br/>Day 8, P &lt; 0.05* </p> <p> </p> <p>* Exact P‐value not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. "><b>Weippl 1984</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Overall therapeutic response was rated by the physician on a 5‐point scale (excellent, good, fair, poor, exacerbated) on days 3 and 5:<br/>Day 3: percentage of "good" or "excellent" responses: therapeutic group 83% (24/29), placebo group 7% (2/27) (P &lt; 0.01)*<br/>Day 5: percentage of "good" or "excellent" responses: therapeutic group 86% (25/29), placebo group 30% (8/27) (P &lt; 0.01)*<br/>b. Cough<br/>Statistically significant improvement (P = 0.05) at the interim visit </p> <p>c. Significantly greater improvement at both visits (P &lt; 0.001)* in rhinorrhoea, nasal congestion, and sneezing. No further data presented.<br/>  </p> <p>* Exact P‐value not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. "><b>Galvez 1985</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Physician's evaluation of overall therapeutic response on a 6‐point scale (difference given by the percentage of participants responding "good" or "excellent" on the medication):<br/>Day 3: treatment group 60%, placebo group 8%, P &lt; 0.01*<br/>Day 5: treatment group 77%, placebo group 21%, P &lt; 0.01*<br/>  </p> <p>* Exact P‐value not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0022" title="ScavinoY .Combination therapy in patients with the common cold. Current Therapeutic Research1985;38(5):746-54. "><b>Scavino 1985</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Overall therapeutic response evaluated by a physician on a 4‐point scale (excellent, good, fair, poor, exacerbated) on days 3 and 5:<br/>Day 3: percentage of participants responding "good" or "excellent": therapeutic group 76%, placebo group 17% (P &lt; 0.01)*<br/>Day 5: percentage of participants responding "good" or "excellent": therapeutic group 88%, placebo group 48% (P &lt; 0.01)*<br/>b. Cough<br/>Evaluation of the percentage of improvement from the baseline score on days 3 and 5:<br/>Day 3: active treatment 54%, placebo 24%<br/>Day 5: active treatment 90%, placebo 60%<br/>  </p> <p>* Exact P‐value not provided.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>P: placebo<br/>pmr: positive manometric result </p> </div> </div> <p> <ol id="CD004976-list-0013"> <li> <p>Rhinorrhoea</p> </li> </ol> </p> <p>Seven trials including a total of 877 cold episodes assessed the effect of an antihistamine‐decongestant combination on rhinorrhoea (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>; <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a>; <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>; <a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>; <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>; <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>). </p> <p>Two trials evaluated rhinorrhoea objectively by counting used tissues, <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>, or by weighing the used tissues (<a href="./references#CD004976-bbs2-0023" title="SchrootenP , LaekemanG , VosP , De MunckG .Community pharmacists as clinical investigators in the self medication area: a double-blind, placebo-controlled study with astemizole-D in the common cold. International Pharmacy Journal1993;7:147-50. ">Schrooten 1993</a>). No difference between groups was found. </p> <p>Five other trials evaluated rhinorrhoea using a subjective severity score. In <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>, no effect of active treatment was noted. In <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>, severity scores for rhinorrhoea were significantly lower in the active treatment group on day two (exact P value not provided) and four (exact P value not provided), but not on days one, three, and five. In <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a>, severity scores for rhinorrhoea were significantly lower in the active treatment group on day two (exact P value not provided) and three (P &lt; 0.01), but not on days one, four and five. In <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>, severity scores for rhinorrhoea were significantly lower in the active treatment group on day three (exact P value not provided), but not on the other nine observation days. Finally, in <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>, there was a significant effect on rhinorrhoea with active treatment compared with control at both evaluation times (P &lt; 0.001). </p> <p>Pooling was not possible. The available results are summarised in <a href="#CD004976-tbl-0007">Table 3</a>. The size of the effect on nasal discharge was reported in only one of the trials with a positive result: in <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> the difference in mean severity score between groups is at most 0.3 severity point on a four‐point scale. We can conclude that although we cannot exclude a small effect on rhinorrhoea on some days of treatment with a combination of antihistamine + decongestant, a clinically relevant effect is unlikely. </p> <p> <ol id="CD004976-list-0014"> <li> <p>Sneezing</p> </li> </ol> </p> <p>Sneezing was investigated in five trials including a total of 718 cold episodes (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>; <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a>; <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>; <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>). There was some effect in four trials (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>; <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>; <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>). In <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>, severity scores for sneezing were significantly lower with active treatment from day two until day five (exact P value not provided). In <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>, severity scores for sneezing were significantly lower with active treatment on days two, three, and four (no P values mentioned). In <a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a>, severity scores for sneezing were significantly lower with active treatment on days two to eight (day two: exact P value not provided; day three: P &lt; 0.001; day four P &lt; 0.01; days six and seven: P &lt; 0.01; and day eight: exact P value not provided). <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a> mentions a significant effect on sneezing with active treatment compared with control at both evaluation times (P &lt; 0.001). <a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a> compared two active combinations and found no difference between groups. </p> <p>Pooling of results was not possible. All available data are presented in <a href="#CD004976-tbl-0007">Table 3</a>. All trials in which this symptom was evaluated found some effect of the active treatment in comparison with placebo. However, the size of the effect was reported in only one trial: in <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>, the difference in mean severity score between groups is at most 0.3 severity point on a four‐point scale. We can tentatively conclude that a combination of antihistamine‐decongestant has some effect on sneezing, but the effect is small and probably not clinically relevant. </p> <p> <ol id="CD004976-list-0015"> <li> <p>Cough</p> </li> </ol> </p> <p>Four trials including a total of 672 cold episodes evaluated the effect of an antihistamine‐decongestant combination on the severity of cough (<a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>; <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>; <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a>; <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>). Neither <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> nor <a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a> found any significant difference in severity of cough between the active treatment group and the control group. In <a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a>, the mean severity score for cough was significantly less on days three, four, and five (exact P value not provided). In the paediatric trial by <a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. ">Weippl 1984</a>, there was an improvement of cough at the interim visit in comparison to control (P = 0.03); however, the active treatment also contained dextromethorphan. Pooling was not possible. All available data are represented in <a href="#CD004976-tbl-0007">Table 3</a>. Results from these four trials are conflicting, precluding the drawing of any conclusions about the effectiveness of antihistamine‐decongestant combinations on cough. </p> </section> <section id="CD004976-sec-0063"> <p><b>Children</b></p> <p>In <a href="./references#CD004976-bbs2-0012" title="HuttonN , WilsonMH , MellitsED , BaumgardnerR , WissowLS , BonuccelliC , et al.Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. Journal of Pediatrics1991;118(1):125-30. ">Hutton 1991</a>, there was no difference between groups in the improvement of symptoms (P = 0.51). In <a href="./references#CD004976-bbs2-0005" title="ClemensCJ , TaylorJA , AlmquistJR , QuinnHC , MehtaA , NaylorGS .Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children?Journal of Pediatrics1997;130(3):463-6. ">Clemens 1997</a>, there was no difference between groups in the proportion of responses reporting an improvement in runny nose or nasal congestion (P = 0.54 and P = 0.94, respectively). </p> </section> </section> <section id="CD004976-sec-0064"> <h6 class="title">2. Objective assessments (rhinomanometry, rhinoscopy)</h6> <p><a href="./references#CD004976-bbs2-0001" title="AschanG .Decongestion of nasal mucous membranes by oral medication in acute rhinitis. A rhinomanometric study to demonstrate synergism between antihistamines and adrenergic substance. Acta Otolaryngologica1974;77(6):433-8. ">Aschan 1974</a> recorded positive rhinomanometric changes in nasal patency in 24 of 30 participants after a single dose of the active treatment. There were no positive changes with placebo (P &lt; 0.001). In <a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. ">Lebacq 1994</a>, phenylpropanolamine + carbinoxamine had some effect on nasal resistance in adult participants 30 minutes to two hours after intake of medication (exact P value not mentioned), but there was no effect in children. The combination of phenylpropanolamine + pheniramine maleate + mepyramine maleate was ineffective. In <a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>, participants' peak nasal flow was evaluated before and after three days of treatment. No clear difference was seen between the active treatment and placebo. Pooling of results was not possible because different outcome measures were used. Results are presented in <a href="#CD004976-tbl-0007">Table 3</a>. Two trials showed positive results in objective nasal patency (<a href="./references#CD004976-bbs2-0001" title="AschanG .Decongestion of nasal mucous membranes by oral medication in acute rhinitis. A rhinomanometric study to demonstrate synergism between antihistamines and adrenergic substance. Acta Otolaryngologica1974;77(6):433-8. ">Aschan 1974</a>; <a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. ">Lebacq 1994</a>); these trials had small sample sizes and took place in an experimental setting. One study had serious methodological problems (<a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. ">Lebacq 1994</a>). The third trial took place in a clinical setting and had a much larger sample size (<a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. ">Robert 2004</a>). This trial showed no effect. We can therefore conclude that antihistamine + decongestant combinations probably have no effect on objectively measured nasal patency in clinical circumstances, although there may be some effect in experimental settings. </p> <p>Effect on results on anterior rhinoscopy: in <a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. ">Lebacq 1994</a>, the condition of the nasal mucosa was assessed at different time points using a four‐point scale (normal, red, violet, blue). There was no difference in the aspect of the nasal mucosa between groups (<a href="#CD004976-tbl-0007">Table 3</a>). In <a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a>, physicians assessed severity of swelling and hyperaemia on days three and five of treatment, and found no significant differences between groups. </p> </section> </section> </section> <section id="CD004976-sec-0065"> <h4 class="title">Combination 2: oral antihistamine‐analgesic combinations</h4> <section id="CD004976-sec-0066"> <h5 class="title">Short description of the studies</h5> <p><a href="./references#CD004976-bbs2-0011" title="Gwaltney JM Jr, WintherB , PatrieJT , HendleyJO .Combined antiviral-antimediator treatment for the common cold. Journal of Infectious Diseases2002;186(2):147-54. ">Gwaltney 2002</a> studied the effects of chlorpheniramine + ibuprofen + intranasal interferon and chlorpheniramine + ibuprofen in comparison with placebo in 150 adult participants with experimental rhinovirus infection. Participants received treatment for 4.5 days, and effectiveness was evaluated by recording daily subjective severity of nasal symptoms. We considered the comparison chlorpheniramine + ibuprofen versus placebo in the review. </p> <p><a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a> included 1167 adult cold participants and assessed the effect of Grippostad, a combined formulation of acetaminophen + caffeine + chlorpheniramine + ascorbic acid in comparison with two references (chlorpheniramine + ascorbic acid and acetaminophen + caffeine + ascorbic acid) and ascorbic acid. Treatment was administered for six days. Participants assessed the severity of their cold symptoms daily, and sum scores were calculated. Data for individual symptoms were not provided. At the end of the treatment period a final global evaluation of effectiveness was made by the participant and the investigator. The proportion of the participants cured was also assessed. We considered the comparison between Grippostad and ascorbic acid (582 participants) in the review. </p> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> included 191 participants and assessed the effectiveness of Benylin Day and Night, a combined formulation consisting of two different combinations of active substances: Benylin Day (paracetamol + phenylpropanolamine) and Benylin Night (paracetamol + diphenhydramine hydrochloride) in comparison to paracetamol. During the five days of treatment, participants reported severity scores for cold symptoms daily including runny nose, nasal congestion, and cough. On day five a final global evaluation was made by physicians and participants (for day and night separately). </p> <p><a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. ">Montijo‐Barrios 2011</a> included 100 children aged 6 to 24 months and compared a combination of buphenine, aminophenazone, and diphenylpyraline (n = 57) to placebo (n = 43). Both groups also received paracetamol. As an outcome they compared the proportion of children at day three, five, and seven with rhinorrhoea, sneezing more than six times per day, moderate to severe irritability, difficulty with eating, noisy breathing, breathing through the mouth, significant tearing, and fever episodes. The amount of milk consumption and the number of hours of sleep during daytime and nighttime were also compared. </p> </section> <section id="CD004976-sec-0067"> <h5 class="title">Primary outcomes</h5> <section id="CD004976-sec-0068"> <h6 class="title">1. Global evaluation of effectiveness</h6> <p>Two trials including a total of 773 participants assessed the global effectiveness of antihistamine + analgesic in the common cold (<a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a>; <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>). </p> <p>In <a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a>, the proportion of participants who were completely cured at the end of the trial was 70% with Grippostad and 43% with the control (ascorbic acid). This difference was significant (OR 0.33, 95% CI 0.23 to 0.46; 582 adults; moderate certainty evidence due to risk of bias). In <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>, overall subjective assessment was measured at the end of the study by asking "on the whole do you think the tablets have helped you?". Significantly more participants receiving the active nighttime medication compared with the control group (paracetamol) responded affirmatively to the question: 73% versus 52% (OR 0.35, 95% CI 0.18 to 0.70; 191 adults; moderate certainty evidence).   </p> <p>We did not pool these data because one of the trials used an active control (<a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a>). As both trials had a favourable result, we can conclude that antihistamine‐analgesic combinations may have a positive effect on subjective general recovery. </p> </section> <section id="CD004976-sec-0069"> <h6 class="title">2. Adverse effects of treatment</h6> <p>All trials reported adverse effects (<a href="./references#CD004976-bbs2-0011" title="Gwaltney JM Jr, WintherB , PatrieJT , HendleyJO .Combined antiviral-antimediator treatment for the common cold. Journal of Infectious Diseases2002;186(2):147-54. ">Gwaltney 2002</a>; <a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a>; <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>; <a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. ">Montijo‐Barrios 2011</a>). Many different adverse effects were described: nasal dryness, nasal irritation, blood‐stained nasal mucus, drowsiness, dry mouth, gastrointestinal upset, loss of appetite, headache, depression, and dizziness. Most of the adverse effects were rare and mentioned in only one trial (<a href="#CD004976-tbl-0008">Table 4</a>; <a href="#CD004976-tbl-0009">Table 5</a>). </p> <div class="table" id="CD004976-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Combination 2: number of trials reporting a specific adverse effect</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004976-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Combination 2: adverse effects data not meta‐analysed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 2/91, placebo 2/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 6/91, placebo 5/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/91, placebo 1/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In all trial groups (n = 1167), 39 participants reported an adverse effects.</p> </td> </tr> </tbody> </table> </div> <section id="CD004976-sec-0070"> <p><b>Total number of participants suffering adverse effects</b></p> <p>In <a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a>, 39 of 1167 participants reported an adverse effect. There were no differences between groups. In <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>, both combinations (day and night) were evaluated together: 11 of 79 participants receiving paracetamol and nine of 82 participants receiving the active treatment mentioned adverse effects (P = 0.57). <a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. ">Montijo‐Barrios 2011</a> did not report adverse effects. </p> </section> <section id="CD004976-sec-0071"> <p><b>Participants suffering drowsiness</b></p> <p>In <a href="./references#CD004976-bbs2-0011" title="Gwaltney JM Jr, WintherB , PatrieJT , HendleyJO .Combined antiviral-antimediator treatment for the common cold. Journal of Infectious Diseases2002;186(2):147-54. ">Gwaltney 2002</a>, five of 61 participants receiving the active treatment and 0 of 30 participants receiving placebo experienced drowsiness (P = 0.03). In <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>, drowsiness was mentioned by five participants receiving paracetamol and four participants receiving the combination therapy (P = 0.68). After pooling, 7% of participants receiving the combination therapy and 3% of participants receiving placebo or paracetamol suffered from drowsiness (OR 1.64, 95% CI 0.48 to 5.59; 2 studies, 272 adults; low certainty evidence; <a href="./references#CD004976-fig-0010" title="">Analysis 2.1</a>). </p> <p>Other adverse effects were very rare, and there were no differences between treatment groups (<a href="#CD004976-tbl-0009">Table 5</a>). We can conclude that the combination of antihistamine with analgesics is generally well tolerated. </p> </section> </section> </section> <section id="CD004976-sec-0072"> <h5 class="title">Secondary outcomes</h5> <section id="CD004976-sec-0073"> <h6 class="title">1. Decrease in the amount, or duration, of individual common cold symptoms</h6> <p>Three trials assessed the effect of an antihistamine‐analgesic combination on the subjective severity of nasal obstruction, rhinorrhoea, and cough (<a href="./references#CD004976-bbs2-0011" title="Gwaltney JM Jr, WintherB , PatrieJT , HendleyJO .Combined antiviral-antimediator treatment for the common cold. Journal of Infectious Diseases2002;186(2):147-54. ">Gwaltney 2002</a>; <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>; <a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. ">Montijo‐Barrios 2011</a>). The symptoms were evaluated daily for five days in two trials (<a href="./references#CD004976-bbs2-0011" title="Gwaltney JM Jr, WintherB , PatrieJT , HendleyJO .Combined antiviral-antimediator treatment for the common cold. Journal of Infectious Diseases2002;186(2):147-54. ">Gwaltney 2002</a>; <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>). Both trials failed to show a significant effect of the active treatment compared with placebo or paracetamol on mean severity scores for nasal obstruction, rhinorrhoea, and cough. <a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. ">Montijo‐Barrios 2011</a> evaluated rhinorrhoea, noisy breathing, and mouth breathing on days three, five, and seven, and found a significant difference in the proportion of children experiencing these symptoms between groups (<a href="#CD004976-tbl-0010">Table 6</a>). </p> <div class="table" id="CD004976-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Combination 2: results antihistamine‐analgesic</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0011" title="Gwaltney JM Jr, WintherB , PatrieJT , HendleyJO .Combined antiviral-antimediator treatment for the common cold. Journal of Infectious Diseases2002;186(2):147-54. "><b>Gwaltney 2002</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Comparisons between baseline ‐ adjusted mean daily symptom scores on days 2 to 5 mentioned in a table. Treatment with oral chlorpheniramine and ibuprofen showed no significant effect on nasal congestion scores on any day during treatment. </p> <p>Day 2: 1.0<br/>Day 3: 1.0<br/>Day 4: 1.6<br/>Day 5: 1.7<br/>b. Rhinorrhoea<br/>Comparisons between baseline ‐ adjusted mean daily symptom scores on days 2 to 5 mentioned in a table. Treatment with oral chlorpheniramine and ibuprofen showed no significant effect on rhinorrhoea scores on any day during treatment.<br/>Day 2: 1.9<br/>Day 3: 1.1<br/>Day 4: 1.7<br/>Day 5: 1.15<br/>c. Sneezing<br/>Comparisons between baseline ‐ adjusted mean daily symptom scores on days 2 to 5 mentioned in a table. Treatment with oral chlorpheniramine and ibuprofen showed a significant effect on sneezing scores only on day 5 of treatment.<br/>Day 2: 2.0<br/>Day 3: 3.2<br/>Day 4: 2.3<br/>Day 5: 6.2; statistically significant (P &lt; 0.05*)<br/>d. Cough<br/>Comparisons between baseline ‐ adjusted mean daily symptom scores on days 2 to 5 mentioned in a table. Treatment with oral chlorpheniramine and ibuprofen showed no significant effect on cough scores on any day during treatment.<br/>Day 2: 3.0<br/>Day 3: 1.8<br/>Day 4: 2.1<br/>Day 5: 1.8 </p> <p> </p> <p>*Exact P values not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. "><b>Koytchev 2003</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>The proportion of participants who were completely cured at the end of the trial:<br/>treatment group: 70%;<br/>control group and reference 1 group: 43% to 45%.<br/>b. Subjective severity assessment of nasal obstruction<br/>Comparison of the subscore referring to blocked nose, cough, and disturbance of sleep quality was performed between the group of participants receiving the active treatment and the group receiving the reference 2. The difference was statistically significant (P &lt; 0.05*). No further data available.<br/>c. Cough<br/>Comparison of the subscore referring to blocked nose, cough, and disturbance of sleep quality was performed between the group of participants receiving the active treatment and the group receiving the reference 2. The difference was statistically significant (P &lt; 0.05*). No further data available. </p> <p> </p> <p>*Exact P values not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '><b>Middleton 1981</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Overall subjective assessment was made after asking the participant the question: "On the whole do you think the tablets have helped you?".<br/>  </p> <p> </p> <p>Daytime:</p> <p>Response<br/>Control Treatment<br/>Yes 47 66<br/>No 52 25<br/>Compared with the control group, a statistically significantly larger number of participants receiving the active medication responded affirmative to the question (P &lt; 0.01*).<br/>b. Subjective severity assessment of nasal obstruction<br/>No significant difference reported between the active substance and placebo in treating nasal congestion.<br/>The results are mentioned in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>c. Rhinorrhoea<br/>No significant difference reported between the active substance and placebo in treating rhinorrhoea.<br/>The results are mentioned in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>d. Sneezing<br/>No significant difference reported between the active substance and placebo in treating sneezing.<br/>The results are mentioned in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>e. Cough<br/>No significant difference reported between the active substance and placebo in treating cough.<br/>The results are mentioned in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>  </p> <p>*Exact P values not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. "><b>Montijo‐Barrios 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DAY 3</p> <p>Active (%) placebo (%)</p> <p>Moderate to severe rhinorrhoea………………….48…………….43 P &lt; 0.05*</p> <p>At least 6/day sneezing…………….……………28………….….28</p> <p>Moderate to severe irritability……………………23……….…….17</p> <p>Difficulty eating…………………………………..32…………..…..37</p> <p>Noisy breathing……………………………………48……….…….41</p> <p>Breathing through mouth……………………….39……………….24 P &lt; 0.01*</p> <p>Significant tearing…………………………………27……………..11 P &lt; 0.01*</p> <p>Fever………………………………………………9…………….…..6</p> <p>Milk consumption (ounces)……………………..18 +/−11…..……18+/−12</p> <p>Number of hours of sleep (daytime)……....….3+/−2…….….....2+/−2</p> <p>Number of hours of sleep (nighttime)…..........9+/−2………...…9+/−2</p> <p> </p> <p>DAY 5</p> <p>Moderate to severe rhinorrhoea………………….48……………….11 P &lt; 0.01*</p> <p>Moderate to severe irritability……………………17…………………9 P &lt; 0.05*</p> <p>Breathing through mouth….…………….………26…………....….16 P &lt; 0.05*</p> <p>Significant tearing……….….……………………27………………..11 P &lt; 0.05*</p> <p>(other symptoms: no significant difference)</p> <p> </p> <p>DAY 7</p> <p>Moderate to severe rhinorrhoea………………….22……………….4 P &lt; 0.01*</p> <p>Difficulty eating……………………….…………..11………………..5 P &lt; 0.05*</p> <p>Breathing through mouth………….…………….16……………….7 P&lt; 0.05*</p> <p>(other symptoms: no significant difference)</p> <p> </p> <p>*Exact P values not provided.</p> </td> </tr> </tbody> </table> </div> <p>Severity of sneezing was studied in <a href="./references#CD004976-bbs2-0011" title="Gwaltney JM Jr, WintherB , PatrieJT , HendleyJO .Combined antiviral-antimediator treatment for the common cold. Journal of Infectious Diseases2002;186(2):147-54. ">Gwaltney 2002</a>. The baseline adjusted mean severity score was significantly lower in the active treatment group, but only on the fifth day of therapy. <a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. ">Montijo‐Barrios 2011</a> did not find a difference between groups for sneezing (<a href="#CD004976-tbl-0010">Table 6</a>). </p> <p>Pooling of data was not possible. Results are summarised in <a href="#CD004976-tbl-0010">Table 6</a>. Based on these results we can conclude that a combination of antihistamines and analgesic probably has no effect on nasal symptoms or cough in adults. We have very weak evidence that there is some effect on nasal symptoms in small children. </p> </section> <section id="CD004976-sec-0074"> <h6 class="title">2. Objective assessments</h6> <p>Not evaluated.</p> </section> </section> </section> <section id="CD004976-sec-0075"> <h4 class="title">Combination 3: oral decongestant‐analgesic combinations</h4> <section id="CD004976-sec-0076"> <h5 class="title">Short description of the studies</h5> <p><a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a> examined the effectiveness of a combination of pseudoephedrine + paracetamol in comparison to placebo, pseudoephedrine, or paracetamol in monotherapy (four study arms). The study included a total of 305 participants with a natural cold. Participants had symptomatic upper respiratory tract infection with pain of at least moderate intensity and nasal obstruction measurable by rhinomanometry. Effectiveness of treatment on nasal obstruction was assessed during the first four hours after administration of one dose by rhinomanometry, during the next three days of treatment by subjective assessment of nasal congestion, and finally by a global assessment of nasal congestion relief at the follow‐up visit after three days of therapy. </p> <p><a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a> examined the effectiveness of a combination of pseudoephedrine + acetylsalicylic acid in comparison to placebo, pseudoephedrine, acetylsalicylic acid in monotherapy (four study arms). The study included a total of 883 participants with a natural cold. Inclusion criteria and methodology were similar to <a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a>. </p> <p><a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a> studied the effect of a single‐dose acetylsalicylic acid + pseudoephedrine and pseudoephedrine + paracetamol compared to placebo in 643 adults with a cold and nasal congestion for five days. Outcomes were the change in nasal congestion score (on an 11‐point scale for severity of nasal congestion) and change in the subjective severity of nasal congestion two, four, and six hours after the ingestion of the study medication. </p> <p><a href="./references#CD004976-bbs2-0016" title="Martinez GallardoF , López FiescoA , ZamoraG .Symptomatic treatment of common cold in children with a new combination of naproxen sodium plus pseudoephedrine hydrochloride: a comparative trial against pseudoephedrine syrup. Proceedings of the Western Pharmacology Society1994;37:157-8. ">Martinez 1994</a> investigated the effectiveness of naproxen + pseudoephedrine compared to pseudoephedrine and placebo in 65 paediatric participants aged 2 to 16 years. Treatment was administrated three times daily for five days in different concentrations, depending on the age of the child. The duration of nasal symptoms (nasal oedema and nasal congestion) was evaluated at the end of the study. </p> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> included 191 participants and studied the effectiveness of Benylin Day and Night, a combined formulation consisting of two different combinations of active substances: Benylin Day (paracetamol + phenylpropanolamine) and Benylin Night (paracetamol + diphenhydramine hydrochloride) compared to paracetamol. This trial was described in the previous section; we considered the day combination here. </p> <p>In <a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a>, 58 participants developed a cold after experimental virus inoculation. They were kept under observation until six days after inoculation and treated with a combination of pseudoephedrine + ibuprofen, or pseudoephedrine or placebo. Subjective severity of cold symptoms (runny nose, nasal obstruction, sneezing, cough) were evaluated daily. Rhinorrhoea was further evaluated by weighing used tissues. Nasal congestion was measured by anterior rhinometry. We considered the comparison between pseudoephedrine + ibuprofen and placebo in the review. </p> <p>In <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>, the effectiveness of two doses (the second dose administered six hours after the first) of pseudoephedrine + paracetamol was compared with placebo in 430 adult participants with a natural cold. Participants were evaluated two hours after each administration. The effectiveness of the treatment was measured against the subjective severity of common cold symptoms (nasal obstruction, sneezing, cough, rhinorrhoea) and was assessed using a five‐point severity scale. </p> </section> <section id="CD004976-sec-0077"> <h5 class="title">Primary outcomes</h5> <section id="CD004976-sec-0078"> <h6 class="title">1. Global evaluation of effectiveness</h6> <p>Only one trial assessed overall subjective effectiveness at the end of the study by asking "on the whole do you think the tablets have helped you?" (<a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>). Significantly more participants receiving the active daytime medication compared with the control group (paracetamol) responded affirmatively to the question: 73% versus 52% (OR 0.28, 95% CI 0.15 to 0.52; 181 participants; moderate certainty evidence) (<a href="./references#CD004976-fig-0011" title="">Analysis 3.1</a>). </p> </section> <section id="CD004976-sec-0079"> <h6 class="title">2. Adverse effects of treatment</h6> <p>Six trials evaluated the adverse effects of analgesic‐decongestive combinations (<a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a>; <a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a>; <a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a>; <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>; <a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a>; <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>). </p> <p>Many different adverse effects were noted, including drowsiness, difficulty sleeping, lethargy, indigestion, nervousness, palpitations, lightheadedness, nausea, vomiting, dizziness, dry mouth, headache, somnolence, fever, abdominal pain, pharyngitis, loss of appetite, depression, giddiness, general gastrointestinal system adverse effects, central nervous system adverse effects, and diarrhoea. </p> <p>The number of trials reporting a specific adverse effect is presented in <a href="#CD004976-tbl-0011">Table 7</a>. We pooled data from different trials where possible (see <a href="./references#CD004976-fig-0012" title="">Analysis 3.2</a>; <a href="./references#CD004976-fig-0013" title="">Analysis 3.3</a>; <a href="./references#CD004976-fig-0014" title="">Analysis 3.4</a>; <a href="./references#CD004976-fig-0015" title="">Analysis 3.5</a>; <a href="./references#CD004976-fig-0016" title="">Analysis 3.6</a>). Other data are summarised in <a href="#CD004976-tbl-0012">Table 8</a>. </p> <div class="table" id="CD004976-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Combination 3: number of trials reporting a specific adverse effect</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervous system disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004976-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Combination 3: adverse effects data not meta‐analysed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 2/91, paracetamol 2/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal upset</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 6/91, paracetamol 5/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal system</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASA + PSE 18/236, ASA 18/239, PSE 12/237, placebo 5/121</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/91, paracetamol 1/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness and sleepiness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 5/91, paracetamol 4/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 0/91, paracetamol 1/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 0/91, paracetamol 1/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Giddy, dizzy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/91, paracetamol 1/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal pains, diarrhoea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/91, paracetamol 0/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 17/481, placebo 9/162</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 8/481, placebo 2/162</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharyngitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 4/481, placebo 2/162</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nervousness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 8/216, placebo 0/214</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difficulty sleeping</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/23, placebo 1/10</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central nervous system</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 4/76, placebo 0/76</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>active treatment 1/76, placebo 1/76</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central nervous system</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASA + PSE 10/236, ASA 2/239, PSE 4/237, placebo 6/121</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ASA: acetylsalicylic acid<br/>PSE: pseudoephedrine </p> </div> </div> <section id="CD004976-sec-0080"> <p><b>Total number of participants experiencing adverse effects</b></p> <p>In six trials (2510 participants) the total number of participants with one or more adverse effects was registered (<a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a>; <a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a>; <a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a>; <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>; <a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a>; <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>). A total of 1644 participants were evaluated: 199/1122 in the active treatment group (17.7%) and 75/675 in the placebo group (11.1%) experienced adverse effects. The OR of an adverse effect with active treatment is 1.62 (95% CI 1.18 to 2.23; 6 studies; 1797 participants; high certainty evidence; <a href="./references#CD004976-fig-0012" title="">Analysis 3.2</a>). The number needed to treat for an additional harmful outcome (NNTH) is 18 (95% CI 9 to 59). </p> </section> <section id="CD004976-sec-0081"> <p><b>Participants experiencing drowsiness, hypersomnia, lethargy, excessive sleepiness, or other central nervous system adverse effects</b></p> <p>This adverse effect was reported in five trials (<a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a>; <a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a>; <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>; <a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a>; <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>). In the five trials, 4.4% of participants suffered from sedation with active treatment and 3.2% with control (OR 1.34, 95% CI 0.76 to 2.37; 5 studies, 1644 adults; moderate certainty evidence; <a href="./references#CD004976-fig-0013" title="">Analysis 3.3</a>). We downgraded the certainty of the evidence by one level to moderate due to imprecision. </p> </section> <section id="CD004976-sec-0082"> <p><b>Dry mouth</b></p> <p>In three trials dry mouth was noted as an adverse effect (<a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a>; <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>; <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>), occurring in 2.6% of participants in the active treatment group and 1.8% of participants in the control group (OR 1.43, 95% CI 0.53 to 3.83; 3 studies, 764 adults; low certainty evidence due to imprecision and inconsistency; <a href="./references#CD004976-fig-0014" title="">Analysis 3.4</a>). </p> </section> <section id="CD004976-sec-0083"> <p><b>Participants experiencing gastrointestinal upset or other gastrointestinal adverse effects</b></p> <p>In the same five trials, 5.8% of participants suffered from some gastrointestinal upset in the active treatment group and 2.7% in the control group (OR 1.71, 95% CI 0.97 to 3.01; 5 trials, 1644 adults; high certainty evidence; <a href="./references#CD004976-fig-0015" title="">Analysis 3.5</a>). </p> </section> <section id="CD004976-sec-0084"> <p><b>Participants experiencing dizziness</b></p> <p>In four trials, 3.8% of participants in the active treatment group and 0.8% of participants in the control group suffered from dizziness (<a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a>; <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>; <a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a>; <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>). This difference was significant: P = 0.009. The OR of dizziness in the active treatment group was 2.86 (95% CI 1.02 to 8.01; 4 trials, 1287 adults; high certainty evidence; <a href="./references#CD004976-fig-0016" title="">Analysis 3.6</a>). </p> <p>In conclusion, adverse effects are overall more frequent with a decongestant + analgesic combination than with control treatment. Specifically, dizziness is more frequent. </p> </section> </section> </section> <section id="CD004976-sec-0085"> <h5 class="title">Secondary outcomes</h5> <section id="CD004976-sec-0086"> <h6 class="title">1. Decrease in the amount, or duration, of individual common cold symptoms</h6> <section id="CD004976-sec-0087"> <p><b>Subjective severity assessment of nasal obstruction</b></p> <p>This symptom was assessed in six trials.</p> <p>In <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>, the severity of nasal obstruction was not significantly different between treatment and placebo groups. Conversely, in <a href="./references#CD004976-bbs2-0016" title="Martinez GallardoF , López FiescoA , ZamoraG .Symptomatic treatment of common cold in children with a new combination of naproxen sodium plus pseudoephedrine hydrochloride: a comparative trial against pseudoephedrine syrup. Proceedings of the Western Pharmacology Society1994;37:157-8. ">Martinez 1994</a>, the active treatment significantly reduced the duration of nasal congestion. </p> <p>In <a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a>, the differences from baseline of nasal congestion scores and nasal relief scores were statistically larger (exact P value not provided) for all active treatments and at all observation intervals compared to placebo. The peak difference was noted at 120 minutes after dosing. There was no clear difference between the different active combinations. </p> <p><a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a> evaluated nasal congestion during five days of therapy on a four‐point scale. There was a difference in the sum of the day scores between the active treatment (4 +/− 3) and the placebo (7 +/− 2; exact P value not provided). </p> <p>In the other trial by <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>, the mean difference in nasal congestion score at the beginning of the trial and after the first and second dose of active medication was evaluated on a five‐point scale. Two hours after the first dose there was a clear decrease (P = 0.002) in favour of active treatment. After the second administration the difference was still significant, but smaller (P = 0.03). </p> <p>In <a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a>, the sum of nasal congestion differences over three days of treatment was significantly higher with active treatment than with placebo (P = 0.004) or paracetamol (P = 0.02). Global nasal congestion relief was also greater with active treatment compared to paracetamol or placebo (P = 0.004). This was not the case when the combination was compared to pseudoephedrine in monotherapy. </p> <p>In <a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a>, the sum of nasal congestion differences over three days was significantly higher with the combination therapy (pseudoephedrine + acetylsalicylic acid) than with placebo (P = 0.048). This was also the case when compared to acetylsalicylic acid (P = 0.016). When compared to pseudoephedrine there was no significant difference (P = 0.371). </p> <p>We could not pool the results of these trials because of differences in outcome measures or lack of adequate data. Results are summarised in <a href="#CD004976-tbl-0013">Table 9</a>. </p> <div class="table" id="CD004976-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Combination 3: results analgesic‐decongestant</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0016" title="Martinez GallardoF , López FiescoA , ZamoraG .Symptomatic treatment of common cold in children with a new combination of naproxen sodium plus pseudoephedrine hydrochloride: a comparative trial against pseudoephedrine syrup. Proceedings of the Western Pharmacology Society1994;37:157-8. "><b>Martinez 1994</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>The duration of the symptom of nasal congestion was significantly reduced on treatment days 3 and 5. Result mentioned in the "Results" chapter of the text. No further data available.<br/>d. Objective nasal obstruction<br/>The duration of the symptom of mucosal oedema was significantly reduced on treatment days 3 and 5 as compared to placebo. Result mentioned in the "Results" chapter of the text. No further data available.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. "><b>Loose 2004</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>(1) Nasal congestion score<br/>The nasal congestion score was statistically significantly different (P &lt; 0.05) for all active treatments and at all observation intervals (2, 4, and 6 hours after intake) compared with placebo.<br/>(2) Relief of nasal congestion<br/>Relief in nasal congestion was statistically significantly better compared to treatment with placebo for all active treatments and at all observation intervals (2, 4, and 6 hours after intake).<br/>Data provided in tables, but it is not clear what the tables represent.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '><b>Middleton 1981</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Overall subjective assessment was made after asking the participant the question: "On the whole do you think the tablets have helped you?".<br/>Nighttime: </p> <p>Response, Control, Treatment<br/>Yes, 56, 75<br/>No, 34, 26<br/>Compared with the control group, a statistically significantly larger number of participants receiving the active medication responded affirmative to the question (P &lt; 0.01).<br/>b. Subjective severity assessment of nasal obstruction<br/>No significant difference reported between the active substance and placebo in treating nasal congestion.<br/>The results are only reported in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>c. Rhinorrhoea<br/>No significant difference reported between the active substance and placebo in treating rhinorrhoea.<br/>The results are only reported in the "Result" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>d. Sneezing<br/>No significant difference reported between the active substance and placebo in treating sneezing.<br/>The results are only reported in the "Result" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>e. Cough<br/>No significant difference reported between the active substance and placebo in treating cough.<br/>The results are only reported in the "Result" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. "><b>Sperber 1989</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Objective nasal obstruction<br/>Overall and daily nasal patency was greater in the treatment group. The days when this difference was most noticeable were day 4 (P = 0.08) and day 5 (P = 0.06). Analysis of the mean values was confounded by high variability between participants.<br/>b. Subjective severity assessment of nasal obstruction<br/>Reduction of nasal congestion rated on a 4‐point scale:<br/>Treatment group 4 ± 3; placebo group 7 ± 2, P &lt; 0.05* (significant difference)<br/>c. Rhinorrhoea<br/>Reduction of nasal congestion rated on a 4‐point scale:<br/>Treatment group 2 ± 2; placebo group 4 ± 3, P &lt; 0.05* (not a significant difference) </p> <p> </p> <p>*Exact P values not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. "><b>Sperber 2000</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Mean difference between the nasal congestion scores at the beginning of the study and after the first and second administration of active medication or placebo (nasal congestion evaluated on 5‐point scale):<br/>Dose 1: active group −1.06; placebo group −0.67, P = 0.002 (statistically significant)<br/>Dose 2: active group −1.26; placebo group −0.98, P = 0.03 (not statistically significant)<br/>b. Rhinorrhoea<br/>Mean difference between the rhinorrhoea score at the beginning of the study and after the first and second administration of active medication or placebo (rhinorrhoea evaluated on 5‐point scale):<br/>Dose 1: active group −0.80; placebo group −0.71, P = 0.12 (not statistically significant)<br/>Dose 2: active group −1.15; placebo group −0.86, P = 0.09 (not statistically significant)<br/>c. Sneezing<br/>Mean difference between the sneezing score at the beginning of the study and after the first and second administration of active medication or placebo (sneezing evaluated on 5‐point scale):<br/>Dose 1: active group −0.84; placebo group −0.79, P = 0.71 (not statistically significant)<br/>Dose 2: active group −0.98; placebo group −0.85, P = 0.15 (not statistically significant)<br/>d. Cough<br/>Mean difference between the cough score at the beginning of the study and after the first and second administration of active medication or placebo (cough evaluated on 5‐point scale):<br/>Dose 1: active group −0.61; placebo group −0.51, P = 0.27 (not statistically significant)<br/>Dose 2: active group −0.78; placebo group −0.58, P = 0.06 (not statistically significant)<br/>Trend suggestive of greater reduction in cough score.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. "><b>Eccles 2006a</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal congestion<br/>Area under nasal airflow conductance curve 0 to 4 h (rhinomanometry)<br/>Mean difference 120.3, 95% CI 66.18 to 174.37, P &lt; 0.0001<br/>Sum of nasal congestion differences 0 to 3 days (4‐point scale)<br/>Mean difference 0.69, 95% CI 0.219 to 1.162, P = 0.004<br/>Global nasal congestion relief (5‐point scale)<br/>Paracetamol + pseudoephedrine: 1.7 +/− 1.2<br/>P &lt; 0.001<br/>Placebo: 1.0 +/− 0.9 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. "><b>Eccles 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal congestion</p> <p> </p> <p>Area under nasal airflow conductance curve 0 to 4 h (rhinomanometry):</p> <p>ASA/PSE vs ASA P &lt; 0.001 at each evaluation time (0 to 1 h, 1 to 2 h, 2 to 3 h, 3 to 4 h) </p> <p>ASA/PSE vs PSE P &gt; 0.5 at each evaluation time (0 to 1 h, 1 to 2 h, 2 to 3 h, 3 to 4 h) </p> <p>ASA/PSE vs placebo P &lt; 0.001 at each evaluation time (0 to 1 h, 1 to 2 h, 2 to 3 h, 3 to 4 h) </p> <p> </p> <p>Sum of subjective nasal congestion intensity difference</p> <p>ASA/PSE vs ASA at 0 to 4 h, P = 0.144; day 3, P = 0.969</p> <p>ASA/PSE vs PSE at 0 to 4 h, P = 0.647; day 3, P = 0.037</p> <p>ASA/PSE vs placebo at 0 to 4 h, P &lt; 0.008; day 3, P = 0.048</p> <p> </p> <p>Total subjective nasal congestion relief</p> <p>ASA/PSE vs ASA at 0 to 4 h, P &lt; 0.001; day 3, P = 0.016</p> <p>ASA/PSE vs PSE at 0 to 4 h, P = 0.890; day 3, P = 0.873</p> <p>ASA/PSE vs placebo at 0 to 4 h, P &lt; 0.001; day 3, P &lt; 0.001</p> <p> </p> <p>Global nasal congestion relief</p> <p>ASA/PSE vs ASA day 3, P = 0.040</p> <p>ASA/PSE vs PSE day 3, P = 0.207</p> <p>ASA/PSE vs placebo day 3, P &lt; 0.001</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ASA: acetylsalicylic acid<br/>CI: confidence interval<br/>PSE: pseudoephedrine </p> </div> </div> <p>We can conclude that decongestant‐analgesic combinations are probably effective in alleviating nasal obstruction. There were some data on the size of the effect in three trials: in <a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a>, the difference in the sum of the severity scores over five days was three points on a four‐point scale; in the second trial of <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>, the difference was at most 1.06 severity points on a five‐point scale; and in <a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a>, the mean sum of nasal congestion differences over three days was 0.69 (on a four‐point scale), and the difference in global nasal congestion relief was 0.7 (on a five‐point scale). </p> </section> <section id="CD004976-sec-0088"> <p><b>Rhinorrhoea</b></p> <p>Three trials assessed the effect on the subjective severity of rhinorrhoea (<a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>; <a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a>; <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>). None of these trials showed a favourable treatment effect. However, in <a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a> there was a reduction of 30% in nasal mucus weight with the active treatment compared with the placebo (P = 0.04). </p> <p>Pooling was not possible. The available data are presented in <a href="#CD004976-tbl-0013">Table 9</a>. We can conclude that decongestant‐analgesic combinations are ineffective in subjectively alleviating rhinorrhoea, although there may be an objectively measurable decrease in mucus secretion. </p> </section> <section id="CD004976-sec-0089"> <p><b>Sneezing</b></p> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> and <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a> also assessed the effect of an analgesic‐decongestive combination on the subjective severity of sneezing. There was no significant effect. The available data are presented in <a href="#CD004976-tbl-0013">Table 9</a>. </p> </section> <section id="CD004976-sec-0090"> <p><b>Cough</b></p> <p>The same two trials also evaluated the effect on cough, finding no effect (<a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a>; <a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a>). </p> </section> </section> <section id="CD004976-sec-0091"> <h6 class="title">2. Objective assessments (rhinomanometry, nasal airflow conductance)</h6> <p>In <a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a>, recipients of the active treatment showed improved nasal patency on rhinomanometry from the pre‐treatment baseline flow rates on days four (P = 0.08) and five (P = 0.06) of treatment. The overall and daily patency tended to be greater in the recipients of pseudoephedrine + ibuprofen compared to placebo. In <a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a>, the combination treatment was more effective than placebo in increasing nasal airflow conductance (P &lt; 0.001). </p> <p>In <a href="./references#CD004976-bbs2-0016" title="Martinez GallardoF , López FiescoA , ZamoraG .Symptomatic treatment of common cold in children with a new combination of naproxen sodium plus pseudoephedrine hydrochloride: a comparative trial against pseudoephedrine syrup. Proceedings of the Western Pharmacology Society1994;37:157-8. ">Martinez 1994</a>, the combination significantly reduced the duration of mucosal oedema on anterior rhinoscopia. </p> </section> </section> </section> <section id="CD004976-sec-0092"> <h4 class="title">Combination 4: oral antihistamine‐decongestant‐analgesic combinations</h4> <section id="CD004976-sec-0093"> <h5 class="title">Short description of the studies</h5> <p><a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a> studied a combination of loratadine + pseudoephedrine + paracetamol in 40 adults with a common cold over a five‐day period. Participants were kept under observation during the first five hours after the first dose of treatment. Global assessment of their cold, somnolence, and general malaise were observed every 20 minutes. During the next five days the feeling of general malaise and common cold symptoms (nasal congestion, rhinorrhoea) were evaluated daily in a diary by participants and on days three and five by a physician. </p> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> included 485 adults and investigated the effectiveness of a single dose of a syrup containing dextromethorphan 15 mg, paracetamol 500 mg, doxylamine 7.5 mg, and ephedrine 8 mg, which was administered in the evening. Follow‐up data were available for 470 participants. Effectiveness was evaluated by comparing the sum score of different symptoms (nasal congestion, runny nose, cough, and pain) and the severity scores of individual symptoms three hours after dosing and within one hour of rising the following morning. </p> <p><a href="./references#CD004976-bbs2-0021" title="SachsenroderL , RenovanzHD , FlachD .Efficacy and tolerance of a combined oral rhinologic agent. Arzneimittelforschung1972;22(2):392-8. ">Sachsenroder 1972</a> studied the effect of 2‐(5,6,7,8‐tetrahydro‐1‐naphtylamino)‐2‐ imidazoline‐HCl (a decongestant) + chlorthenoxazin (an anti‐inflammatory medication) + chlorphenamine (Cimporhin) compared with chlorthenoxazin and placebo in 165 adult participants suffering from rhinorrhoea and flu‐like symptoms. The effect on rhinorrhoea was evaluated as 'good' or 'bad' on days one, two, and three of treatment. We considered the comparison between Cimporhin and placebo in the review. </p> <p><a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a> studied the effect of a combination of doxylamine + ephedrine + paracetamol + dextromethorphan on night symptoms of the common cold in 70 adult participants. A cross‐over design was used. Participants were randomly divided into two groups: the first night one group received the placebo, and the other group received the active treatment; the second night this was reversed. At the end of the study, effectiveness was assessed by rating the severity of common cold symptoms including nasal congestion, nasal discharge, sneezing, and cough on a six‐point scale and by assessing the relief of global cold symptoms. The numbers of positive ratings after one dose of active or placebo syrup were compared. </p> <p><a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a> included 201 children between 2 and 12 years of age with an acute respiratory infection and compared the effect of paracetamol versus diphenhydramine + paracetamol + pseudoephedrine. Outcome measures were the frequency of runny nose, stuffy nose, and cough; the sum of severity scores (on a four‐point scale) of different symptoms; and the clinical recovery ratios on the third and fifth days. </p> <p><a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> included 53 adults with symptoms of cold or flu. The intervention consisted of a single dose of a combination of paracetamol, pseudoephedrine, dextromethorphan, and chlorpheniramine. The study compared the difference in the total symptom score (sum of scores of individual cold symptoms on a four‐point severity score) and severity scores of cough and nasal symptoms after 15, 30, 60, 120, 180, and 240 minutes. Furthermore, they evaluated global assessment on a five‐point scale at 240 min and compared the frequency of adverse effects in both treatment groups. </p> </section> <section id="CD004976-sec-0094"> <h5 class="title">Primary outcome</h5> <section id="CD004976-sec-0095"> <h6 class="title">1. Global evaluation of effectiveness</h6> <p>Five trials including a total of 896 participants assessed the global effectiveness of oral combinations of antihistamine‐decongestant‐analgesic on the course of the common cold (<a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a>; <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>; <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>; <a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>; <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a>). The combination showed some effect in two trials (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>; <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>). </p> <p>In <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>, participants received one dose before bedtime and rated their general feeling (useless, almost useless, not very good, good, very good, excellent) in the morning. More participants receiving the active treatment scored the active syrup as 'good' to 'excellent' compared with those receiving the placebo syrup (exact P value not provided). </p> <p>In <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>, overall relief was measured on a five‐point severity scale the morning following the nighttime intake of medication. The severity rating with active treatment was significantly lower than with placebo (P &lt; 0.001); more participants receiving the active treatment rated their overall symptom relief during the night as 'good' or 'very good' on rising the following morning (50.2% versus 31.9%). </p> <p>Three trials showed no effect of the treatment. In <a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a>, no significant difference was found between groups in the general evolution of the common cold. In <a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>, of 201 included children, 109 were evaluated for clinical recovery on day three, and 83 on day five. There was no meaningful difference in recovery rate. <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> found no difference in total symptom score on any of the evaluation times, nor at the global evaluation point. </p> <p>We pooled data from two trials (<a href="./references#CD004976-fig-0017" title="">Analysis 4.1</a>) (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>; <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>). Measured in the morning after an evening dose, significantly more participants evaluated the active evening dose treatment as beneficial (OR 0.47, 95% CI 0.33 to 0.67; 2 studies, 548 adults; low certainty evidence due to risk of bias and imprecision; <a href="./references#CD004976-fig-0017" title="">Analysis 4.1</a>). Other results are shown in <a href="./references#CD004976-fig-0018" title="">Analysis 4.2</a>; <a href="./references#CD004976-fig-0019" title="">Analysis 4.3</a>; <a href="#CD004976-tbl-0014">Table 10</a>. </p> <div class="table" id="CD004976-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Combination 4: results antihistamine‐decongestant‐analgesic</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. "><b>Blanco 2000</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Comparison of severity ratings on the third day of treatment between treatment groups: results are graphically displayed and summarised in a table. It is not clear what is presented in the table.<br/>On the graphs, P values are mentioned when there is a statistically significant difference: for general unwell feeling, there is no significant difference.<br/>b. Subjective severity assessment of nasal obstruction<br/>Comparison of severity ratings on the third and fifth day of treatment between treatment groups: results are graphically displayed and summarised in a table. It is not clear what is presented in the table. In the graphs, P values are mentioned when there is a statistically significant difference: for nasal congestion, P = 0.041.<br/>c. Effect on results on anterior rhinoscopy<br/>Comparison of severity ratings on the third and fifth day of treatment between treatment groups: results are graphically displayed and summarised in a table. It is not clear what is presented in the table. In the graphs, P values are mentioned when there is a statistically significant difference: for anterior rhinoscopy, P = 0.045 on the third day.<br/>d. Rhinorrhoea<br/>Comparison of severity ratings on the third day of treatment between treatment groups: results are graphically displayed and summarised in a table. It is not clear what is presented in the table. In the graphs, P values are mentioned when there is a statistically significant difference: for anterior rhinorrhoea, P = 0.012.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0021" title="SachsenroderL , RenovanzHD , FlachD .Efficacy and tolerance of a combined oral rhinologic agent. Arzneimittelforschung1972;22(2):392-8. "><b>Sachsenroder 1972</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Rhinorrhoea<br/>Number of participants rating the efficacy of the product "good" or "bad" in treating the symptom of rhinrrhoea on days 1, 2, and 3 of taking medications.<br/>Ap 67 (n = 52), Z 95‐Rhi (n = 52), placebo (n = 55). Difference:<br/>Day 1: good 18, 27, 9; bad 34, 25, 46 (significant)<br/>Day 2: good 30, 34, 18; bad 22, 18, 37 (not significant)<br/>Day 3: good 36, 40, 20; bad 16, 10, 35 (not significant)<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. "><b>Mizoguchi 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Overall relief (scale: 0 = very poor, 1 = poor, 2 = fair, 3 = good, 4 = very good)<br/>Day 2 morning: T 2.4 +/− 1.01, P 1.98 +/− 1.11, P &lt; 0.001<br/>b. Nasal congestion (0 = much worse, 1 = somewhat worse, 2 = about the same, 3 = somewhat better, 4 = much better)<br/>Hour 3, day 1: T 2.59 +/− 0.72, P 2.43 +/− 0.68, P = 0.012<br/>Day 2 morning: T 2.29 +/− 0.98, P 2.00 +/− 1.10, P = 0.002<br/>c. Runny nose (0 = much worse, 1 = somewhat worse, 2 = about the same, 3 = somewhat better, 4 = much better)<br/>Hour 3, day 1: T 2.73 +/− 0.78, P 2.56 +/− 0.75, P = 0.017<br/>Day 2 morning: T 2.49 +/− 0.97, P 2.16 +/− 1.12, P = 0.001<br/>d. Cough (0 = much worse, 1 = somewhat worse, 2 = about the same, 3 = somewhat better, 4 = much better)<br/>Hour 3, day 1: T 2.72 +/− 0.77, P 2.46 +/− 0.82, P = 0.012<br/>Day 2 morning: T 2.50 +/− 0.97, P 2.08 +/− 1.11, P = 0.002<br/>Percentage (%) of participants improved (no P values provided)<br/>1) Hour 3, day 1:<br/>Nasal congestion: T 55.4, P 44.7<br/>Runny nose: T 58.9, P 51<br/>Cough: T 56.7, P 43.3<br/>  </p> <p>2) Day 2 morning:<br/>Nasal congestion: T 45.2, P 36.2<br/>Runny nose: T 54.3, P 40.6<br/>Cough: T 52.3, P 38<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. "><b>Thackray 1978</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Number of participants rating the formulation as "good, very good or excellent" on the morning after the previous night's dose:<br/>n = 58<br/>Active treatment: 35/58 </p> <p>Placebo: 25/58</p> <p>P &lt; 0.05*<br/>b. Subjective severity assessment of nasal obstruction<br/>Number of participants rating the formulation as "good, very good, excellent" on the morning after the previous night's dose:<br/>n = 58<br/>Active treatment: 35/58 </p> <p>Placebo 25/58</p> <p>P &lt; 0.05*<br/>c. Rhinorrhoea<br/>Number of participants rating the formulation as "good, very good, excellent" on the morning after the previous night's dose:<br/>n = 55<br/>Active treatment: 35/55 </p> <p>Placebo 21/55</p> <p>P &lt; 0.05*<br/>d. Sneezing<br/>Number of participants rating the formulation as "good, very good, excellent" on the morning after the previous night's dose:<br/>n = 30<br/>Active treatment: 25/30 </p> <p>Placebo 20/30</p> <p>P = 0.14<br/>e. Cough<br/>Number of participants rating the formulation as "good, very good, excellent" on the morning after the previous night's dose:<br/>Active treatment: 57.6% </p> <p>Placebo 32.2%</p> <p>P &lt; 0.01</p> <p> </p> <p>*Exact P value not provided.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. "><b>Unuvar 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical score</p> <p>Day 3:</p> <p>Treatment: 4.0 +/− 2.8</p> <p>Paracetamol: 4.1 +/− 2.6</p> <p>P = 0.81</p> <p>Day 5:</p> <p>Treatment: 1.7 +/− 1.4</p> <p>Paracetamol: 2.0 +/− 1.6</p> <p>P =0.39</p> <p>Nasal stuffiness</p> <p>Day 3:</p> <p>Treatment: 27/86</p> <p>Paracetamol: 21/62</p> <p>P = 0.75</p> <p>Day 5:</p> <p>Treatment: 0/86</p> <p>Paracetamol: 4/62</p> <p>P = 0.016<br/>Runny nose </p> <p>Day 3:</p> <p>Treatment: 28/86</p> <p>Paracetamol: 25/62</p> <p>P = 0.33</p> <p>Day 5:</p> <p>Treatment: 7/86</p> <p>Paracetamol: 8/62</p> <p>P = 0.49<br/>Cough </p> <p>Day 3:</p> <p>Treatment: 13/86</p> <p>Paracetamol: 14/62</p> <p>P = 0.24</p> <p>Day 5:</p> <p>Treatment: 2/86</p> <p>Paracetamol: 4/62<br/>P = 0.29<br/>  </p> <p>Note: treatment = paracetamol + diphenhydramine + pseudoephedrine </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. "><b>Zhang 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Total symptom score: active treatment (A) n = 25; placebo (P) n = 27. Only graphical data available. No significant difference between groups during the 4 hours follow‐up after a single administration. </p> <p>(P values at 15 min, 30 min, 1 h, 2 h, 3 h, 4 h were 0.95, 0.72, 0.74, 0.77, 0.52, 0.90, respectively). Global assessment of response to treatment (P = 0.95) </p> <p> </p> <p>b. Nasal congestion (adjusted mean (SE))</p> <p>baseline: A 1.2 (0.93) P 1.2 (0.92)</p> <p>15 min: A −0.32 (0.086) P −0.31 (0.084) P = 0.9337</p> <p>30 min: A −0.59 (0.119) P −0.6 (0.115) P = 0.96</p> <p>1 hour: A −0.61 (0.127) P −0.68 (0.124) P = 0.6521</p> <p>2 hours: A −0.91 (0.138) P −1.02 (0.134) P = 0.5384</p> <p>3 hours: A −1.04 (0.156) P −1.14 (0.152) P = 0.6409</p> <p>4 hours: A −1.19 (0.162) P −1.28 (0.157) P = 0.9618</p> <p> </p> <p>c. Runny nose (adjusted mean (SE))</p> <p>baseline: A 2 (0.35) P 1.9 (0.55)</p> <p>15 min: A −0.20 (0.081) P −0.18 (0.080) P = 0.8711</p> <p>30 min: A −0.48 (0.116) P −0.32 (0.114) P = 0.2919</p> <p>1 hour: A −0.54 (0.145) P −0.61 (0.143) P = 0.6940</p> <p>2 hours: A −0.78 (0.148) P −0.65 (0.146) P = 0.5132</p> <p>3 hours: A −0.89 (0.161) P −0.98 (0.159) P = 0.6751</p> <p>4 hours: A −1.12 (0.149) P −0.97 (0.147) P = 0.4692</p> <p> </p> <p>d. Sneezing (adjusted mean (SE))</p> <p>baseline: A 1.7 (0.79) P 1.6 (0.75)</p> <p>15 min: A −0.10 (0.089) P −0.24 (0.088) P = 0.2279</p> <p>30 min: A −0.25 (0.103) P −0.42 (0.10215) P = 0.2203</p> <p>1 hour: A −0.50 (0.126) P −0.80 (0.124) P = 0.0785</p> <p>2 hours: A −0.67 (0.138) P −0.86 (0.136) P = 0.3117</p> <p>3 hours: A −0.83 (0.138) P −1.03 (0.136) P = 0.2938</p> <p>4 hours: A −0.88 (0.135) P −1.11 (0.133) P = 0.2064</p> <p> </p> <p>e. Cough (adjusted mean (SE))</p> <p>baseline: A 1.6 (1.04) P 1.3 (0.94)</p> <p>15 min: A −0.11 (0.071) P −0.06 (0.078) P = 0.5969</p> <p>30 min: A −0.28 (0.077) P −0.25 (0.084) P = 0.7506</p> <p>1 hour: A −0.49 (0.116) P −0.33 (0.12) P = 0.3222</p> <p>2 hours: A −0.51 (0.109) P −0.45 (0.119) P = 0.6759</p> <p>3 hours: A −0.53 (0.116) P −0.53 (0.127) P = 0.9838</p> <p>4 hours: A −0.72 (0.131) P −0.59 (0.143) P = 0.4599</p> <p> </p> <p>*Exact P value not provided.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>P: placebo<br/>SE: standard error<br/>T: active treatment </p> </div> </div> </section> <section id="CD004976-sec-0096"> <h6 class="title">2. Adverse effects of treatment</h6> <p>Adverse effects were reported in five trials and included drowsiness, somnolence, gingival swelling, hypersomnia, insomnia, dizziness, palpitations, giddiness, diarrhoea, headache, abdominal pain, and vomiting (<a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a>; <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>; <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>; <a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>; <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a>). Data are summarised in <a href="#CD004976-tbl-0015">Table 11</a>. </p> <div class="table" id="CD004976-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Combination 4: adverse effects data not meta‐analysed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over design: all participants took active formulation. 19 adverse effects occurred, equally distributed between active and control formulation. No further numbers reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 participants with active treatment reported 9 adverse effects.</p> <p>9 participants with control treatment reported 10 adverse effects.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant with active treatment reported 1 adverse effect.</p> <p>3 participants with control treatment reported 1 adverse effect.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsy or sleepy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a> </p> <p><a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not more frequent with active treatment; numbers not mentioned</p> <p>T 1/25, P 0/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Giddiness/drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over design: adverse effects reported by 7 participants when taking active treatment and 4 participants when taking placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 2/224, P 1/208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 2/224, P 1/208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 1/224, P 0/208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> <p><a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 1/224, P 1/208</p> <p>T 0/25, P 1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 1/224, P 1/208</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>P: placebo<br/>T: active treatment </p> </div> </div> <section id="CD004976-sec-0097"> <p><b>Total number of participants experiencing adverse effects</b></p> <p>In three trials, the total number of participants with one or more adverse effects was registered (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>; <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>; <a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>; <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a>). A total of 673 participants were evaluated in these trials, 356 with active treatment and 317 with control. In <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>, all participants (70) received the active treatment and placebo due to the cross‐over design. In one trial, no adverse effects occurred (<a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>). In <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>, 19 adverse effects occurred, of which 11 (16%) could be attributed to the formulations; these were equally distributed between the active and control groups. In <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>, five (2%) participants receiving the active medication experienced nine adverse effects, and nine (4%) participants receiving the placebo experienced 10 adverse effects. <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> reported three participants with adverse effects in the control group and one participant with an adverse effect in the treatment group.  </p> </section> <section id="CD004976-sec-0098"> <p><b>Participants experiencing suffering drowsiness or somnolence</b></p> <p>Three trials evaluated the incidence of drowsiness or somnolence (<a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a>; <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>; <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>). A total of 542 participants were included in these three trials: 379 in the active treatment group, 337 in the placebo group, and 70 who received both the placebo and the active treatment in a cross‐over design. In <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>, seven participants with the active treatment and four with the placebo felt giddy or drowsy. In <a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a>, no more participants felt sleepy with the active treatment than with the placebo. In <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>, two participants in the active treatment group and one participant in the placebo group experienced somnolence. In <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a>, one participant experienced somnolence. </p> </section> </section> </section> <section id="CD004976-sec-0099"> <h5 class="title">Secondary outcomes</h5> <section id="CD004976-sec-0100"> <h6 class="title">1. Decrease in the amount, or duration, of individual common cold symptoms</h6> <section id="CD004976-sec-0101"> <p><b>Subjective severity assessment of nasal obstruction</b></p> <p>Five trials assessed the effect of the antihistamine‐decongestant‐analgesic combination on the subjective severity of nasal obstruction, all of which showed some effect. </p> <p>In <a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a>, participants were evaluated on the third and fifth day of treatment using a five‐point severity score. In participants who received active treatment, some decrease in nasal congestion was observed on the third day of treatment (P = 0.041). </p> <p>In <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>, participants rated the effect of the medication on nasal obstruction (useless, almost useless, not very good, good, very good, excellent) in the morning. More participants with active treatment scored the active syrup as good to excellent than those with the placebo syrup (exact P value not provided). </p> <p>In <a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>, there was a significant difference in frequency of nasal stuffiness on the fifth day (P = 0.016), but not on the third day of therapy. In <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>, severity of nasal congestion was evaluated on a five‐point scale three hours after receiving the medication and the following morning. Severity scores were significantly lower with active treatment at both evaluation times (P = 0.012, and P = 0.002). <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> found no significant difference between groups in decrease of severity of nasal obstruction on a five‐point severity score at any of the evaluation times. </p> <p>Pooling of results was not possible. The results are summarised in <a href="#CD004976-tbl-0014">Table 10</a>. We can conclude that a combination of decongestant‐antihistamine‐analgesic may have some favourable effect on nasal obstruction. However, the size of this effect and its clinical relevance are not clear. The effect size was evaluated in one trial, and the difference in severity score was at most 0.29 on a five‐point severity scale (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>). </p> </section> <section id="CD004976-sec-0102"> <p><b>Rhinorrhoea</b></p> <p>Six trials assessed the effect of an antihistamine‐decongestant‐analgesic combination on the subjective severity of rhinorrhoea, of which four showed some effect. </p> <p><a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a> found a significantly greater reduction of rhinorrhoea compared with placebo on the third treatment day. In <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>, more participants evaluated the active syrup as beneficial for rhinorrhoea compared with placebo (exact P value not provided). In <a href="./references#CD004976-bbs2-0021" title="SachsenroderL , RenovanzHD , FlachD .Efficacy and tolerance of a combined oral rhinologic agent. Arzneimittelforschung1972;22(2):392-8. ">Sachsenroder 1972</a>, significantly more participants receiving the active treatment rated the effect on rhinorrhoea as 'good' compared with placebo treatment (P &lt; 0.001) on each of the three treatment days. Finally, in <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>, severity of runny nose was evaluated on a five‐point scale three hours after intake of medication and the following morning. At both evaluation times, severity scores were significantly lower with active treatment (P = 0.017 and P = 0.001). </p> <p>In contrast, in <a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>, there were not significantly more children without rhinorrhoea on days three or five with the combination therapy in comparison with paracetamol. <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> found no significant difference in the decrease of severity of rhinorrhoea on a five‐point severity score at any of the evaluation times. </p> <p>Due to differences in outcome measures and lack of adequate data, pooling was not possible. The available results are summarised in <a href="#CD004976-tbl-0014">Table 10</a>. We can conclude that a combination containing decongestant‐antihistamine‐analgesic may have some favourable effect on rhinorrhoea in adults. The effect size could be evaluated in one trial (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>): the difference in severity score was at most 0.33 severity points on a five‐point severity scale. However, the results in children were equivocal. </p> </section> <section id="CD004976-sec-0103"> <p><b>Sneezing</b></p> <p><a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a> assessed the effect of an antihistamine‐decongestive‐analgesic combination on the subjective severity of sneezing. The trial showed no beneficial effect compared with placebo (P = 0.14). <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> found no significant difference in decrease of severity of sneezing on a five‐point severity score at any of the evaluation times.<br/>  </p> </section> <section id="CD004976-sec-0104"> <p><b>Cough</b></p> <p>Four trials evaluated the action of an antihistamine‐decongestant‐analgesic combination on the symptom of cough in the common cold (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>; <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>; <a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a>; <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a>). Two trials showed some effect (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>; <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>). The active treatment in both trials contained dextromethorphan. In <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>, there was a clear difference between the number of participants rating the formulation as 'good, very good or excellent' on the morning after the dose received the night before (P &lt; 0.01). In <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>, at both evaluation times, severity scores were significantly lower with the active treatment (P = 0.0004 and P &lt; 0.001). <a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> found no significant difference in decrease of severity of cough on a four‐point severity score at any of the evaluation times, despite the presence of dextromethorphan in the active treatment. </p> <p>In contrast, the paediatric trial by <a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. ">Unuvar 2007</a> failed to show any effect on cough. </p> <p>It was not possible to draw any conclusions on the effectiveness of a combination of antihistamine‐decongestant‐analgesic for cough in adults since in both trials where some effect was seen, it may have been due to the presence of dextromethorphan. This effect size could be evaluated in one trial (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>): change in severity score was at most 0.42 severity points on a five‐point severity scale. In children there was no effect. </p> </section> </section> <section id="CD004976-sec-0105"> <h6 class="title">2. Objective assessments (rhinoscopy)</h6> <p>On anterior rhinoscopy in <a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a>, a favourable effect on oedema of the nasal mucosa was seen on the third treatment day (P = 0.056) (<a href="#CD004976-tbl-0014">Table 10</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004976-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004976-sec-0106"></div> <section id="CD004976-sec-0107"> <h3 class="title" id="CD004976-sec-0107">Summary of main results</h3> <p>In this review we evaluated the effectiveness of four different combinations of over‐the‐counter (OTC) treatments for the common cold. All four combinations showed a general benefit in adults and children aged over six years. Where pooling of results was possible, we found an NNTB of four for the combination of antihistamine‐decongestant. The combination of antihistamine‐analgesic was beneficial in the two trials, and the combination of analgesic‐decongestant was beneficial in the one trial providing data on this outcome. The combination of antihistamine‐analgesic‐decongestant was more effective than control in two of the five trials, one of which was large and of high methodological quality (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>). General improvement is a significant outcome since the literature shows that people experiencing a common cold find their generalised symptoms and functional impairment more important than specific symptoms (<a href="./references#CD004976-bbs2-0071" title="BarretB , BrownR , MundtM , SafdarN , DyeL , MaberryR , et al.The Wisconsin Upper Respiratory Symptom Survey is responsive, reliable, and valid. Journal of Clinical Epidemiology2005;58:609-17.">Barret 2005</a>). </p> <p>Most combinations containing decongestants reduced nasal obstruction, and there may be some effect on rhinorrhoea. It is unclear whether antihistamine‐analgesic‐decongestant combinations have some additional effect on cough, since in the trials with some effect, the active treatment also contained an antitussive. Antihistamine‐decongestant combinations may have some effect on the subjective severity of sneezing, but not on the first day of treatment. However, when the size of the effect was reported (which was rarely the case), it was invariably small (less that one point on a four‐ or five‐point severity scale). </p> <p>Adverse effects were not always clearly reported, but based on the available data we found that adverse effects were usually more frequent with the active treatment than with control. Dry mouth and insomnia were more frequent with antihistamine‐decongestant, and dizziness was more frequent with analgesic‐decongestant combinations. The combinations antihistamine‐analgesic‐decongestant and antihistamine‐analgesic were well tolerated, which is rather remarkable as they contain similar products as the other two combinations. It is unclear whether the treatment benefits justify this cost of adverse effects. In a study on severity reduction in the common cold, <a href="./references#CD004976-bbs2-0072" title="BarretB , HarabanB , BrownD , ZhangZ , BrownR .Sufficiently important difference for common cold: severity reduction. Annals of Family Medicine2007;5:216-23.">Barret 2007</a> found that a sufficiently important difference meaning "the smallest amount of patient‐valued benefit that an intervention would require in order to justify associated costs, risk and other harms" was about 25% for a cheap treatment without adverse effects. The effect found on severity of specific symptoms is much lower than this. </p> </section> <section id="CD004976-sec-0108"> <h3 class="title" id="CD004976-sec-0108">Overall completeness and applicability of evidence</h3> <p>Although the number of included studies was small, most studies included participants suffering from a community‐acquired common cold, investigated current combinations of cold medications, and evaluated clinically relevant outcomes (subjective symptom assessment by the participants). The results of this systematic review therefore seem generalisable. </p> </section> <section id="CD004976-sec-0109"> <h3 class="title" id="CD004976-sec-0109">Quality of the evidence</h3> <p>The most striking finding is that despite the large number of combination products and formulations on the market, and the vast amounts sold, there are only a limited number of studies evaluating their effectiveness, especially in young children. The most studied combination was antihistamines combined with decongestants (eight trials in adults (1091 participants), two trials in young children (113 participants), and four trials including older children (214 participants)). The least studied combination was antihistamines with analgesics (three trials in adults (1508 participants) and one trial in young children (100 participants)). For analgesics with decongestants, we found six trials in adults and one trial in children (2525 participants), and for the combination of antihistamines with analgesics and decongestants, we found five trials in adults and one trial in children (1014 participants). The identified trials differed from each other in every possible aspect: definitions of the common cold, inclusion and exclusion criteria, settings, method of infection (natural (N = 28) or experimental (N = 2)), interventions, control, and outcome measures. Pooling of results was rarely possible, and our conclusions are based on a global assessment of the results of each trial (effective or not effective) rather than on numerical data. The overall quality of the included trials was acceptable, although often a clear description of the methods used was missing. In some of the (often older) trials, data required to judge the methodological rigour were not reported, that is mostly information related to the randomisation process. However, the results of these older studies were in line with the more recent, higher‐quality studies, therefore we believe this does not pose a threat to the validity of the meta‐analysis. Reporting of methods was generally poor, and there were large differences in design, participants, interventions, and outcomes. The certainty of evidence was mostly moderate to low due to imprecision or risk of bias. </p> </section> <section id="CD004976-sec-0110"> <h3 class="title" id="CD004976-sec-0110">Potential biases in the review process</h3> <p>Despite our extensive searches, it is possible that we did not identify all relevant trials, as it seems unlikely that so few trials have been performed in view of the vast market for an active preparation. Our results might be over‐optimistic, and publication bias cannot be excluded. </p> <p>In most trials it was unclear how the participants were recruited, that is it is not clear if the included participants were actively seeking care for their symptoms of the common cold. This may jeopardise the generalisability of the findings. This also raises some ethical issues, as treatments with possible adverse effects may have been given to participants with minor self‐limiting illnesses. </p> <p>We excluded illnesses with a possible bacterial cause or potentially non‐self‐limiting course, or conditions that might interfere with the natural course of the common cold (such as allergies). We excluded allergies because antihistamines are an effective treatment for them. </p> <p>We included studies using active controls because we felt that this made the review more comprehensive, as a comparison with an active control allowed us to assess the added value of the combination versus a single substance or a current treatment. </p> <p>One trial reported cold episodes as unit of analysis (<a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>). This trial has been included in the meta‐analysis (<a href="./full#CD004976-tbl-0001">summary of findings Table 1</a>). Since the common cold is a short, acute, benign condition, and the vast majority of participants were included only once (199 participants had 1 cold, 36 had 2 colds, and 7 had 3 colds), we do not think that this introduces meaningful bias. </p> <p>As not all trials reported on the occurrence of adverse effects, it is possible that the number of adverse effects is underestimated. Some trials evaluated the immediate effect of one dose of active medication, whilst other trials looked at the effectiveness over the duration of the cold. Although these are very different outcomes, both were relevant in view of the goals of this review. </p> </section> <section id="CD004976-sec-0111"> <h3 class="title" id="CD004976-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>Our results are in line with the results of similar reviews. <a href="./references#CD004976-bbs2-0088" title="SmithMB , FeldmanW .Over-the-counter cold medications. A critical review of clinical trials between 1950 and 1991. JAMA1993;269(17):2258-63.">Smith 1993</a> extensively reviewed the effectiveness of OTC cold medications and concluded that there was very little evidence of their effectiveness in young children, but that some medications and combinations were effective in adolescents and adults, which is confirmed by our findings. <a href="./references#CD004976-bbs2-0089" title="SmithSM , SchroederK , FaheyT .Over-the-counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD001831. [DOI: 10.1002/14651858.CD001831.pub5]">Smith 2014</a> found that there was no good evidence of effectiveness of OTC medication for acute cough, but that results of trials were conflicting. In our review we found some evidence of the effectiveness in cough in adults with the combination of antihistamine‐analgesic‐decongestant, which was mainly due to the results of one trial not included in the review by Smith (<a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>). However, the active treatment in this trial also contained dextromethorphan. <a href="./references#CD004976-bbs2-0073" title="DeckxL , De SutterAIM , GuoL , MirNA , vanDrielML .Nasal decongestants in monotherapy for the common cold. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD009612. [DOI: 10.1002/14651858.CD009612.pub2]">Deckx 2016</a> concluded that a single oral dose of nasal decongestant is modestly effective for short‐term relief of congestion in adults, and that these medications also provide benefit after regular use over three to five days. This is in accordance with our findings that combinations with decongestants decrease nasal obstruction. A review by <a href="./references#CD004976-bbs2-0075" title="EcclesR .Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. Journal of Clinical Pharmacy and Therapeutics2006;31:309-19.">Eccles 2006b</a> on the efficacy and safety of OTC analgesics in the treatment of common cold and flu found that there is little information on the use of analgesics in treating colds. Safety and efficacy data must be related to other pain and fever models. <a href="./references#CD004976-bbs2-0075" title="EcclesR .Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. Journal of Clinical Pharmacy and Therapeutics2006;31:309-19.">Eccles 2006b</a> concluded that these medications were effective, which confirms our findings that most combinations showed some general benefit. <a href="./references#CD004976-bbs2-0074" title="De SutterA , SaraswatA , vanDrielML .Antihistamines for the common cold. Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009345. [DOI: 10.1002/14651858.CD009345.pub2]">De Sutter 2015</a> concluded that antihistamines have a limited short‐term beneficial effect on severity of overall symptoms, which may explain some of the effect we found in the combinations with antihistamines. </p> <p>Regarding the possible risks, it must be noted that in 2005 the US Food and Drug Administration (FDA) issued a warning for OTC nasal preparations containing phenylpropanolamine because of the increased risk of intracranial bleeding (<a href="./references#CD004976-bbs2-0076" title="Food and Drug Administration, Department of Health and Human Services.21 CFR parts 310, 341, and 357. Phenylpropanolamine-containing drug products for over-the-counter human use. Tentative final monographs. Federal Register/proposed rules2005;70(245):75988-97.">FDA 2005</a>). Moreover, the Annual Report of the American Association of Poison Control Centers' Naional Poison Data System places analgesics, antihistamines, and cold/cough medication in the top 25 drug categories most frequently involved in human exposures, both in children and adults (<a href="./references#CD004976-bbs2-0078" title="GumminD , MowryJ , SpykerD , BrooksD , BeuhlerM , RiversL , et al.2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report. Clinical Toxicology2019;57(12):1220-413.">Gummin 2018</a>). A report from the US Centers for Disease Control and Prevention identified more than 1500 emergency room visits in 2004 and 2005 for children under two years of age who had been given cough or cold products, and a review by the FDA identified 123 deaths related to the use of such products in children under six years of age over the past few decades (<a href="./references#CD004976-bbs2-0087" title="SharfsteinJM , NorthM , SerwintJR .Over the counter but no longer under the radar - pediatric cough and cold medications. New England Journal of Medicine2007;357(23):2321-3.">Sharfstein 2007</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004976-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram of searches after 2012." data-id="CD004976-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram of searches after 2012.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004976-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004976-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antihistamine‐decongestant, Outcome 1: Global evaluation" data-id="CD004976-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antihistamine‐decongestant, Outcome 1: Global evaluation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antihistamine‐decongestant, Outcome 2: Adverse effects: all" data-id="CD004976-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antihistamine‐decongestant, Outcome 2: Adverse effects: all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antihistamine‐decongestant, Outcome 3: Adverse effects: drowsiness, hypersomnia, and excessive sleepiness" data-id="CD004976-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antihistamine‐decongestant, Outcome 3: Adverse effects: drowsiness, hypersomnia, and excessive sleepiness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antihistamine‐decongestant, Outcome 4: Adverse effects: dry mouth" data-id="CD004976-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antihistamine‐decongestant, Outcome 4: Adverse effects: dry mouth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antihistamine‐decongestant, Outcome 5: Adverse effects: insomnia" data-id="CD004976-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antihistamine‐decongestant, Outcome 5: Adverse effects: insomnia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antihistamine‐decongestant, Outcome 6: Adverse effects: gastrointestinal upset" data-id="CD004976-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Antihistamine‐decongestant, Outcome 6: Adverse effects: gastrointestinal upset </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Antihistamine‐analgesic, Outcome 1: Adverse effects: drowsiness, hypersomnia, and excessive sleepiness" data-id="CD004976-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Antihistamine‐analgesic, Outcome 1: Adverse effects: drowsiness, hypersomnia, and excessive sleepiness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Analgesic‐decongestant, Outcome 1: Global evaluation" data-id="CD004976-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Analgesic‐decongestant, Outcome 1: Global evaluation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Analgesic‐decongestant, Outcome 2: Adverse effects: all" data-id="CD004976-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Analgesic‐decongestant, Outcome 2: Adverse effects: all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Analgesic‐decongestant, Outcome 3: Adverse effects: drowsiness, hypersomnia, lethargy, excessive sleepiness and other central nervous system adverse effects" data-id="CD004976-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Analgesic‐decongestant, Outcome 3: Adverse effects: drowsiness, hypersomnia, lethargy, excessive sleepiness and other central nervous system adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Analgesic‐decongestant, Outcome 4: Adverse effects: dry mouth" data-id="CD004976-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Analgesic‐decongestant, Outcome 4: Adverse effects: dry mouth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Analgesic‐decongestant, Outcome 5: Adverse effects: gastrointestinal" data-id="CD004976-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Analgesic‐decongestant, Outcome 5: Adverse effects: gastrointestinal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Analgesic‐decongestant, Outcome 6: Adverse effects: dizziness, lightheadedness" data-id="CD004976-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Analgesic‐decongestant, Outcome 6: Adverse effects: dizziness, lightheadedness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antihistamine‐analgesic‐decongestant, Outcome 1: Global evaluation: on the morning after evening dosing" data-id="CD004976-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Antihistamine‐analgesic‐decongestant, Outcome 1: Global evaluation: on the morning after evening dosing </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antihistamine‐analgesic‐decongestant, Outcome 2: Global evaluation: after 3 days of treatment" data-id="CD004976-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Antihistamine‐analgesic‐decongestant, Outcome 2: Global evaluation: after 3 days of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004976-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/urn:x-wiley:14651858:media:CD004976:CD004976-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Antihistamine‐analgesic‐decongestant, Outcome 3: Global evaluation: after 5 days of treatment" data-id="CD004976-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_t/tCD004976-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Antihistamine‐analgesic‐decongestant, Outcome 3: Global evaluation: after 5 days of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/media/CDSR/CD004976/image_n/nCD004976-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004976-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antihistamine‐decongestant compared to placebo for the common cold</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihistamine‐decongestant compared to placebo for the common cold</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> otherwise healthy adults and children with common cold symptoms<br/><b>Setting:</b> multicentre, university hospital, general practice. Studies were performed in the UK, Peru, Spain, Belgium, Austria, and Finland.<br/><b>Intervention:</b> antihistamine‐decongestant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antihistamine‐decongestant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.31<br/>(0.20 to 0.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>565<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Participants or physicians evaluated the overall response to the treatment at end of follow‐up. Treatment failure means participants or physicians did not evaluate the treatment as beneficial.   </p> <p>On the final evaluation day (follow‐up: 3 to 10 days), 41% of participants in the placebo group had a favourable response, compared to 66% of participants in the active treatment group.  </p> <p>It should be noted that 1 trial reported number of colds as the unit of analysis (<a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. ">Bye 1980</a>). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>298 per 1000<br/>(223 to 363) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: all</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.58<br/>(0.78 to 3.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>842<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>328 per 1000<br/>(195 to 498) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: drowsiness, hypersomnia, and excessive sleepiness</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.38<br/>(0.63 to 3.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>692<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In 2 of the 5 studies reporting this adverse effect, it was less frequent with active treatment, whilst in the other 3 studies it was less frequent with placebo. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/>(35 to 148) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: dry mouth</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.75<br/>(1.74 to 8.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/>(48 to 190) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: insomnia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.89<br/>(0.88 to 9.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>344<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(26 to 227) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: gastrointestinal upset</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.81<br/>(0.64 to 12.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>296<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(8 to 141) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because most trials are at risk of bias due to lack of reporting on blinding, randomisation, and allocation method; two trials are also at risk of reporting bias.<br/><sup>b</sup>Downgraded one level due to imprecision: wide confidence interval includes 1.<br/><sup>c</sup>Downgraded two levels due to serious inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antihistamine‐decongestant compared to placebo for the common cold</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004976-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antihistamine‐analgesic compared to placebo for the common cold</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihistamine‐analgesic compared to placebo for the common cold</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> otherwise healthy adults and children with common cold symptoms<br/><b>Setting:</b> general practice, or setting not mentioned. Studies performed in the USA and the UK.<br/><b>Intervention:</b> antihistamine‐analgesic<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b> </b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antihistamine‐analgesic</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.33<br/>(0.23 to 0.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>582<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The active treatment also contained caffeine and ascorbic acid; control was ascorbic acid. </p> <p>Outcome based on results of <a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a>, reported on day 6. </p> <p>In <a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a>, the proportion of participants who were completely cured at the end of the trial was 70% with Grippostad and 43% with control (ascorbic acid). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>303 per 1000<br/>(233 to 377) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: drowsiness, hypersomnia, and excessive sleepiness</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.64<br/>(0.48 to 5.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The active treatment also contained caffeine, which also may have adverse effects; wide confidence interval including 1: uncertain whether adverse effects are more frequent with treatment. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/>(16 to 162) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to risk of bias (random sequence generation and allocation concealment unclear, inadequate blinding).<br/><sup>b</sup>Downgraded one level due to imprecision: limited number of participants; broad confidence interval including 1.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Antihistamine‐analgesic compared to placebo for the common cold</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004976-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Analgesic‐decongestant compared to placebo for the common cold</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Analgesic‐decongestant compared to placebo for the common cold</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> otherwise healthy adults and children with common cold symptoms<br/><b>Setting:</b> university hospital, general practice, or setting not mentioned. Studies performed in the UK, Germany, and the USA.<br/><b>Intervention:</b> analgesic‐decongestant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with analgesic‐decongestant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.28<br/>(0.15 to 0.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>181<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Only <a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> assessed this outcome. On day 5, overall subjective effectiveness at the end of the study was assessed by asking "on the whole do you think the tablets have helped you?".  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>578 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>277 per 1000<br/>(170 to 416) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: all</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.62<br/>(1.18 to 2.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1797<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000<br/>(129 to 218) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: drowsiness, hypersomnia, lethargy, excessive sleepiness, and other central nervous system adverse effects </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.34<br/>(0.76 to 2.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1644<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/>(24 to 72) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: dry mouth</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.43<br/>(0.53 to 3.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>764<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/>(10 to 67) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: gastrointestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.71<br/>(0.97 to 3.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1644<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000<br/>(26 to 81) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: dizziness, lightheadedness</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.86<br/>(1.02 to 8.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1287<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(9 to 64) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to lack of reporting on blinding, randomisation, and allocation concealment. One study was also at risk of randomisation and allocation bias, and one study was at risk of reporting bias.<sup> </sup><br/><sup>b</sup>Downgraded one level due to imprecision: wide confidence interval includes 1.<br/><sup>c</sup>Downgraded one level due to inconsistency between trial results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Analgesic‐decongestant compared to placebo for the common cold</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004976-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antihistamine‐analgesic‐decongestant compared to placebo for the common cold</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antihistamine‐analgesic‐decongestant compared to placebo for the common cold</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> otherwise healthy adults or children with common cold symptoms<br/><b>Setting:</b> paediatric clinic (1 study), setting not mentioned (2 studies). Studies performed in Turkey, the USA, and the UK.<br/><b>Intervention:</b> antihistamine‐analgesic‐decongestant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antihistamine‐analgesic‐decongestant</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation: after 3 days of treatment (included children 2 to 12 years old only) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.34<br/>(0.09 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>109<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome reported as clinical recovery.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>938 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>836 per 1000<br/>(574 to 952) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation: after 5 days of treatment (included children 2 to 12 years old only) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.17<br/>(0.49 to 2.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>83<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome reported as clinical recovery.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>489 per 1000<br/>(286 to 694) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global evaluation: on the morning after evening dosing (included adults only)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.47<br/>(0.33 to 0.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>548<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In <a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a>, participants rated their general feeling (useless, almost useless, not very good, good, very good, excellent) in the morning. </p> <p>In <a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a>, overall relief was measured on a 5‐point severity scale the morning following the nighttime intake of medication.  </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>658 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>475 per 1000<br/>(388 to 563) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to lack of reporting on random sequence generation, allocation concealment, and blinding.<sup> </sup>One study was at risk of attrition bias.<br/><sup>b</sup>Downgraded one level due to imprecision: confidence interval includes 1. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Antihistamine‐analgesic‐decongestant compared to placebo for the common cold</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Combination 1: number of trials reporting specific adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gingival swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Combination 1: number of trials reporting specific adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Combination 1: adverse effects data not meta‐analysed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nervousness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 5/133, placebo 3/128; P = 0.51</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. ">Berkowitz 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 5/133, placebo 2/128; P = 0.45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment: 13/38, placebo 10/35; P = 0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. ">Curley 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/38, placebo 0/35; P = 0.33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palpitations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/44, placebo 0/48; P = 0.29</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. ">Virtanen 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 8/44, placebo 11/48; P = 0.25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0007" title="DebelicM , RadielovicP .Therapy of banal rhinitis. Double-blind controlled clinical study. Schweizerische Rundschau fur Medizin Praxis1973;62(35):1074-7. ">Debelic 1973</a> (comparison of 2 active treatments) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clemastine + phenylpropanolamine (= treatment)<br/>Adverse effects:<br/>Insomnia 4<br/>Sleepiness 0<br/>Dry mouth 4<br/>Dizziness 3<br/>Palpitations 0<br/>Nausea 0 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belladonna, chlorpheniramine, phenylpropanolamine (= control)<br/>Adverse effects:<br/>Insomnia 3<br/>Sleepiness 5<br/>Dry mouth 7<br/>Dizziness 2<br/>Palpitations 4<br/>Nausea 1 </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Combination 1: adverse effects data not meta‐analysed</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Combination 1: results antihistamine‐decongestant</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0001" title="AschanG .Decongestion of nasal mucous membranes by oral medication in acute rhinitis. A rhinomanometric study to demonstrate synergism between antihistamines and adrenergic substance. Acta Otolaryngologica1974;77(6):433-8. "><b>Aschan 1974</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Objective nasal obstruction<br/>Promethazine + ephedrine: pmr 15/15; placebo: pmr 0/15. P &lt; 0.001<br/>Clemastine + phenylpropanolamine: pmr 14/15; placebo: pmr 0/15. P &lt; 0.001<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0002" title="BerkowitzRB , ConnellJT , DietzAJ , GreensteinSM , TinkelmanDG .The effectiveness of the non sedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Annals of Allergy1989;63(4):336-9. "><b>Berkowitz 1989</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>1. Overall response evaluated by physicians on a 4‐point scale: day 3, P = 0.01; day 5, P = 0.02 in favour of active treatment<br/>2. Overall response evaluated by participants on a 4‐point scale: day 3, P = 0.02 in favour of active treatment<br/>No further data available.<br/>b. Subjective severity assessment of nasal obstruction<br/>Mean scores: active treatment/placebo<br/>Day 1: 1.8/2.1<br/>Day 3: 1.7/1.9<br/>Day 3: 1.4/1.7<br/>Day 4: 1.3/1.6<br/>Day 5: 1.2/1.5<br/>P ≤0.05 for all presented days*<br/>c. Rhinorrhoea<br/>Mean scores: active treatment/placebo<br/>Day 1: 1.8/1.9<br/>Day 2: 1.5/1.9, P &lt; 0.05*<br/>Day 3: 1.4/1.5<br/>Day 4: 1.2/1.4, P &lt; 0.05*<br/>Day 5: 1.1/1.3<br/>d. Sneezing<br/>Mean scores: active treatment/placebo<br/>Day 1: 0.9/1<br/>Day 2: 0.6/0.9, P &lt; 0.05*<br/>Day 3: 0.5/0.7, P &lt; 0.05*<br/>Day 4: 0.3/0.6, P &lt; 0.05*<br/>Day 5: 0.3/0.5, P &lt; 0.05*<br/>e. Cough<br/>Mean scores: active treatment/placebo<br/>Day 1: 1.2/1.3<br/>Day 2: 1.2/1.2<br/>Day 3: 1.0/1.1<br/>Day 4: 0.8/1.0<br/>Day 5: 0.8/0.9<br/>No statistically significant difference </p> <p> </p> <p>*Exact P values not provided.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0004" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al.Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. British Medical Journal1980;281(6234):189-90. "><b>Bye 1980</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Severity score significantly reduced on day 1.<br/>b. Rhinorrhoea<br/>Severity score not significantly reduced with active treatment compared with placebo.<br/>c. Sneezing<br/>Severity score of sneezing significantly reduced on days 2, 3, and 4 in the active group in comparison with the placebo group.<br/>d. Cough<br/>Severity score not significantly reduced with active treatment compared with placebo.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0005" title="ClemensCJ , TaylorJA , AlmquistJR , QuinnHC , MehtaA , NaylorGS .Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children?Journal of Pediatrics1997;130(3):463-6. "><b>Clemens 1997</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Proportion of participants with improvement of nasal congestion 2 hours after intake of:<br/>active treatment 41/84 (48.8%); placebo 40/79 (50.6%); P = 0.94<br/>b. Rhinorrhoea<br/>Proportion of participants with improvement of nasal congestion 2 hours after intake of:<br/>active treatment 42/83 (50.6%); placebo 46/80 (57.5%); P = 0.48<br/>Comparison between scores made on 7‐point Likert scale:<br/>active treatment 4.69; placebo 4.76; P = 0.56<br/>c. Cough<br/>Proportion of participants with improvement of nasal congestion 2 hours after intake of:<br/>active treatment 24/49 (49.0%); placebo 28/65 (43.1%); P = 0.66<br/>Comparison between scores made on 7‐point Likert scale:<br/>active treatment 4.67; placebo 4.57; P = 0.53<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0006" title="CurleyFJ , IrwinRS , PratterMR , StiversDH , DoernGV , VernagliaPA , et al.Cough and the common cold. American Review of Respiratory Disease1988;138(2):305-11. "><b>Curley 1988</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>(1) Graphical display of mean severity score shows a significant difference on:<br/>Day 1: P = 0.01<br/>Day 2: P = 0.05<br/>Day 3: P = 0.01<br/>Day 4: P = 0.01<br/>Day 5: P = 0.01<br/>No further data available.<br/>(2) Prevalence of nasal obstruction after 14 days of treatment:<br/>active treatment 6/38, placebo 20/35. P &lt; 0.001<br/>b. Rhinorrhoea<br/>(1) Graphical display of mean severity score shows a significant difference on:<br/>Day 2: P = 0.05<br/>Day 3: P = 0.01<br/>No further data available.<br/>(2) Prevalence of nasal obstruction after 14 days of treatment:<br/>active group: 14/38; placebo group: 12/35; P = 0.82<br/>c. Cough<br/>(1) Graphical display of mean severity score shows a significant difference on:<br/>Day 3: P = 0.05<br/>Day 4: P = 0.05<br/>Day 5: P = 0.05<br/>No further data available.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0012" title="HuttonN , WilsonMH , MellitsED , BaumgardnerR , WissowLS , BonuccelliC , et al.Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. Journal of Pediatrics1991;118(1):125-30. "><b>Hutton 1991</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>(1) Effect is expressed as "severity score changes" and presented as z‐score: negative z‐score means "less than average improvement", positive z‐score means "more than average improvement".<br/>z‐score on "congested and runny nose":<br/>active treatment −0.166, placebo +0.194; difference not significant<br/>(2) Number of parents reporting "improvement" of runny or congested nose:<br/>active treatment: 16/30; placebo 19/24; P = 0.05<br/>b. Rhinorrhoea<br/>(1) Effect is expressed as "severity score changes" and presented as z‐score: negative z‐score means "less than average improvement", positive z‐score means "more than average improvement".<br/>z‐score on "congested and runny nose":<br/>active treatment −0.166, placebo +0.194; difference not significant<br/>(2) Number of parents reporting "improvement" of runny or congested nose:<br/>active treatment: 16/30; placebo 19/24; P = 0.05<br/>c. Cough<br/>(1) Effect is expressed as "severity score changes" and presented as z‐score: negative z‐score means "less than average improvement", positive z‐score means "more than average improvement".<br/>z‐score on "cough":<br/>active treatment +0.024, placebo −0.058; difference not significant<br/>(2) Number of parents reporting "improvement" of cough:<br/>active treatment 20/30; placebo 14/24; not statistically significant<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0014" title="Lebacq E Jr, GlineJP , JoueP , StockisA , CalderonP , Van SchoorO , et al.Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis. Clinical Trials and Meta-analysis1994;29(2-3):113-24. "><b>Lebacq 1994</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Objective nasal obstruction<br/>Nasal resistance as percentage of pre‐value<br/>P (placebo) (n = 6), A1 (combination 1) (n = 6), A2 (combination 2) (n = 6)<br/>Adult:<br/>0.5 h postdose: P 116%; A1 61% (P &lt; 0.05)*; A2 106%<br/>1 h postdose: P 96%; A1 52% (P &lt; 0.05)*; A2 96%<br/>2 h postdose: P 100%; A1 58% (P &lt; 0.05)*; A2 81%<br/>4 h postdose: P 103%; A3 77%; A2 83%<br/>6.5 h postdose: P 100%; A1 72%; A2 77%<br/>11 h postdose: P 96%; A1 69%; A2 76%<br/>*Significantly different from placebo<br/>Children:<br/>0.5 h postdose: P 96%; A1 63%; A2 115%<br/>1 h postdose: P 68%; A1 70%; A2 99%<br/>2 h postdose P 60%; A1 75%; A2 112%<br/>4 h postdose: P 103%; A3 77%; A2 83%<br/>6.5 h postdose: P 64%, A1 78%; A2 97%<br/>11 h postdose: P 65%; A1 72%; A2 99%<br/>No significant difference<br/>b. Subjective severity assessment of nasal obstruction<br/>Severity assessment is presented in 6 scores on a 3‐point scale. There was no difference between treatment groups. We show (as an example) results of 1 evaluation point (2 hours after intake of medication).<br/>Median score<br/>1. adults, 2. children<br/>Placebo (n = 6) 2; placebo (n = 6) 2<br/>A1 (n = 6) 2; A1 (n = 6) 1.5<br/>A2 (n = 6) 2; A5 (n = 6) 2<br/>A1 = combination 1, A2 = combination 2<br/>c. Effects assessed by anterior rhinoscopia<br/>Rhinoscopia results are presented as median of 6 scores on a 3‐point scale. There was no difference between treatment groups. We show (as an example) results of 1 evaluation point (2 hours after intake of medication).<br/>Median score<br/>1. adults 2. children<br/>Placebo (n = 6) 2; placebo (n = 6) 1.5<br/>A1 (n = 6) 2; A1 (n = 6) 1<br/>A2 (n = 6) 2; A5 (n = 6) 1.5<br/>A1 = combination 1, A2 = combination<br/>* Exact P‐value not provided. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0020" title="Common Cold Collaborative Group, RobertM , LlorensM , GarciaE , LuriaX .Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. European Journal of Internal Medicine2004;15(4):242-7. "><b>Robert 2004</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Evaluation of overall efficacy was made by the investigators on a 4‐point scale. Percentage of participants rating "good" or "excellent" was 75.8% (n = 100) for the treatment group and 57.6% (n = 104) for the control group (P &lt; 0.001)*.<br/>b. Objective nasal obstruction<br/>In the "Results" chapter of the paper it is reported that no differences were observed between treatment and placebo groups regarding an increase of mean values for nasal peak flow carried out before and after 3 days of treatment.<br/>  </p> <p>* Exact P‐value not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0028" title="VirtanenH .A slow release combined preparation (dexchlorpheniramine + pseudoephedrine) for symptomatic treatment of the common cold. Journal of Laryngology and Otology1983;97(2):159-63. "><b>Virtanen 1983</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Graphical presentation of mean severity scores of nasal obstruction register during 10 days (treatment on first 5 days) shows no significant difference between treatment groups. No further data available.<br/>b. Rhinorrhoea<br/>Graphical presentation of mean severity scores of nasal obstruction register during 10 days (treatment on first 5 days) shows no significant difference between treatment groups, except for day 3 (P &lt; 0.05)*.<br/>No further data presented.<br/>c. Sneezing<br/>Graphical presentation of mean severity scores of nasal obstruction register during 10 days (treatment on first 5 days) shows a significant difference between treatment groups on:<br/>Day 2, P &lt; 0.05*<br/>Day 3, P &lt; 0.001<br/>Day 4, P &lt; 0.01*<br/>Day 5, P &lt; 0.001<br/>Day 6, P &lt; 0.01*<br/>Day 7, P &lt; 0.01*<br/>Day 8, P &lt; 0.05* </p> <p> </p> <p>* Exact P‐value not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0029" title="WeipplG .Therapeutic approaches to the common cold in children. Clinical Therapeutics1984;6(4):475-82. "><b>Weippl 1984</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Overall therapeutic response was rated by the physician on a 5‐point scale (excellent, good, fair, poor, exacerbated) on days 3 and 5:<br/>Day 3: percentage of "good" or "excellent" responses: therapeutic group 83% (24/29), placebo group 7% (2/27) (P &lt; 0.01)*<br/>Day 5: percentage of "good" or "excellent" responses: therapeutic group 86% (25/29), placebo group 30% (8/27) (P &lt; 0.01)*<br/>b. Cough<br/>Statistically significant improvement (P = 0.05) at the interim visit </p> <p>c. Significantly greater improvement at both visits (P &lt; 0.001)* in rhinorrhoea, nasal congestion, and sneezing. No further data presented.<br/>  </p> <p>* Exact P‐value not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0010" title="GalvezJ .Symptomatic treatment of patients with the common cold. Clinical Trials Journal1985;22(6):489-97. "><b>Galvez 1985</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Physician's evaluation of overall therapeutic response on a 6‐point scale (difference given by the percentage of participants responding "good" or "excellent" on the medication):<br/>Day 3: treatment group 60%, placebo group 8%, P &lt; 0.01*<br/>Day 5: treatment group 77%, placebo group 21%, P &lt; 0.01*<br/>  </p> <p>* Exact P‐value not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0022" title="ScavinoY .Combination therapy in patients with the common cold. Current Therapeutic Research1985;38(5):746-54. "><b>Scavino 1985</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Overall therapeutic response evaluated by a physician on a 4‐point scale (excellent, good, fair, poor, exacerbated) on days 3 and 5:<br/>Day 3: percentage of participants responding "good" or "excellent": therapeutic group 76%, placebo group 17% (P &lt; 0.01)*<br/>Day 5: percentage of participants responding "good" or "excellent": therapeutic group 88%, placebo group 48% (P &lt; 0.01)*<br/>b. Cough<br/>Evaluation of the percentage of improvement from the baseline score on days 3 and 5:<br/>Day 3: active treatment 54%, placebo 24%<br/>Day 5: active treatment 90%, placebo 60%<br/>  </p> <p>* Exact P‐value not provided.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>P: placebo<br/>pmr: positive manometric result </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Combination 1: results antihistamine‐decongestant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Combination 2: number of trials reporting a specific adverse effect</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Combination 2: number of trials reporting a specific adverse effect</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Combination 2: adverse effects data not meta‐analysed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 2/91, placebo 2/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 6/91, placebo 5/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/91, placebo 1/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. ">Koytchev 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In all trial groups (n = 1167), 39 participants reported an adverse effects.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Combination 2: adverse effects data not meta‐analysed</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Combination 2: results antihistamine‐analgesic</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0011" title="Gwaltney JM Jr, WintherB , PatrieJT , HendleyJO .Combined antiviral-antimediator treatment for the common cold. Journal of Infectious Diseases2002;186(2):147-54. "><b>Gwaltney 2002</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Comparisons between baseline ‐ adjusted mean daily symptom scores on days 2 to 5 mentioned in a table. Treatment with oral chlorpheniramine and ibuprofen showed no significant effect on nasal congestion scores on any day during treatment. </p> <p>Day 2: 1.0<br/>Day 3: 1.0<br/>Day 4: 1.6<br/>Day 5: 1.7<br/>b. Rhinorrhoea<br/>Comparisons between baseline ‐ adjusted mean daily symptom scores on days 2 to 5 mentioned in a table. Treatment with oral chlorpheniramine and ibuprofen showed no significant effect on rhinorrhoea scores on any day during treatment.<br/>Day 2: 1.9<br/>Day 3: 1.1<br/>Day 4: 1.7<br/>Day 5: 1.15<br/>c. Sneezing<br/>Comparisons between baseline ‐ adjusted mean daily symptom scores on days 2 to 5 mentioned in a table. Treatment with oral chlorpheniramine and ibuprofen showed a significant effect on sneezing scores only on day 5 of treatment.<br/>Day 2: 2.0<br/>Day 3: 3.2<br/>Day 4: 2.3<br/>Day 5: 6.2; statistically significant (P &lt; 0.05*)<br/>d. Cough<br/>Comparisons between baseline ‐ adjusted mean daily symptom scores on days 2 to 5 mentioned in a table. Treatment with oral chlorpheniramine and ibuprofen showed no significant effect on cough scores on any day during treatment.<br/>Day 2: 3.0<br/>Day 3: 1.8<br/>Day 4: 2.1<br/>Day 5: 1.8 </p> <p> </p> <p>*Exact P values not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0013" title="KoytchevR , VlahovV , BacratchevaN , GieselB , Gawronska-SzklarzB , WojcickiJ , et al.Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. International Journal of Clinical Pharmacology and Therapeutics2003;41(3):114-25. "><b>Koytchev 2003</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>The proportion of participants who were completely cured at the end of the trial:<br/>treatment group: 70%;<br/>control group and reference 1 group: 43% to 45%.<br/>b. Subjective severity assessment of nasal obstruction<br/>Comparison of the subscore referring to blocked nose, cough, and disturbance of sleep quality was performed between the group of participants receiving the active treatment and the group receiving the reference 2. The difference was statistically significant (P &lt; 0.05*). No further data available.<br/>c. Cough<br/>Comparison of the subscore referring to blocked nose, cough, and disturbance of sleep quality was performed between the group of participants receiving the active treatment and the group receiving the reference 2. The difference was statistically significant (P &lt; 0.05*). No further data available. </p> <p> </p> <p>*Exact P values not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '><b>Middleton 1981</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Overall subjective assessment was made after asking the participant the question: "On the whole do you think the tablets have helped you?".<br/>  </p> <p> </p> <p>Daytime:</p> <p>Response<br/>Control Treatment<br/>Yes 47 66<br/>No 52 25<br/>Compared with the control group, a statistically significantly larger number of participants receiving the active medication responded affirmative to the question (P &lt; 0.01*).<br/>b. Subjective severity assessment of nasal obstruction<br/>No significant difference reported between the active substance and placebo in treating nasal congestion.<br/>The results are mentioned in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>c. Rhinorrhoea<br/>No significant difference reported between the active substance and placebo in treating rhinorrhoea.<br/>The results are mentioned in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>d. Sneezing<br/>No significant difference reported between the active substance and placebo in treating sneezing.<br/>The results are mentioned in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>e. Cough<br/>No significant difference reported between the active substance and placebo in treating cough.<br/>The results are mentioned in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>  </p> <p>*Exact P values not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0019" title="Montijo-BarriosE , CadenaF , Ramirez-MayansJA , Gutierrez-CastellonP .Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age [Ensayo clínico sobre el efecto de la bufenina, aminofenazona y el clorhidrato de difenilpiralina en el tratamiento del resfriado común en niños de seis a 24 meses de edad]. Revista de Investigacion Clinica2011;63:335-43. "><b>Montijo‐Barrios 2011</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DAY 3</p> <p>Active (%) placebo (%)</p> <p>Moderate to severe rhinorrhoea………………….48…………….43 P &lt; 0.05*</p> <p>At least 6/day sneezing…………….……………28………….….28</p> <p>Moderate to severe irritability……………………23……….…….17</p> <p>Difficulty eating…………………………………..32…………..…..37</p> <p>Noisy breathing……………………………………48……….…….41</p> <p>Breathing through mouth……………………….39……………….24 P &lt; 0.01*</p> <p>Significant tearing…………………………………27……………..11 P &lt; 0.01*</p> <p>Fever………………………………………………9…………….…..6</p> <p>Milk consumption (ounces)……………………..18 +/−11…..……18+/−12</p> <p>Number of hours of sleep (daytime)……....….3+/−2…….….....2+/−2</p> <p>Number of hours of sleep (nighttime)…..........9+/−2………...…9+/−2</p> <p> </p> <p>DAY 5</p> <p>Moderate to severe rhinorrhoea………………….48……………….11 P &lt; 0.01*</p> <p>Moderate to severe irritability……………………17…………………9 P &lt; 0.05*</p> <p>Breathing through mouth….…………….………26…………....….16 P &lt; 0.05*</p> <p>Significant tearing……….….……………………27………………..11 P &lt; 0.05*</p> <p>(other symptoms: no significant difference)</p> <p> </p> <p>DAY 7</p> <p>Moderate to severe rhinorrhoea………………….22……………….4 P &lt; 0.01*</p> <p>Difficulty eating……………………….…………..11………………..5 P &lt; 0.05*</p> <p>Breathing through mouth………….…………….16……………….7 P&lt; 0.05*</p> <p>(other symptoms: no significant difference)</p> <p> </p> <p>*Exact P values not provided.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Combination 2: results antihistamine‐analgesic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Combination 3: number of trials reporting a specific adverse effect</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervous system disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Combination 3: number of trials reporting a specific adverse effect</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0012"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Combination 3: adverse effects data not meta‐analysed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 2/91, paracetamol 2/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal upset</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 6/91, paracetamol 5/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal system</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASA + PSE 18/236, ASA 18/239, PSE 12/237, placebo 5/121</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/91, paracetamol 1/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness and sleepiness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 5/91, paracetamol 4/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 0/91, paracetamol 1/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 0/91, paracetamol 1/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Giddy, dizzy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/91, paracetamol 1/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal pains, diarrhoea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '>Middleton 1981</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/91, paracetamol 0/90</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 17/481, placebo 9/162</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 8/481, placebo 2/162</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharyngitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. ">Loose 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 4/481, placebo 2/162</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nervousness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. ">Sperber 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 8/216, placebo 0/214</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difficulty sleeping</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. ">Sperber 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 1/23, placebo 1/10</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central nervous system</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active treatment 4/76, placebo 0/76</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. ">Eccles 2006a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>active treatment 1/76, placebo 1/76</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central nervous system</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. ">Eccles 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASA + PSE 10/236, ASA 2/239, PSE 4/237, placebo 6/121</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ASA: acetylsalicylic acid<br/>PSE: pseudoephedrine </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Combination 3: adverse effects data not meta‐analysed</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0013"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Combination 3: results analgesic‐decongestant</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0016" title="Martinez GallardoF , López FiescoA , ZamoraG .Symptomatic treatment of common cold in children with a new combination of naproxen sodium plus pseudoephedrine hydrochloride: a comparative trial against pseudoephedrine syrup. Proceedings of the Western Pharmacology Society1994;37:157-8. "><b>Martinez 1994</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>The duration of the symptom of nasal congestion was significantly reduced on treatment days 3 and 5. Result mentioned in the "Results" chapter of the text. No further data available.<br/>d. Objective nasal obstruction<br/>The duration of the symptom of mucosal oedema was significantly reduced on treatment days 3 and 5 as compared to placebo. Result mentioned in the "Results" chapter of the text. No further data available.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0015" title="LooseI , WinkelM .Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. Arzneimittelforschung2004;54(9):513-21. "><b>Loose 2004</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>(1) Nasal congestion score<br/>The nasal congestion score was statistically significantly different (P &lt; 0.05) for all active treatments and at all observation intervals (2, 4, and 6 hours after intake) compared with placebo.<br/>(2) Relief of nasal congestion<br/>Relief in nasal congestion was statistically significantly better compared to treatment with placebo for all active treatments and at all observation intervals (2, 4, and 6 hours after intake).<br/>Data provided in tables, but it is not clear what the tables represent.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0017" title='MiddletonRS .Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold. British Journal of Clinical Practice1981;35(9):297-300. '><b>Middleton 1981</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Overall subjective assessment was made after asking the participant the question: "On the whole do you think the tablets have helped you?".<br/>Nighttime: </p> <p>Response, Control, Treatment<br/>Yes, 56, 75<br/>No, 34, 26<br/>Compared with the control group, a statistically significantly larger number of participants receiving the active medication responded affirmative to the question (P &lt; 0.01).<br/>b. Subjective severity assessment of nasal obstruction<br/>No significant difference reported between the active substance and placebo in treating nasal congestion.<br/>The results are only reported in the "Results" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>c. Rhinorrhoea<br/>No significant difference reported between the active substance and placebo in treating rhinorrhoea.<br/>The results are only reported in the "Result" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>d. Sneezing<br/>No significant difference reported between the active substance and placebo in treating sneezing.<br/>The results are only reported in the "Result" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>e. Cough<br/>No significant difference reported between the active substance and placebo in treating cough.<br/>The results are only reported in the "Result" chapter of the article. There are no tables or graphics showing the data from which the conclusions were drawn.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0024" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG .Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145-60. "><b>Sperber 1989</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Objective nasal obstruction<br/>Overall and daily nasal patency was greater in the treatment group. The days when this difference was most noticeable were day 4 (P = 0.08) and day 5 (P = 0.06). Analysis of the mean values was confounded by high variability between participants.<br/>b. Subjective severity assessment of nasal obstruction<br/>Reduction of nasal congestion rated on a 4‐point scale:<br/>Treatment group 4 ± 3; placebo group 7 ± 2, P &lt; 0.05* (significant difference)<br/>c. Rhinorrhoea<br/>Reduction of nasal congestion rated on a 4‐point scale:<br/>Treatment group 2 ± 2; placebo group 4 ± 3, P &lt; 0.05* (not a significant difference) </p> <p> </p> <p>*Exact P values not provided.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0025" title="SperberSJ , TurnerRB , SorrentinoJV , O'ConnorRR , RogersJ , Gwaltney JM Jr.Effectiveness of pseudoephedrine plus acetaminophen for treatment of symptoms attributed to the paranasal sinuses associated with the common cold. Archives of Family Medicine2000;9(10):979-85. "><b>Sperber 2000</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Subjective severity assessment of nasal obstruction<br/>Mean difference between the nasal congestion scores at the beginning of the study and after the first and second administration of active medication or placebo (nasal congestion evaluated on 5‐point scale):<br/>Dose 1: active group −1.06; placebo group −0.67, P = 0.002 (statistically significant)<br/>Dose 2: active group −1.26; placebo group −0.98, P = 0.03 (not statistically significant)<br/>b. Rhinorrhoea<br/>Mean difference between the rhinorrhoea score at the beginning of the study and after the first and second administration of active medication or placebo (rhinorrhoea evaluated on 5‐point scale):<br/>Dose 1: active group −0.80; placebo group −0.71, P = 0.12 (not statistically significant)<br/>Dose 2: active group −1.15; placebo group −0.86, P = 0.09 (not statistically significant)<br/>c. Sneezing<br/>Mean difference between the sneezing score at the beginning of the study and after the first and second administration of active medication or placebo (sneezing evaluated on 5‐point scale):<br/>Dose 1: active group −0.84; placebo group −0.79, P = 0.71 (not statistically significant)<br/>Dose 2: active group −0.98; placebo group −0.85, P = 0.15 (not statistically significant)<br/>d. Cough<br/>Mean difference between the cough score at the beginning of the study and after the first and second administration of active medication or placebo (cough evaluated on 5‐point scale):<br/>Dose 1: active group −0.61; placebo group −0.51, P = 0.27 (not statistically significant)<br/>Dose 2: active group −0.78; placebo group −0.58, P = 0.06 (not statistically significant)<br/>Trend suggestive of greater reduction in cough score.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0008" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al.Efficacy of a paracetamol-pseudoephedrine combination for treatment of nasal congestion and pain-related symptoms in upper respiratory tract infection. Current Medical Research2006;22(12):2411-8. "><b>Eccles 2006a</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal congestion<br/>Area under nasal airflow conductance curve 0 to 4 h (rhinomanometry)<br/>Mean difference 120.3, 95% CI 66.18 to 174.37, P &lt; 0.0001<br/>Sum of nasal congestion differences 0 to 3 days (4‐point scale)<br/>Mean difference 0.69, 95% CI 0.219 to 1.162, P = 0.004<br/>Global nasal congestion relief (5‐point scale)<br/>Paracetamol + pseudoephedrine: 1.7 +/− 1.2<br/>P &lt; 0.001<br/>Placebo: 1.0 +/− 0.9 </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0009" title="EcclesR , VoelkerM .Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118-25. "><b>Eccles 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasal congestion</p> <p> </p> <p>Area under nasal airflow conductance curve 0 to 4 h (rhinomanometry):</p> <p>ASA/PSE vs ASA P &lt; 0.001 at each evaluation time (0 to 1 h, 1 to 2 h, 2 to 3 h, 3 to 4 h) </p> <p>ASA/PSE vs PSE P &gt; 0.5 at each evaluation time (0 to 1 h, 1 to 2 h, 2 to 3 h, 3 to 4 h) </p> <p>ASA/PSE vs placebo P &lt; 0.001 at each evaluation time (0 to 1 h, 1 to 2 h, 2 to 3 h, 3 to 4 h) </p> <p> </p> <p>Sum of subjective nasal congestion intensity difference</p> <p>ASA/PSE vs ASA at 0 to 4 h, P = 0.144; day 3, P = 0.969</p> <p>ASA/PSE vs PSE at 0 to 4 h, P = 0.647; day 3, P = 0.037</p> <p>ASA/PSE vs placebo at 0 to 4 h, P &lt; 0.008; day 3, P = 0.048</p> <p> </p> <p>Total subjective nasal congestion relief</p> <p>ASA/PSE vs ASA at 0 to 4 h, P &lt; 0.001; day 3, P = 0.016</p> <p>ASA/PSE vs PSE at 0 to 4 h, P = 0.890; day 3, P = 0.873</p> <p>ASA/PSE vs placebo at 0 to 4 h, P &lt; 0.001; day 3, P &lt; 0.001</p> <p> </p> <p>Global nasal congestion relief</p> <p>ASA/PSE vs ASA day 3, P = 0.040</p> <p>ASA/PSE vs PSE day 3, P = 0.207</p> <p>ASA/PSE vs placebo day 3, P &lt; 0.001</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>ASA: acetylsalicylic acid<br/>CI: confidence interval<br/>PSE: pseudoephedrine </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Combination 3: results analgesic‐decongestant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0014"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Combination 4: results antihistamine‐decongestant‐analgesic</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. "><b>Blanco 2000</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Comparison of severity ratings on the third day of treatment between treatment groups: results are graphically displayed and summarised in a table. It is not clear what is presented in the table.<br/>On the graphs, P values are mentioned when there is a statistically significant difference: for general unwell feeling, there is no significant difference.<br/>b. Subjective severity assessment of nasal obstruction<br/>Comparison of severity ratings on the third and fifth day of treatment between treatment groups: results are graphically displayed and summarised in a table. It is not clear what is presented in the table. In the graphs, P values are mentioned when there is a statistically significant difference: for nasal congestion, P = 0.041.<br/>c. Effect on results on anterior rhinoscopy<br/>Comparison of severity ratings on the third and fifth day of treatment between treatment groups: results are graphically displayed and summarised in a table. It is not clear what is presented in the table. In the graphs, P values are mentioned when there is a statistically significant difference: for anterior rhinoscopy, P = 0.045 on the third day.<br/>d. Rhinorrhoea<br/>Comparison of severity ratings on the third day of treatment between treatment groups: results are graphically displayed and summarised in a table. It is not clear what is presented in the table. In the graphs, P values are mentioned when there is a statistically significant difference: for anterior rhinorrhoea, P = 0.012.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0021" title="SachsenroderL , RenovanzHD , FlachD .Efficacy and tolerance of a combined oral rhinologic agent. Arzneimittelforschung1972;22(2):392-8. "><b>Sachsenroder 1972</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Rhinorrhoea<br/>Number of participants rating the efficacy of the product "good" or "bad" in treating the symptom of rhinrrhoea on days 1, 2, and 3 of taking medications.<br/>Ap 67 (n = 52), Z 95‐Rhi (n = 52), placebo (n = 55). Difference:<br/>Day 1: good 18, 27, 9; bad 34, 25, 46 (significant)<br/>Day 2: good 30, 34, 18; bad 22, 18, 37 (not significant)<br/>Day 3: good 36, 40, 20; bad 16, 10, 35 (not significant)<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. "><b>Mizoguchi 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Overall relief (scale: 0 = very poor, 1 = poor, 2 = fair, 3 = good, 4 = very good)<br/>Day 2 morning: T 2.4 +/− 1.01, P 1.98 +/− 1.11, P &lt; 0.001<br/>b. Nasal congestion (0 = much worse, 1 = somewhat worse, 2 = about the same, 3 = somewhat better, 4 = much better)<br/>Hour 3, day 1: T 2.59 +/− 0.72, P 2.43 +/− 0.68, P = 0.012<br/>Day 2 morning: T 2.29 +/− 0.98, P 2.00 +/− 1.10, P = 0.002<br/>c. Runny nose (0 = much worse, 1 = somewhat worse, 2 = about the same, 3 = somewhat better, 4 = much better)<br/>Hour 3, day 1: T 2.73 +/− 0.78, P 2.56 +/− 0.75, P = 0.017<br/>Day 2 morning: T 2.49 +/− 0.97, P 2.16 +/− 1.12, P = 0.001<br/>d. Cough (0 = much worse, 1 = somewhat worse, 2 = about the same, 3 = somewhat better, 4 = much better)<br/>Hour 3, day 1: T 2.72 +/− 0.77, P 2.46 +/− 0.82, P = 0.012<br/>Day 2 morning: T 2.50 +/− 0.97, P 2.08 +/− 1.11, P = 0.002<br/>Percentage (%) of participants improved (no P values provided)<br/>1) Hour 3, day 1:<br/>Nasal congestion: T 55.4, P 44.7<br/>Runny nose: T 58.9, P 51<br/>Cough: T 56.7, P 43.3<br/>  </p> <p>2) Day 2 morning:<br/>Nasal congestion: T 45.2, P 36.2<br/>Runny nose: T 54.3, P 40.6<br/>Cough: T 52.3, P 38<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. "><b>Thackray 1978</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Global efficacy<br/>Number of participants rating the formulation as "good, very good or excellent" on the morning after the previous night's dose:<br/>n = 58<br/>Active treatment: 35/58 </p> <p>Placebo: 25/58</p> <p>P &lt; 0.05*<br/>b. Subjective severity assessment of nasal obstruction<br/>Number of participants rating the formulation as "good, very good, excellent" on the morning after the previous night's dose:<br/>n = 58<br/>Active treatment: 35/58 </p> <p>Placebo 25/58</p> <p>P &lt; 0.05*<br/>c. Rhinorrhoea<br/>Number of participants rating the formulation as "good, very good, excellent" on the morning after the previous night's dose:<br/>n = 55<br/>Active treatment: 35/55 </p> <p>Placebo 21/55</p> <p>P &lt; 0.05*<br/>d. Sneezing<br/>Number of participants rating the formulation as "good, very good, excellent" on the morning after the previous night's dose:<br/>n = 30<br/>Active treatment: 25/30 </p> <p>Placebo 20/30</p> <p>P = 0.14<br/>e. Cough<br/>Number of participants rating the formulation as "good, very good, excellent" on the morning after the previous night's dose:<br/>Active treatment: 57.6% </p> <p>Placebo 32.2%</p> <p>P &lt; 0.01</p> <p> </p> <p>*Exact P value not provided.<br/>  </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0027" title="UnuvarE , YildizI , KilicA , ToprakS , Selvi AslanS , AydinS , et al.Is acetaminophen as effective as an antihistamine-decongestant-acetaminophen combination in relieving symptoms of acute nasopharyngitis in children? A randomised, controlled trial. International Journal of Pediatric Otorhinolaryngology2007;71(8):1277-85. "><b>Unuvar 2007</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical score</p> <p>Day 3:</p> <p>Treatment: 4.0 +/− 2.8</p> <p>Paracetamol: 4.1 +/− 2.6</p> <p>P = 0.81</p> <p>Day 5:</p> <p>Treatment: 1.7 +/− 1.4</p> <p>Paracetamol: 2.0 +/− 1.6</p> <p>P =0.39</p> <p>Nasal stuffiness</p> <p>Day 3:</p> <p>Treatment: 27/86</p> <p>Paracetamol: 21/62</p> <p>P = 0.75</p> <p>Day 5:</p> <p>Treatment: 0/86</p> <p>Paracetamol: 4/62</p> <p>P = 0.016<br/>Runny nose </p> <p>Day 3:</p> <p>Treatment: 28/86</p> <p>Paracetamol: 25/62</p> <p>P = 0.33</p> <p>Day 5:</p> <p>Treatment: 7/86</p> <p>Paracetamol: 8/62</p> <p>P = 0.49<br/>Cough </p> <p>Day 3:</p> <p>Treatment: 13/86</p> <p>Paracetamol: 14/62</p> <p>P = 0.24</p> <p>Day 5:</p> <p>Treatment: 2/86</p> <p>Paracetamol: 4/62<br/>P = 0.29<br/>  </p> <p>Note: treatment = paracetamol + diphenhydramine + pseudoephedrine </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. "><b>Zhang 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. Total symptom score: active treatment (A) n = 25; placebo (P) n = 27. Only graphical data available. No significant difference between groups during the 4 hours follow‐up after a single administration. </p> <p>(P values at 15 min, 30 min, 1 h, 2 h, 3 h, 4 h were 0.95, 0.72, 0.74, 0.77, 0.52, 0.90, respectively). Global assessment of response to treatment (P = 0.95) </p> <p> </p> <p>b. Nasal congestion (adjusted mean (SE))</p> <p>baseline: A 1.2 (0.93) P 1.2 (0.92)</p> <p>15 min: A −0.32 (0.086) P −0.31 (0.084) P = 0.9337</p> <p>30 min: A −0.59 (0.119) P −0.6 (0.115) P = 0.96</p> <p>1 hour: A −0.61 (0.127) P −0.68 (0.124) P = 0.6521</p> <p>2 hours: A −0.91 (0.138) P −1.02 (0.134) P = 0.5384</p> <p>3 hours: A −1.04 (0.156) P −1.14 (0.152) P = 0.6409</p> <p>4 hours: A −1.19 (0.162) P −1.28 (0.157) P = 0.9618</p> <p> </p> <p>c. Runny nose (adjusted mean (SE))</p> <p>baseline: A 2 (0.35) P 1.9 (0.55)</p> <p>15 min: A −0.20 (0.081) P −0.18 (0.080) P = 0.8711</p> <p>30 min: A −0.48 (0.116) P −0.32 (0.114) P = 0.2919</p> <p>1 hour: A −0.54 (0.145) P −0.61 (0.143) P = 0.6940</p> <p>2 hours: A −0.78 (0.148) P −0.65 (0.146) P = 0.5132</p> <p>3 hours: A −0.89 (0.161) P −0.98 (0.159) P = 0.6751</p> <p>4 hours: A −1.12 (0.149) P −0.97 (0.147) P = 0.4692</p> <p> </p> <p>d. Sneezing (adjusted mean (SE))</p> <p>baseline: A 1.7 (0.79) P 1.6 (0.75)</p> <p>15 min: A −0.10 (0.089) P −0.24 (0.088) P = 0.2279</p> <p>30 min: A −0.25 (0.103) P −0.42 (0.10215) P = 0.2203</p> <p>1 hour: A −0.50 (0.126) P −0.80 (0.124) P = 0.0785</p> <p>2 hours: A −0.67 (0.138) P −0.86 (0.136) P = 0.3117</p> <p>3 hours: A −0.83 (0.138) P −1.03 (0.136) P = 0.2938</p> <p>4 hours: A −0.88 (0.135) P −1.11 (0.133) P = 0.2064</p> <p> </p> <p>e. Cough (adjusted mean (SE))</p> <p>baseline: A 1.6 (1.04) P 1.3 (0.94)</p> <p>15 min: A −0.11 (0.071) P −0.06 (0.078) P = 0.5969</p> <p>30 min: A −0.28 (0.077) P −0.25 (0.084) P = 0.7506</p> <p>1 hour: A −0.49 (0.116) P −0.33 (0.12) P = 0.3222</p> <p>2 hours: A −0.51 (0.109) P −0.45 (0.119) P = 0.6759</p> <p>3 hours: A −0.53 (0.116) P −0.53 (0.127) P = 0.9838</p> <p>4 hours: A −0.72 (0.131) P −0.59 (0.143) P = 0.4599</p> <p> </p> <p>*Exact P value not provided.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>P: placebo<br/>SE: standard error<br/>T: active treatment </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Combination 4: results antihistamine‐decongestant‐analgesic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004976-tbl-0015"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Combination 4: adverse effects data not meta‐analysed</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Result</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over design: all participants took active formulation. 19 adverse effects occurred, equally distributed between active and control formulation. No further numbers reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 participants with active treatment reported 9 adverse effects.</p> <p>9 participants with control treatment reported 10 adverse effects.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant with active treatment reported 1 adverse effect.</p> <p>3 participants with control treatment reported 1 adverse effect.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsy or sleepy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0003" title="Blanco de la MoraE , CardilloL , De la Barrera, MarkyB .Efficacy and safety of loratadine, pseudoephedrine and acetaminophen in the non-sedating symptomatic treatment of the common cold. Investigacion Medica Internacional2000;24:14-25. ">Blanco 2000</a> </p> <p><a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not more frequent with active treatment; numbers not mentioned</p> <p>T 1/25, P 0/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Giddiness/drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0026" title="ThackrayP .A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate. Journal of Internal Medicine1978;6(2):161-5. ">Thackray 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over design: adverse effects reported by 7 participants when taking active treatment and 4 participants when taking placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 2/224, P 1/208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 2/224, P 1/208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 1/224, P 0/208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> <p><a href="./references#CD004976-bbs2-0030" title="ZhangY , MallefetP .Time-to-onset of cold and flu symptom relief: a randomized, double-blind, placebo controlled pilot study for a multi-symptom combination product. International Journal of Clinical Pharmacology and Therapeutics2018;56(12):604-11. ">Zhang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 1/224, P 1/208</p> <p>T 0/25, P 1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004976-bbs2-0018" title="MizoguchiH , WilsonA , JerdackGR , HulleJD , GoodaleM , GrenderJM , et al.Efficacy of a single evening dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. International Journal of Clinical Pharmacology and Therapeutics2007;45(4):230-6. ">Mizoguchi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T 1/224, P 1/208</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>P: placebo<br/>T: active treatment </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Combination 4: adverse effects data not meta‐analysed</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/full#CD004976-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004976-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antihistamine‐decongestant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Global evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.33, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Adverse effects: all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.78, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adverse effects: drowsiness, hypersomnia, and excessive sleepiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.63, 3.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adverse effects: dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.75 [1.74, 8.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse effects: insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [0.88, 9.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse effects: gastrointestinal upset <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.64, 12.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antihistamine‐decongestant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004976-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antihistamine‐analgesic</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Adverse effects: drowsiness, hypersomnia, and excessive sleepiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.48, 5.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antihistamine‐analgesic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004976-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Analgesic‐decongestant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Global evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.15, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Adverse effects: all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.18, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Adverse effects: drowsiness, hypersomnia, lethargy, excessive sleepiness and other central nervous system adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.76, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Adverse effects: dry mouth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.53, 3.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Adverse effects: gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.97, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Adverse effects: dizziness, lightheadedness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [1.02, 8.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Analgesic‐decongestant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004976-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antihistamine‐analgesic‐decongestant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Global evaluation: on the morning after evening dosing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.33, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Global evaluation: after 3 days of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.09, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Global evaluation: after 5 days of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.49, 2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antihistamine‐analgesic‐decongestant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004976.pub4/references#CD004976-tbl-0019">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004976.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004976-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004976-note-0024">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004976-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD004976-note-0017">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD004976-note-0023">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD004976-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD004976-note-0025">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD004976-note-0015">Português</a> </li> <li class="section-language"> <a class="" href="ro#CD004976-note-0026">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD004976-note-0014">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD004976-note-0022">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004976-note-0020">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004976-note-0021">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004976\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004976\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004976\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004976\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004976\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004976.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004976.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004976.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004976.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004976.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716190096"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004976.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716190100"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004976.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d997389fc1bf6',t:'MTc0MDcxNjE5MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 